• KOL
  • Harry Roger Büller
  •  

    Prominent publications by Harry Roger Büller

    KOL Index score: 23031

    BACKGROUND:  Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide.

    OBJECTIVES: To establish a common international consensus addressing practical, clinically relevant questions in this setting.

    METHODS: An international consensus working group of experts was set up to develop guidelines according to an evidence-based medicine approach, using the GRADE system.

    RESULTS: For the ...

    Also Ranks for: Vte Patients |  venous thromboembolism |  prophylaxis lmwh |  3 months |  practice guidelines
    KOL Index score: 20177

    OBJECTIVES: The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.

    BACKGROUND: Three bleeding risk-prediction schemes have been derived for and validated in patients with AF: HEMORR(2)HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall ...

    Also Ranks for: Atrial Fibrillation |  bled bleeding |  hemorr2hages atria |  intracranial hemorrhage |  topic risk
    KOL Index score: 17342

    This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key ...

    Also Ranks for: Antithrombotic Therapy |  grade 1a |  venous thromboembolic disease |  vka lmwh |  inr range
    KOL Index score: 16684

    PURPOSE: Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment. Furthermore, the incidence of such events in these patients is dependent on the achieved International Normalized Ratio (INR). The aim of this study was to assess the incidence of venous thromboembolic recurrence and major ...

    Also Ranks for: Venous Thromboembolism |  bleeding complications |  patients malignancy |  retrospective analysis |  international normalized
    KOL Index score: 16378

    BACKGROUND: Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor Xa, might be more suitable than conventional anticoagulants in the management of cancer-associated venous thromboembolism. The aim of this study was to assess the efficacy and safety of edoxaban compared with ...

    Also Ranks for: Venous Thromboembolism |  patients cancer |  hazard ratio |  clinically relevant bleeding |  factor inhibitors
    KOL Index score: 15975

    BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.

    METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), ...

    Also Ranks for: Warfarin Patients |  hazard ratio |  venous thromboembolism |  pulmonary embolism |  primary efficacy outcome
    KOL Index score: 15905

    ESSENTIALS: Cancer patients are at high risk of venous thromboembolism (VTE). In this study, cases and controls were cancer patients who did or did not develop VTE. von Willebrand factor (VWF) levels were higher if compared with controls and correlated with cancer stage. VWF and ADAMTS-13 are associated with the occurrence of VTE in cancer.

    BACKGROUND: Patients with cancer are at high risk of venous thromboembolism (VTE). ADAMTS-13 regulates von Willebrand factor (VWF) activity, which ...

    Also Ranks for: Willebrand Factor |  venous thromboembolism |  vte cancer |  vwf adamts13 |  khorana score
    KOL Index score: 15571

    BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.

    METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or ...

    Also Ranks for: Oral Rivaroxaban |  venous thromboembolism |  vitamin antagonist |  continued treatment |  hazard ratio
    KOL Index score: 15512

    BACKGROUND: After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.

    METHODS: In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after ...

    Also Ranks for: Hip Replacement |  dabigatran enoxaparin |  venous thromboembolism |  etexilate versus |  primary efficacy outcome
    KOL Index score: 15505

    CONTEXT: Previous studies have evaluated the safety of relatively complex combinations of clinical decision rules and diagnostic tests in patients with suspected pulmonary embolism.

    OBJECTIVE: To assess the clinical effectiveness of a simplified algorithm using a dichotomized clinical decision rule, D-dimer testing, and computed tomography (CT) in patients with suspected pulmonary embolism.

    DESIGN, SETTING, AND PATIENTS: Prospective cohort study of consecutive patients with clinically ...

    Also Ranks for: Pulmonary Embolism |  computed tomography |  dimer testing |  patients suspected |  3 months
    KOL Index score: 15415

    BACKGROUND: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery.

    METHODS: In a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral dabigatran etexilate (50, 150 mg twice daily, 300 mg once daily, 225 mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) ...

    Also Ranks for: Total Hip |  dabigatran etexilate |  thromboembolic events |  knee replacement |  vte patients
    KOL Index score: 14849

    BACKGROUND: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer potential for prophylaxis against venous thromboembolism (VTE) after total knee replacement surgery.

    METHODS: In this randomized, double-blind study, 2076 patients undergoing total knee replacement received dabigatran etexilate, 150 mg or 220 mg once-daily, starting with a half-dose 1-4 hours after surgery, or subcutaneous enoxaparin ...

    Also Ranks for: Subcutaneous Enoxaparin |  oral dabigatran |  total knee replacement |  venous thromboembolism |  prevention vte
    KOL Index score: 14797

    BACKGROUND: The standard initial treatment of hemodynamically stable patients with pulmonary embolism is intravenous unfractionated heparin, requiring laboratory monitoring and hospitalization.

    METHODS: We conducted a randomized, open-label trial involving 2213 patients with acute symptomatic pulmonary embolism to compare the efficacy and safety of the synthetic antithrombotic agent fondaparinux with those of unfractionated heparin and to document noninferiority in terms of efficacy. ...

    Also Ranks for: Unfractionated Heparin |  pulmonary embolism |  initial treatment |  subcutaneous fondaparinux |  intravenous injections
    KOL Index score: 14727

    OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.

    DESIGN: Systematic review and meta-analysis.

    DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).

    STUDY SELECTION: Randomised controlled trials and prospective cohort ...

    Also Ranks for: Anticoagulant Treatment |  recurrent vte |  unprovoked venous |  10 years |  95 confidence interval

     

    Harry Roger Büller: Influence Statistics

    Sample of concepts for which Harry Roger Büller is among the top experts in the world.
    Concept World rank
    strategy abdominal pelvic #1
    segmental subsegmental #1
    clinically suspected dvt #1
    evaluable patients apixaban #1
    rfviia fondaparinux #1
    ufh grade #1
    dvt 56 #1
    doses 75 microg #1
    thromboembolism relatives #1
    outcome clinically #1
    edoxabantreated #1
    bleeding clinically #1
    vte risk coc #1
    presentation category #1
    coagulation fibrinolytic proteins #1
    relative risks carriers #1
    pyridines recurrence #1
    xainhibitors #1
    lmwh plasma levels #1
    reduceddose noacs #1
    patients treatment duration #1
    tb402 12 kg1 #1
    venous thrombosis pregnancy #1
    ddimer levels cdr #1
    severe presentation patients #1
    fetal loss carriers #1
    fviii homocysteine #1
    ldfr symptomatic legs #1
    efficiency subgroups #1
    rnapc2 groups #1
    association protein levels #1
    previous surveys netherlands #1
    laalleles platelets #1
    matisse clinical trials #1
    95 intracranial #1
    plateletactivating antibodies risk #1
    heparin initial treatment #1
    intrinsic coagulation vivo #1
    treatment venous #1
    doacs initial heparin #1
    lowmolecularweight heparin category #1
    submassive elevated ctni #1
    current comprehensions #1
    anticoagulants probability #1
    pvo qscan #1
    lmwh rtap #1
    intensity vkas doacs #1
    vte procoagulant activity #1
    uesvt uedvt #1
    treated vka #1
    strategies abdominal pelvic #1
    plasma concentration fviii #1
    timeperiod #1
    pulmonary angiography strategies #1
    withheld #1
    pulmonary embolism carriers #1
    diagnosis deepvein thrombosis #1
    rnapc2 united states #1
    thrombosis vte #1
    coagulation factors markers #1
    proximal extent ipe #1
    recurrent dvt dvt #1
    cancer patients uedvt #1
    fxiaso enoxaparin #1
    fondaparinux rfviia injection #1
    dvt impedance plethysmography #1
    cdrs patients #1
    patients tests prevalence #1
    subcutaneous length life #1
    ddimer test patients #1
    total vte patients #1
    frequency venous thromboembolism #1
    hokusaivte study #1
    ecq ankle brachial #1
    avws prevalence #1
    therapeutic doses lmwh #1
    efficacy vte #1
    scores occult cancer #1
    patients wells rule #1
    smoking graft patency #1
    extended treatment edoxaban #1
    guidelines abi #1
    progression vte #1
    gastrointestinal cancer edoxaban #1
    normal ddimer result #1
    synthetic selective factor #1
    hokusai‐vte trial #1
    individualized duration #1
    anticoagulant treatment patients #1
    preferred oral anticoagulant #1
    lmwh venous thrombosis #1
    vka recipients #1
    ml1 ctpa #1
    predefined outcomes #1
    qscan #1
    strategies diagnostic management #1
    lmwhmediated #1
    standardintensity vkas #1
    3633 patients edoxaban #1
    elevated levels fviii #1
    milliliter enoxaparin #1
    treatment idraparinux #1
    pulmonary angiography study #1
    normal ddimer concentration #1
    amplify trial #1
    increasing levels ft4 #1
    animal female heparin #1
    successful attenuation #1
    edoxaban east asian #1
    patients unexplained dvt #1
    ft4 level patients #1
    cip diagnostic management #1
    standard treatment idraparinux #1
    age recurrent vte #1
    treat thrombosis #1
    65±9years #1
    d‐dimer test #1
    predefined outcomes vte #1
    venous thrombosis mutations #1
    nadroparin therapeutic dose #1
    probabilityscan #1
    recurrent vte doacs #1
    submassive incidence #1
    daily dalteparin treatment #1
    ccus 4 #1
    preference doacs #1
    topic thrombophlebitis #1
    ddimer test #1
    casedescription #1
    extra hospital visits #1
    factor viii relatives #1
    heparin survival #1
    individuals air travel #1
    safety clinical utility #1
    major bleeds vka #1
    dvt symptomatic #1
    strategies ultrasonography #1
    baseline pvo #1
    patients laalleles #1
    protein resistance control #1
    simplified rule proportion #1
    timerequirement #1
    patients ivte #1
    single dose tb402 #1
    lmwh edoxaban #1
    reduceddose noacs warfarin #1
    venography feasibility #1
    95 3633 patients #1
    anticoagulants chemotherapy #1
    patients clinical probability #1
    carriers recurrence #1
    edoxaban warfarin groups #1
    clinical uedvt #1
    excluded pulmonary #1
    incidental symptomatic vte #1
    original wells #1
    venous thrombosis recurrence #1
    inr range ttr #1
    factual hemorrhage heparin #1
    rivaroxaban dvt treatment #1
    matisse trials #1
    uedvt recurrent vte #1
    prediction models recurrence #1
    mutation relatives #1
    method factor #1
    thrice daily gentamicin #1
    studies 3 months #1
    initial treatment patients #1
    specificity pulmonary embolism #1
    symptomatic recurrent #1
    acquired atiii deficiency #1
    administration lmwh #1
    noacs prevention #1
    incidence ctni #1
    wells rule primary #1
    isolated deficiencies proteins #1
    cdr dimer #1
    crptest #1
    einsteinextension #1
    378 patients edoxaban #1
    noncarriers annual incidence #1
    months standard therapy #1
    smoking patency #1
    extensive screening cancer #1
    inr studies #1
    scores riete score #1
    vte addition #1
    cus strategies #1
    chromogenic endotoxin #1
    25mg apixaban #1
    oral edoxaban dose #1
    guideline adherence justification #1
    puerperium diagnostic suspicion #1
    quantitative ddimer tests #1
    edoxaban dalteparin #1
    absolute annual incidences #1
    limited screening 95 #1
    clinical presentation category #1
    intestinal microbiota coagulation #1
    rhir lmwh #1
    ventricular dysfunction edoxaban #1
    relatives antithrombin #1
    3633 patients edoxabantreated #1
    double heterozygous carriers #1
    cdr physicians #1
    apixaban conventional therapy #1
    patients khorana #1
    coagulationinhibiting #1
    org heparin #1
    fviii normal levels #1
    lmwh replacement #1
    axa activity 5 #1
    ventilation lung scanning #1
    tests prevalence abi #1
    international thrombosis experts #1
    initial heparin edoxaban #1
    included patients study #1
    venous thromboembolism idraparinux #1
    influenza case patients #1
    wells clinical #1
    protein levels mortality #1
    gentamicin patients netilmicin #1
    qscan 3 weeks #1
    calf dvt ultrasound #1
    doacs cirrhosis patients #1
    orthopedic thromboprophylaxis #1
    leg veins patients #1
    relatives elevated levels #1
    patients reduceddose noacs #1
    venous thrombosis hyperglycemia #1
    xageneration #1
    ultrasonography dvt #1
    embolism suspected #1
    69 conclusions #1
    fviii venous thromboembolism #1
    clinical probability patients #1
    age∗10μg #1
    messages justification #1
    threemonth incidence #1
    pregnancyrelated complications relatives #1
    intracranial clinical presentation #1
    crt cvc #1
    carriers pulmonary embolism #1
    acenocoumarol heparin #1
    —brachial #1
    scan pulmonary embolism #1
    ultrasonography diagnostic #1
    idraparinux recurrent thromboembolism #1
    combination cdrs #1
    hokusai‐vte cancer study #1
    superficial thrombophlebitis incidence #1
    uesvt #1
    nadroparin patients #1
    vivo coagulation factor #1
    netherlands vka #1
    residual thrombotic mass #1
    enoxaparin warfarin antiplatelet #1
    annual incidence patients #1
    recurrent thrombosis pts #1
    prolactin venous thrombosis #1
    graft patency patency #1
    leg ultrasonography patients #1
    compression ultrasound dvt #1
    venous thrombus growth #1
    vte airline pilots #1
    mutation arg506 #1
    pulmonary embolism idraparinux #1
    elevated biomarkers hospital #1
    chest perfusion scan #1
    vte study #1
    level loss patency #1
    clinical decision rule #1
    rule dimer #1
    doacs anatomical extent #1
    prothrombin 20210a mutation #1
    nadroparin aspirin #1
    atherosclerosis hemophilia patients #1
    patients compression ultrasonography #1
    neoplasms heparin #1
    s1p1activation #1
    thrombophilia late loss #1
    weight heparinoid #1
    prophylaxis idraparinux #1
    studies ttr #1
    netherlands lmwh #1
    patency smokers #1
    idraparinux 25 #1
    heparins vitamin antagonists #1
    prospective management study #1
    compression ultrasonography presentation #1
    consensus strategy strategy #1
    combination nonhigh cdr #1
    initial heparin patients #1
    uedvt clinical #1
    scenarioanalysis #1
    respondents 60 #1
    dvt 69 #1
    vte trial #1
    outcome recurrent #1
    cancer cdr #1
    sspe proximal #1
    dvt costs #1
    selective beta‐blocker treatment #1
    efficacy conventional treatment #1
    mdct expert radiologist #1
    ddimer test result #1
    evaluable patients 95 #1
    hokusai vte cancer #1
    dimer clinical #1
    iii plg #1
    pulmonary embolism role #1
    hellp syndrome mutations #1
    protein mortality #1
    ankle brachial prevalence #1
    dimer test #1
    controlled trials thrombophilia #1
    023 relatives #1
    departments orthopedic surgery #1
    malignancy achieved inr #1
    embolism radionuclide #1
    patients artificial graft #1
    efficacy outcome #1
    uesvt recurrent vte #1
    avidin placebo #1
    wellscdrscore #1
    tinaquant assay comparison #1
    20210a mutation #1
    beta thromboglobulin org #1
    enoxaparin initial treatment #1
    analysis hokusai #1
    rtap lmwh #1
    probability categories #1
    idraparinux months #1
    patients acute recurrent #1
    ultrasonography leg veins #1
    edoxaban cancer patients #1
    time recombinant #1
    idraparinux vte #1
    fxainhibitors #1
    aged nadroparin #1
    apc resistance factor #1
    enoxaparin heparin treatment #1
    diagnostic management patients #1
    endotoxemia tests #1
    tb402 enoxaparin #1
    anticoagulants double #1
    relatives normal fviii #1
    anticoagulant fondaparinux #1
    d‐dimer level #1
    antithrombotic prescriptions adherence #1
    rivaroxaban standard therapy #1
    oral administration bsf #1
    vitamin anticoagulants #1
    95ci tb402 #1
    patients advanced malignancy #1
    fviii women #1
    levels procoagulant factors #1
    50 years combination #1
    elevated fviii #1
    pvo ctscan #1
    ctscanreading #1
    dose rnapc2 #1
    quantitative dimer #1
    replacement vka #1
    patients idraparinux #1
    fibrinolysis levels #1
    fetal loss stillbirth #1
    tests pulmonary embolism #1
    5 years lmwh #1
    adjunct thrombolysis #1
    heparins cancer spread #1
    crp test patients #1
    clinically suspected cancer #1
    diagnostic strategies patients #1
    elevated cardiac troponins #1
    dose response apixaban #1
    venography tests #1
    clinical probability risk #1
    hokusaivte trial #1
    einstein dvt patients #1
    12 months edoxaban #1
    ambulatory computers #1
    non‐invasive diagnostic work‐up #1
    tb402 prevention #1
    recommendations dvt #1
    models development studies #1
    p0424 #1
    vkas lmwh #1
    death category #1
    pioped study study #1
    simplified geneva score #1
    thromboembolism 3 #1
    dalteparin 6 months #1
    uedvt terms #1
    age multiple comorbidities #1
    53 amputations #1
    khorana #1
    departments pharmacological prophylaxis #1
    pulmonary embolism fondaparinux #1
    extended anticoagulation doacs #1
    suspected perfusion scan #1
    combined training gps #1
    enoxaparin vkas treatment #1
    obese hemophilic patients #1
    500 org #1
    travel‐related venous thrombosis #1
    heparin initial #1
    patients deep #1
    advanced malignancy #1
    dvt 3 #1
    pulmonary embolism basis #1
    patients initial heparin #1
    cart lower levels #1
    role exclusion #1
    death venous thromboembolism #1
    probability lung scan #1
    activecontrol placebo #1
    patients antithrombotic prescriptions #1
    reduceddose noacs stroke #1
    5‐snp scores #1
    current practise #1
    placebo 25mg apixaban #1
    venous thromboembolism episode #1
    symptomatic legs dvt #1
    2630 pilots #1
    rnapc2 patients #1
    ultrasound strategies patients #1
    wells rules #1
    cstatistic major bleeding #1
    category fxainhibitors #1
    somittrial #1
    netherlands 5 years #1
    rivaroxaban acute dvt #1
    p0001 saline #1
    vka netherlands #1
    cdrscore #1
    combination cdr #1
    embolism sensitivity #1
    pharmacological methods prophylaxis #1
    symptomatic pts #1
    95 elevated ctni #1
    idraparinux versus #1
    nondiagnostic lung scan #1
    survival lmwh #1
    rnapc2 groups placebo #1
    uesvt patients #1
    ufh grade 1a #1
    intravenous injections lmwh #1
    rabinov #1
    risk homozygous women #1
    conventional therapy enoxaparin #1
    undvt #1
    normohomocysteinemic relatives hyperhomocysteinaemia #1
    platelets iqr #1
    aged venous #1
    variable d‐dimer thresholds #1
    doac recipients #1
    fondaparinux unfractionated #1
    ipe expert radiologists #1
    single‐detector row #1
    initial treatment dvt #1
    pulmonary embolism life #1
    randomized studies efficacy #1
    probability ventilation #1
    vitamin antagonists time #1
    category perelated death #1
    vte day #1
    false normal #1
    cancer edoxaban #1
    patients examiner #1
    patients tb402 #1
    probability cdr #1
    oral rivaroxaban treatment #1
    equinox study #1
    bleeding risk treatment #1
    women elevated levels #1
    efficacy heparin therapy #1
    prothrombin individuals #1
    screening carriers #1
    ultrasound compression ultrasound #1
    standardintensity vkas doacs #1
    acenocoumarol efficacy #1
    diagnostic strategies strategies #1
    diagnostic strategy primary #1
    failure cip #1
    enoxaparin primary efficacy #1
    low levels ft4 #1
    polyethylenglycolhirudin #1
    poc test patients #1
    study centre duration #1
    anticoagulation period #1
    prevalence coagulation #1
    constans score #1
    cancer patients ufh #1
    ventilation scan chest #1
    presentation 1 week #1
    relevant major #1
    5 avidin infusion #1
    comparison vidas assay #1
    major bleeding cancer #1
    123362 #1
    local radiologist #1
    patients inherited thrombophilia #1
    subsequent symptomatic cancer #1
    vte occurred #1
    wells cdr #1
    silent dvt #1
    cancer patients cvcs #1
    patients enoxaparin vkas #1
    combination ddimer testing #1
    dalteparin vte treatment #1
    36 papers #1
    thrombo‐embolic events #1
    pulmonary embolism metaanalysis #1
    subsequent diagnosis malignancy #1
    symptomatic recurrent vte #1
    normal dimer #1
    idraparinux standard therapy #1
    einsteindvt #1
    test venography #1
    easier monitoring #1
    elevated fviii age #1
    patients advanced prostate #1
    double reports #1
    enoxaparin tb402 #1
    fetal loss miscarriage #1
    ldf diagnosis #1
    factor viii homocysteine #1
    calfvein thrombi #1
    obese controls difference #1
    5395 patients #1
    warfarin cstatistic #1
    97 compression ultrasonography #1
    0·2 3633 patients #1
    perelated death classification #1
    0·620·74 #1
    duration heparin treatment #1
    normal venogram #1
    clinically relevant disease #1
    realtime bmode ultrasonography #1
    subcutaneous nadroparin placebo #1
    abnormal ipg #1
    compression ultrasonography patients #1
    uesvt median #1
    abelacimab #1
    ctscan qscan #1
    idrabiotaparinux idraparinux #1
    nonhigh cdr #1
    followup overt cancer #1
    acute recurrent patients #1
    subcutaneous idraparinux #1
    safety 60 dose #1
    principal safety #1
    cdr normal #1
    intravenous unfractionated #1
    vte arterial #1
    vte location #1
    tests venography #1
    safety idraparinux #1
    progression svt #1
    extended anticoagulation apixaban #1
    impedance thrombophlebitis #1
    fxainhibitors vka recipients #1
    rabinovpaulin #1
    fviii vte #1
    cdr ddimer levels #1
    oral apixaban treatment #1
    vte fatal #1
    rate recurrent #1
    infections gentamicin #1
    obstetric complications relatives #1
    normotensive patients studies #1
    heparin vitamin antagonist #1
    ddimer result #1
    250 patients cancer #1
    orthopedic surgery netherlands #1
    normal levels fviii #1
    ili score #1
    2 diagnostic management #1
    placebo rnapc2 #1
    revascularisation procedures patients #1
    dvt anticoagulants #1
    asymptomatic extension #1
    heparin vitamin #1
    united states rnapc2 #1
    treatment cumulative incidence #1
    members symptomatic carriers #1
    patients mismatched scan #1
    patients malignancy #1
    idraparinux #1
    presence venous thrombosis #1
    fviii concentration #1
    recurrent vte immobilization #1
    early time recurrence #1
    older patients cdr #1
    anticoagulant treatment vte #1
    types major bleeding #1
    patients normal tests #1
    adjusted dose ufh #1
    3 rfviia #1
    excluding pulmonary #1
    normal lung scan #1
    prescriptionbased #1
    botticelli dvt dose‐ranging #1
    recurrence major bleeding #1
    recurrent vte statin #1
    rule exclusion #1
    apixaban extended treatment #1
    compression ultrasonography detection #1
    inherited thrombophilia patients #1
    2479 relatives #1
    acenocoumarol therapy acenocoumarol #1
    feasibility venography #1
    heparin acenocoumarol #1
    presentation major #1
    risk percentage points #1
    vte risk day #1
    travel venous thromboembolism #1
    compression ultrasonography #1
    deepvein thrombosis incidence #1
    9 incidence #1
    echocardiography normotensive patients #1
    lmwh users incidence #1
    ivte clinical practice #1
    dose daily edoxaban #1
    proximal location ipe #1
    suspected cdr #1
    survival fondaparinux #1
    apc resistance tests #1
    208791 #1
    doubleheterozygotes #1
    cancer 145 patients #1
    unexplained dvt patients #1
    year prophylaxis #1
    cancer patients cdr #1
    management study #1
    simple diagnostic strategy #1
    carriers thrombophilic defects #1
    pulmonary angiography ultrasonography #1
    relatives mutation #1
    reocclusion antithrombotic drug #1
    matisse dvt #1
    positive vte #1
    pulmonary embolism studies #1
    apixaban randomized patients #1
    bleeding rates quality #1
    perelated death category #1
    levonorgestrel desogestrelcontaining #1
    rivaroxaban lmwh vka #1
    heparins data #1
    heparin org 10172 #1
    elevated fviii patients #1
    protecht shr #1
    relatives normal levels #1
    respondents lmwh #1
    lmwh delivery #1
    elderly patients dvt #1
    presenting location women #1
    rnapc2 inhibition #1
    travellers thrombosis #1
    postthrombotic symptoms patients #1
    risk pulmonary embolism #1
    combination cdrscore #1
    lmprovement #1
    lowmolecularweight heparin 95 #1
    venous thrombosis vwf #1
    vitamin antagonists treatment #1
    deep vein thrombosis #1
    cstatistic model discrimination #1
    rfviia 3 #1
    lmwh departments #1
    bleeding risk lmwh #1
    abnormal vaginal bleeding #1
    category death #1
    recurrence bleeding risk #1
    wound haematoma #1
    cdr ddimer test #1
    vte difference #1
    prevention topic guidelines #1
    referral basis #1
    carriers relative risks #1
    wells simplified #1
    proportion pulmonary embolism #1
    cancer patients patients #1
    750 μg l1 #1
    venous thromboembolism edoxaban #1
    patients protein deficiencies #1
    idraparinux placebo #1
    8h flight #1
    uesvt mortality #1
    svt lmwh #1
    presenting location vte #1
    monoclonal antibodies apc #1
    00515 #1
    amplify trial apixaban #1
    prophylaxis crt #1
    women factor leiden #1
    cvc crt #1
    laalleles #1
    rule cdr #1
    perfusion scan #1
    sensitivity 100 percent #1
    0·2 edoxabantreated #1
    acute treatment lmwh #1
    absolute thrombotic risk #1
    baseline characteristics duration #1
    presenting vte location #1
    mortality postthrombotic symptoms #1
    loss subsequent pregnancy #1
    quantitative ddimer testing #1
    control anticardiolipin antibodies #1
    heparins inhibition #1
    deficiency proteins #1
    relatives tafi levels #1
    wellsrule #1
    5mg apixaban #1
    gogh dvt trial #1
    standard therapy months #1
    pulmonary embolism tests #1
    bleeding einstein #1
    upper extremity uedvt #1
    cdrscore combination #1
    embolism randomized #1
    vkas efficacy #1
    hemorrhage heparin #1
    standalone ddimer testing #1
    7268 patients suspected #1
    fviii hyperhomocysteinemia #1
    tb402 50 #1
    560 pharmacies #1
    thrombophlebitis tomography #1
    suspected symptomatic #1
    safety outcome #1
    systematic search cteph #1
    incidence venous #1
    riskstroponin #1
    547253 #1
    patients uedvt uesvt #1
    death vte studies #1
    studies doac treatment #1
    quantitative ddimer test #1
    controlledstudy #1
    393 patients warfarin #1
    sgs pretest probability #1
    patients retropubic prostatectomy #1
    aptt org 10172 #1
    aptt org #1
    pvoq #1
    embolism wells #1
    alternative diagnoses patients #1
    practiceassistants #1
    wellscdr #1
    popliteal veins sensitivity #1
    pulmonary embolism #1
    idraparinux 6 months #1
    selective ddimer thresholds #1
    long haul flights #1
    chest perfusion scintigraphy #1
    procoagulant factors levels #1
    vka share #1
    longhaul flight #1
    doacs factor #1
    elderly outpatients combination #1
    women edoxaban #1
    thrombosis vitamin #1
    pulmonary embolism cdr #1
    wells rule exclusion #1
    tsh antitpo #1
    relevant bleeding #1
    local radiologist experts #1
    beneficial lmwh #1
    flebography #1
    heparinoid #1
    cancer clinical presentation #1
    severity clinical presentation #1
    tomography angiography vte #1
    avidin vte #1
    falsenormal #1
    ddimer test combination #1
    ivte #1
    thrombophilia patients doacs #1
    clinically suspected uedvt #1
    abdominal pelvic strategies #1
    decisions duration #1
    hokusaivte trial patients #1
    phase doacs #1
    lmwh immobilization #1
    lmwhs 95 #1
    symptomatic venous #1
    ifngamma pselectin #1
    idraparinux vitamin antagonist #1
    recurrent thromboembolism enoxaparin #1
    7268 patients #1
    simplified wells rule #1
    unexplained dvt #1
    cancer patients cancer #1
    failure diagnostic management #1
    heparins cancer patients #1
    antidote vitamin #1
    elevated ctni patients #1
    coagulation clinical #1
    thiazoles venous #1
    outpatients symptomatic dvt #1
    idraparinux patients #1
    avidin idrabiotaparinux #1
    molecular weight fondaparinux #1
    achieved inr patients #1
    dalteparin major bleeding #1
    50 rivaroxaban #1
    edoxaban risk factors #1
    sustained antithrombotic effects #1
    clinical probability exclusion #1
    early discharge strategies #1
    failure rate efficiency #1
    org aptt #1
    thromboembolism treated #1
    warfarin cancer patients #1
    12 kg1 enoxaparin #1
    study ecq #1
    reported incidence vte #1
    lowmolecularweight heparin treatment #1
    3 idraparinux #1
    ldf cus #1
    rfviia idraparinux #1
    distal clots #1
    treatment experimental thrombosis #1
    proportion 75 years #1
    association travel #1
    questionnaires thrombosis #1
    suspected deep #1
    vitamin antagonist patients #1
    6 months avidin #1
    rivaroxaban replacement #1
    hyperhomocysteinemia relatives #1
    vka treatment treatment #1
    oral anticoagulants phase #1
    probability normal #1
    enoxaparin vkas #1
    acenocoumarol initial treatment #1
    15 lmwh #1
    standard therapy rivaroxaban #1
    exclusion pulmonary #1
    desogestrelcontaining coagulation factors #1
    bmi fondaparinux #1
    dimer result #1
    lmwh acute treatment #1
    common alternative diagnoses #2
    surgical casts #2
    pentasaccharide fondaparinux #2
    95 dvt #2
    ate cancer patients #2
    incidental vte #2
    ageadjusted ddimer testing #2
    patients low probability #2
    blood coagulation rnapc2 #2
    vte elevated fviii #2
    statins recurrent vte #2
    subsegmental emboli #2
    tinaquant vidas #2
    c1173t dimorphism #2
    secondary efficiency #2
    extended constans score #2
    95 cancer patients #2
    enoxaparin difference #2
    clinically suspected #2
    death vte #2
    single administration tb402 #2
    medscape #2
    hellp syndrome prevalence #2
    clinical probability estimate #2
    n832 #2
    exclusion pulmonary embolism #2
    rnapc2 #2
    screening fvl #2
    central localization #2
    comparator individuals 95 #2
    8292 patients #2
    alife study #2
    hmb primary outcome #2
    rivaroxaban 30 bid #2
    antagonists vka #2
    primary healthcare secondary #2
    cancer addition #2
    hyperglycemia diagnosis #2
    composite scores area #2
    amuse strategy #2
    safety pravastatin therapy #2
    pravastatin therapy children #2
    primary hospitalbased strategies #2
    simplired test #2
    cancer recurrent vte #2
    rule combined #2
    vte 12 #2
    heparin nadroparin #2
    levothyroxine exposure #2
    heparin administered #2
    interleukin‐10 response #2
    hokusai vte #2
    life treatment duration #2
    oral direct inhibitors #2
    intrinsic cascade #2
    17 apixaban #2
    suspected upper #2
    warfarintreated #2
    treatment ttr #2
    bleeding rate patients #2
    annual incidences #2
    vte orthopedic surgery #2
    gcpg #2
    subcutaneous length #2
    diagnostic lung #2
    rfviia injection rfviia #2
    undiagnosed malignancy #2
    3306 patients #2
    thromboembolism thrombophilia #2
    sustained antithrombotic #2
    prothrombin pulmonary embolism #2
    8 wk risk #2
    gauge plethysmography #2
    crnm bleeds #2
    ufh survival #2
    raskob #2
    sr34006 #2
    treated edoxaban #2
    embolism safely #2
    failure rate strategy #2
    embolism deep #2
    endogenous activated protein #2
    analysis venous #2
    suspected pulmonary #2
    20210a mutations #2
    risk khorana #2
    efficiency original score #2
    blood coagulation inhibition #2
    uedvt efficiency #2
    plasma concentrations endotoxin #2
    uedvt performance #2
    enoxaparin warfarin #2
    rivaroxaban thiazoles #2
    ultrasonography patients #2
    absolute incidence #2
    arterial thrombotic disease #2
    relevant patient subgroups #2
    incidence recurrent #2
    standardised time intervals #2
    healthcare settings findings #2
    compression doppler #2
    pregnancy venous thrombosis #2
    patients peripheral graft #2
    impedance plethysmography patients #2
    fviii increased risk #2
    pregnancy coc #2
    protein rnapc2 #2
    received edoxaban #2
    vidas assay #2
    thyroid hormone coagulation #2
    primary efficacy outcome #2
    fibrinolysis pentoxifylline #2
    apixaban enoxaparin warfarin #2
    heparin treatment influenza #2
    simplified wells #2
    travel venous #2
    mutations cleavage sites #2
    exclude pulmonary #2
    bleeding edoxaban #2
    mutation 35 #2
    normal ddimer test #2
    ventilation scanning #2
    patients prior vte #2
    principal safety outcome #2
    nematode anticoagulant #2
    test cancer #2
    major bleeding intermediate #2
    coagulation fibrinolytic #2
    pharmacological strategies #2
    intermediate phenotype vte #2
    f5 r506q #2
    hemorr2hages atria scores #2
    thrombosis normal #2
    uptake noacs #2
    risk deep #2
    ufh 6 months #2
    heparin compounds #2
    cha2ds2vasc nri #2
    computed venous #2
    mutations propeptide #2
    hokusai vtecancer study #2
    euro138 #2
    brain metastases doacs #2
    fvl carriers carriers #2
    influenza prothrombotic state #2
    limits cancer #2
    employees longhaul flight #2
    serum tnf activity #2
    secondary strategies #2
    n1423 #2
    impedance plethysmography diagnosis #2
    concomitant thrombophilic #2
    plasma d‐dimer concentration #2
    risk anticoagulation therapy #2
    recombinant nematode #2
    thrombophilic defects risk #2
    biomarkers casecontrol studies #2
    anticoagulated patients permanent #2
    deficiencies proteins #2
    recurrent deep #2
    pulmonary embolism efficacy #2
    vitamin antagonists quality #2
    patients hemorr2hages #2
    decision rule #2
    scan normal #2
    coagulation factors prolactin #2
    sspe patients patients #2
    major clinically #2
    lmwh users #2
    embolism primary #2
    dimer thresholds #2
    clinical pretest probability #2
    recurrent vte risk #2
    adapted ddimer thresholds #2
    nonpermanent heart failure #2
    idraparinux vitamin #2
    duration anticoagulant treatment #2
    major bleeding recurrent #2
    quality warfarin treatment #2
    pulmonary embolism purpose #2
    recombinant hirudin cgp #2
    cdr variables cdr #2
    lowmolecularweight heparin women #2
    bleeding occurred #2
    global public awareness #2
    ddimer determination #2
    efficiency diagnostic strategies #2
    months 25 #2
    negative ageadjusted ddimer #2
    endotoxininduced activation coagulation #2
    presentation dvt #2
    thromboinflammation cardiovascular disease #2
    beta‐receptor blockade #2
    venous thrombophlebitis #2
    outcome symptomatic #2
    wells cdr cdr #2
    incidental venous #2
    crd42017056309 #2
    symptomatic outpatients #2
    influenza coagulation #2
    current clinical challenges #2
    years 36 #2
    venographically #2
    wells cdr patients #2
    major bleeding edoxaban #2
    fibrinolytic proteins #2
    pulmonary embolism asthma #2
    hospitalbased strategies #2
    ddimer assay #2
    heparin effective #2
    uedvt cancer patients #2
    duration anticoagulant #2
    venous thromboembolism enoxaparin #2
    rnapc2 doses #2
    exposure flights #2
    major bleeding cindexes #2
    bleeding complications treatment #2
    angioplasty clopidogrel #2
    computerized impedance #2
    lower clinical utility #2
    relation coagulation factors #2
    6 months scores #2
    recurrence thromboembolism #2
    administration rviia #2
    score dimer #2
    clinical prediction model #2
    performance constans rule #2
    vte svt #2
    women therapeutic doses #2
    factor iia #2
    95 comparator individuals #2
    treated anticoagulants #2
    patients oral factor #2
    amadeus study #2
    nct00633893 #2
    fibrinolysis influenza #2
    normohomocysteinemic relatives #2
    patients abi measurement #2
    measurement ankle brachial #2
    mdct reference standard #2
    patients khorana score #2
    treatment deep #2
    graft occlusion patients #2
    cdr wells cdr #2
    vte 1000 personyears #2
    rule proportion #2
    levels coagulation factors #2
    95 0·2 #2
    prolactin relation #2
    efficiency strategy #2
    referred patients secondary #2
    lmwh efficacy #2
    resource utilisation treatment #2
    vitamin antagonist rivaroxaban #2
    venous #2
    apixaban lmwh vka #2
    suspected pulmonary embolism #2
    coumarin sensitivity #2
    plasmin activity inhibition #2
    inflammation neutrophils thrombosis #2
    age‐adjusted d‐dimer testing #2
    vein compressibility #2
    regression pravastatin #2
    thrombophilic disorders #2
    acquired antithrombin #2
    model cancer patients #2
    hasbled score hemorr2hages #2
    mild risk factor #2
    low‐molecular‐weight heparin #2
    events severe #2
    khorana protecht #2
    atria hemorr2hages #3
    idrabiotaparinux warfarin #3
    dvt major #3
    gestalt probability #3
    protein thrombophilia #3
    primary wells rule #3
    heparin heparin #3
    pulmonary embolism models #3
    platelet agents #3
    clinical models patients #3
    inhibition blood coagulation #3
    pulmonary embolism primary #3
    venous thromboembolism #3
    prolactin controls #3
    wells rule dvt #3
    vte denmark #3
    thombosis #3
    dimer blood #3
    heparins cancer #3
    combination wells score #3
    ddimer assays #3
    vte performance #3
    plethysmography impedance #3
    safely #3
    influence heparins #3
    simplified wells specificity #3
    lmwh #3
    patients wells #3
    ipe cancer patients #3
    stable acute #3
    recombinant hirudin rhir #3
    prevalence hemostatic abnormalities #3
    cohort study employees #3
    patients 6 months #3
    svt vte #3
    outcome venous #3
    vte 3 #3
    thrombophilic defect #3
    standard therapy treatment #3
    desogestrelcontaining #3
    dvt systematic differences #3
    diagnosis pulmonary embolism #3
    “gestalt #3
    patients venous #3
    healthy donor fmt #3
    apc protective #3
    older children vte #3
    mutation venous #3
    95 wells rule #3
    subcutaneous lmwh #3
    pulmonary embolism‐related death #3
    factor viiic #3
    venous thrombosis cancer #3
    definition perelated death #3
    vte major burden #3
    approaches primary #3
    incidence enoxaparin #3
    pad smokers #3
    nct00643201 #3
    outpatient treatment dvt #3
    antithrombin iii concentrate #3
    presenting location #3
    predictable pharmacokinetics #3
    composite stroke #3
    02011 #3
    multiple comorbidities polypharmacy #3
    studies hemorrhage #3
    adult patients vte #3
    thromboembolism low #3
    single diagnostic #3
    failurerate #3
    6575 years #3
    coagulation influence #3
    venous thrombosis travel #3
    selectine #3
    venous arterial #3
    hokusai‐vte #3
    venous thrombosis positive #3
    mechanisms heparin #3
    cancer active cancer #3
    compensated dic #3
    capillary blood sample #3
    diagnosis deep #3
    hasbled #3
    ddimer threshold #3
    cancer patients ate #3
    ultrasonography strategies #3
    20210ga #3
    tfindependent #3
    axa activity #3
    discontinuation ufh #3
    enoxaparin follow #3
    bleeding major #3
    pph lmwh #3
    rnapc2 fviia #3
    activecontrol #3
    negative predictive proportion #3
    hf severity risk #3
    thrombophlebitis treatment #3
    recurrent thromboembolic #3
    coagulation air travel #3
    endogenous apc #3
    treatment vka #3
    patients ft4 level #3
    treatment vte recurrence #3
    diagnosis pulmonary #3
    age annual incidence #3
    dalteparin difference #3
    safely exclude #3
    deep vein #3
    cardiac troponine #3
    incidental pulmonary embolism #3
    therapy venous #3
    einstein studies #3
    einstein patients #3
    nadroparin placebo #3
    studies cus strategies #3
    dose reduction edoxaban #3
    cancer patients ipe #3
    3633 patients #3
    ft4 risk #3
    efficacy heparin #3
    embolism‐related #3
    patients proximalvein thrombosis #3
    idiopathic venous #3
    tinaquant assay #3
    low probability models #3
    idrabiotaparinux #3
    introduction mdct #3
    favour lmwh #3
    treatment lowmolecularweight heparin #3
    female hemorrhage humans #3
    venous thromboembolism thrombophilia #3
    monoclonal replacement #3
    revised geneva efficiency #3
    vein thrombosis #3
    lmwh pph #3
    gestalt 95 #3
    travel venous thrombosis #3
    vte low #3
    safely excluded #3
    heparin edoxaban #3
    ventilation scan #3
    fxiaso #3
    pulmonary embolism gestalt #3
    products follow #3
    factors prothrombin #3
    12month study period #3
    bleeding 3 #3
    extensive screening #3
    normal result #3
    einstein dvt #3
    strategies efficiency #3
    dip placebo #3
    dvt primary #3
    knee factor #3
    warfarin subgroup #3
    crt cancer patients #3
    safety acenocoumarol #3
    placebo n4 #3
    vte venous thrombosis #3
    primary rule #3
    topic heparin heparin #3
    treatment vitamin antagonists #3
    death clinical studies #3
    cdr combination #3
    detection dvt #3
    patients gastrointestinal cancer #3
    impedance predictive #3
    thiophenes venous #3
    ctnt risk stratification #3
    time venous thrombosis #3
    patients ultrasonography #3
    tb‐402 #3
    lowmolecularweight heparin placebo #3
    chemotherapy prophylaxis #3
    proximalvein thrombosis #3
    100 years year #3
    wells rule gestalt #3
    normal ctnt presentation #3
    patients incidental vte #3
    users incidence #3
    outpatients dvt #3
    administration rnapc2 #3
    treatment low #3
    prevalence avws #3
    alternative diagnoses #3
    iii deficiency #3
    recurrence thrombophlebitis #3
    cancer randomised trials #3
    sensitivity compression #3
    baseline values placebo #3
    intravenous loading dose #3
    lowmolecularweight humans length #3
    incidence total vte #3
    venous thromboembolism apixaban #3
    3month vte incidence #3
    dvt hip #3
    dvt einstein #3
    probability dimer #3
    3month incidence #3
    female humans inhibitors #3
    patients 6575 years #3
    subcutaneous fondaparinux #3
    thromboembolism background #3
    patients venography #3
    oral hormonal cross #3
    rfviia injection #4
    venous thromboembolism patients #4
    episode venous #4
    protecht #4
    thromboembolism occurred #4
    thromboembolism treatment #4
    vte highincome countries #4
    abdomen relationship #4
    clinically relevant bleeding #4
    diagnostic management #4
    lmwh female heparin #4
    received warfarin #4
    criteria dose reduction #4
    vte treatment patients #4
    thrombophilia 95 #4
    nct00571649 #4
    mbe patients #4
    “reversal #4
    advanced cancer 95 #4
    netherlands pulmonary #4
    thrombosis uedvt #4
    activation fibrinolytic #4
    vitamin antagonist treatment #4
    chinese korean ethnicity #4
    lowmolecularweight heparin #4
    point dimer #4
    thrombosis deep #4
    ultrasonography venous #4
    primary failure rate #4
    patient category #4
    extended treatment #4
    women normal levels #4
    patient education treatment #4
    embolism dimer #4
    vte global #4
    cleavage sites apc #4
    thromboembolism study #4
    embolism tomography #4
    ddimer assay patients #4
    impedance plethysmography #4
    rule pulmonary #4
    serial impedance plethysmography #4
    population rivaroxaban #4
    0651 #4
    global disease burden #4
    enoxaparin female humans #4
    vte global burden #4
    enoxaparin day #4
    tinaquant #4
    patients dimer #4
    thrombosis symptomatic #4
    335 patients #4
    lmwhs standard heparin #4
    fibrin generation test #4
    warfarin 3 months #4
    serial impedance #4
    thromboembolism systematic #4
    estrogen therapy patients #4
    apixaban efficacy #4
    hemorr2hages #4
    postthrombotic symptoms #4
    global burden vte #4
    travel thrombosis #4
    oral rivaroxaban #4
    chemotherapy vte prophylaxis #4
    150 microg levonorgestrel #4
    pregnancies carriers #4
    thrombosis ischemic stroke #4
    proximal patients #4
    patients edoxaban #4
    diagnostic prediction models #4
    procoagulant factors #4
    total vte #4
    safety pravastatin #4
    clot resolution #4
    rviia thrombin generation #4
    embolism roc #4
    chromogenic compounds #4
    preexisting heparin #4
    bleeding anticoagulants #4
    venography patients #4
    series venograms #4
    negative point #4
    patients venous thromboembolism #4
    thromboembolism factor #4
    gramnegative bacteria humans #4
    contraindications treatment #4
    patients alternative diagnosis #4
    cancer vwf #4
    life duration #4
    3587 #4
    disease burden vte #4
    daily netilmicin #4
    dutch orthopedic #4
    hyperhomocysteinemic relatives #4
    risk vkas #4
    thromboembolism arterial #4
    patients submassive #4
    rivaroxaban 20 #4
    recurrent vte months #4
    refuted #4
    control anticoagulation #4
    thromboembolism vitamin #4
    probability prospective #4
    chads2 p0001 #4
    levels ft4 #4
    chemotherapy shr #4
    primary pulmonary embolism #4
    dimer assays #4
    clot lysis patients #4
    questionnaires venous #4
    diagnostic management strategies #4
    coagulation factors risk #4
    arterial thrombotic #4
    lowmolecular weight heparins #4
    ageadjusted cutoff patients #4
    predilution postdilution #4
    150 microg desogestrel #4
    noacs netherlands #4
    vte netherlands #4
    thrombophilic families #4
    disease vte #4
    35±4 #4
    embolism background #4
    coagulation endotoxin #4
    vitamin antagonists patients #4
    risk occult cancer #4
    measurement abi #4
    vka treatment #4
    symptomatic deep #4
    hemostatic profile #4
    women apc resistance #4
    thrombosis air #4
    vitamin antagonists #4
    venous thrombosis levels #4
    prophylaxis lmwh #4
    leiden carriers #4
    noacs cancer patients #4
    patients clinically #4
    edoxaban patients #4
    patients fondaparinux #4
    patients nonpermanent #4
    doac studies #4
    patients primary healthcare #4
    treatment unfractionated heparin #4
    lmwh cancer patients #4
    death survey #4
    vte total #4
    amadeus trial #4
    idiopathic venous thrombosis #4
    patients crcl 60 #4
    diagnosis uedvt #4
    dose noacs #4
    10172 #4
    6 months prophylaxis #4
    sankyo #4
    normal ctpa #5
    daiichi sankyo #5
    endotoxin chimpanzees #5
    specificity thrombophlebitis #5
    inhibition plasminogen activation #5
    thromboembolism idraparinux #5
    iii plasminogen #5
    patients parenteral anticoagulants #5
    diagnosis questionnaire #5
    endotoxin testing #5
    dimer combination #5
    2 rules #5
    deepvein thrombosis #5
    secondary dvt #5
    pregnancy pph #5
    treatment fondaparinux #5
    cdr patients #5
    clinical probability #5
    elevated plasma level #5
    dvt prevalence #5
    thromboembolism thrombosis #5
    gestalt #5
    coc pregnancy #5
    rivaroxaban enoxaparin vka #5
    outcome major #5
    embolism reproducibility #5
    day rivaroxaban #5
    vte patients cancer #5
    thrombosis upper #5
    endogenous activated #5
    risk prediction scores #5
    low‐molecular‐weight #5
    coronary angioplasty angioplasty #5
    fh patients cvd #5
    adjusted dimer #5
    pulmonary embolism patients #5
    asymptomatic carriers mutation #5
    secondary venous thrombosis #5
    thromboembolism studies #5
    repeated ultrasonography #5
    preschool contraceptives #5
    thrombophlebitis ultrasonography #5
    severe pph women #5
    fviia rnapc2 #5
    bleeding cancer #5
    upper extremity thrombosis #5
    suspected uedvt #5
    patients pulmonary embolism #5
    fviii families #5
    molecularweight heparin #5
    lmwh recommended #5
    thromboembolism #5
    sensitivity negative predictive #5
    hirudin treatment #5
    ventricular dysfunction echocardiography #5
    medea study #5
    low molecularweight humans #5
    women warfarin #5
    phlebography plethysmography #5
    heparin compared #5
    patients recurrent dvt #5
    antithrombotic drug treatment #5
    vte 6 #5
    outpatients hospital #5
    pad smoking #5
    netilmicin patients #5
    8491 #5
    venous thromboembolism studies #5
    diagnostic strategies #5
    thrombosis leg #5
    burden vte #5
    exclusion venous thromboembolism #5
    patients wells score #5
    thrombosis primary #5
    cgp 39393 #5
    predilution #5
    patients subtherapeutic #5
    compression ultrasound #5
    cancer strategy #5
    previous venous thromboembolism #5
    lmwh incidence #5
    consensus strategy #5
    vte factor #5
    transfusion blood loss #5
    vka patients #5
    recurrent dvt patients #5
    8292 #5
    clinical presentation clinical #5
    clinical probability assessment #5
    patients superficial thrombophlebitis #5
    treatment acute dvt #5
    panwards #5
    factor leiden 95 #5
    incidence prognostic significance #5
    efficiency patients #5
    ft4 level #5
    southern latin america #5
    isolated calfvein thrombosis #5
    hokusai #5
    amplify #6
    lmwh cancer #6
    probability pulmonary #6
    funding bayer #6
    39393 #6
    factor leiden carriers #6
    warfarin venous thromboembolism #6
    patients suspected #6
    efficiency proportion #6
    svt extension #6
    leiden #6
    proportion cancer patients #6
    12month cumulative incidence #6
    assay fibrin #6
    thrombosis guidelines #6
    severe antithrombin #6
    endotoxininduced activation #6
    duration rivaroxaban #6
    subcutaneous nadroparin #6
    repeatedly normal #6
    synthetic pentasaccharides #6
    treatment ufh #6
    patients uedvt #6
    simplired dimer #6
    enoxaparin incidence #6
    perioperative blood loss #6
    thrombophilic defects #6
    lmwh users users #6
    compression stockings patients #6
    effects levonorgestrel #6
    patients lowmolecularweight heparin #6
    subjects vte #6
    neoplasms pulmonary embolism #6
    393 patients #6
    049 95 #6
    vte controls #6
    anticoagulant treatment #6
    effects ufh #6
    cancer primary patients #6
    c1173 #6
    recurrent pulmonary #6
    incidence recurrence #6
    combined utility #6
    oral anticoagulants dabigatran #6
    severe dic #6
    patients proximal #6
    thromboembolism bleeding #6
    vte cancer #6
    ultrasonography normal #6
    vte anticoagulant treatment #6
    treatment svt #6
    isolated deficiencies #6
    venograms #6
    treatment pulmonary embolism #6
    stressinduced hyperglycaemia #6
    fviia inhibition #6
    dvt trial #6
    rate major bleeding #6
    endotoxin assays #6
    dabigatran etexilate dabigatran #6
    elisapositive #6
    daily gentamicin #6
    low absolute risk #6
    oral edoxaban #6
    d‐dimer testing #6
    risk increasing levels #6
    selective beta #6
    embolism pulmonary #6
    dimer cut #6
    conventional therapy treatment #6
    patients anticoagulation clinic #6
    women hyperhomocysteinemia #6
    10±4 #6
    patients tests #6
    embolism ventricular #6
    outcome occurred #6
    initial heparin treatment #6
    dalteparin dose #6
    grade 1a ufh #6
    levonorgestrel desogestrel #6
    vka #6
    pembqol questionnaire #6
    patients pulmonary angiography #6
    symptomatic legs #6
    patients iohexol #6
    edoxaban efficacy #6
    myocardial infarction ctni #6
    clinically relevant subgroups #6
    patients diagnostic #6
    pulmonary embolism presence #6
    wells rule #6
    risk khorana score #6
    apixaban treatment dose #6
    arterial cardiovascular #6
    anticoagulants hemorrhage #6
    standardized morbidity ratio #6
    blood coagulation mechanism #6
    anticoagulants female #6
    treatment intermittent claudication #6
    subcutaneous low #6
    patients factor mutation #6
    ft4 patients #6
    diagnostic workup #6
    symptoms intermittent claudication #6
    prevalence vte #6
    antagonists treatment #6
    fixeddose regimen #6
    597939 #7
    pulmonary embolism sensitivity #7
    diagnosis venous thrombosis #7
    aspirin combined #7
    venous thrombosis treatment #7
    tnf injection #7
    negative ddimer test #7
    dvt ipg #7
    silent pulmonary embolism #7
    lung scan #7
    diagnostic suspicion #7
    factor female humans #7
    thromboembolism vte #7
    etexilate oral #7
    perelated death #7
    relation levels #7
    220 dabigatran #7
    major bleeding vkas #7
    vitamin antagonists vka #7
    unselected women #7
    major bleeding rate #7
    patients standard heparin #7
    thrombophlebitis adolescent #7
    carriers venous thromboembolism #7
    protein protein deficiencies #7
    680 #7
    relation prolactin levels #7
    primary efficacy #7
    blood coagulation humans #7
    combination ipg #7
    leg ultrasonography #7
    recurrent dvt #7
    placebo rivaroxaban #7
    neoplasms pulmonary #7
    heparin org #7
    administration bsf #7
    prothrombin risk #7
    noncompressibility #7
    vka therapy #7
    carriers defects #7
    thrombophilia pregnancy loss #7
    inhibitor apixaban #7
    treatment doac #7
    statin treatment risk #7
    presence cteph #7
    antithrombin protein #7
    day initial treatment #7
    general practitioners guideline #7
    ufh treatment #7
    specific antidotes #7
    major bleeding #7
    tb402 #7
    thromboembolism adult #7
    coagulation humans #7
    spiral sensitivity #7
    deepvein thrombosis patients #7
    plasma levels ifngamma #7
    incidence recurrent vte #7
    rates edoxaban #7
    nondiagnostic lung scans #7
    anticoagulant parameters #7
    primary dvt #7
    levels factor viii #7
    phenprocoumon polymorphism #7
    negative predictive npv #7
    proportion older patients #7
    ottawa score #7
    vte cancer diagnosis #7
    arterial cardiovascular disease #7
    mutations factor viii #7
    thromboembolism total #7
    stockings control #7
    doppler skin #7
    mpc1609 #7
    embolism prospective #7
    rivaroxaban 10 #7
    dimer tests #8
    agnelli #8
    deficiency antithrombin #8
    severe preeclampsia patients #8
    treatment venous thrombosis #8
    proximal deep #8
    anticoagulants antineoplastic #8
    increased fibrinolytic #8
    oral apixaban #8
    lmwh grade 1a #8
    administration low #8
    objectively confirmed #8
    oac adherence #8
    1599 patients #8
    point ultrasonography #8
    leiden prothrombin #8
    150 enoxaparin #8
    oral glucocorticoids risk #8
    thrombosis prophylaxis #8
    years cumulative incidence #8
    enoxaparin vka #8
    inherited thrombophilic #8
    unprovoked vte patients #8
    thrombosis adolescent #8
    probability lung #8
    patients extended anticoagulation #8
    nondiagnostic scan #8
    contrast venography #8
    testing rule #8
    vte score #8
    tests pulmonary #8
    wells scores #8
    euro55 #8
    overt cancer #8
    prevention vte #8
    optimal intensity #8
    fxi aso #8
    pvoct #8
    recurrent vte mb #8
    bnp ctnt #8
    discontinuation anticoagulant treatment #8
    international organisations #8
    initial heparin #8
    consecutive outpatients #8
    venous thrombosis hyperhomocysteinaemia #8
    physicians stockings #8
    current approach #8
    low clinical probability #8
    arg506 factor #8
    patients symptomatic vte #8
    compression surveys #8
    persistent risk factors #8
    heparin vitamin antagonists #8
    symptomatic deepvein thrombosis #8
    ageadjusted ddimer cutoff #8
    funding daiichi #8
    nafronyl #8
    chemotherapy low risk #8
    structured algorithm #8
    dimer concentration #8
    97 95 #8
    patients excluded #8
    ufh initial treatment #8
    cancer pulmonary embolism #8
    analysis apixaban #8
    inr values patients #8
    risk employees #8
    comorbidity polypharmacy #8
    acute symptomatic vte #8
    xii deficient #8
    prospective management #8
    p0001 hasbled score #8
    anticoagulation unprovoked vte #8
    vitamin antagonists vkas #8
    levonorgestrelcontaining #8
    risks dvt #8
    vka lmwh #8
    occult cancer patients #8
    aged phlebography #8
    normal computed #8
    products humans #8
    0·2 #8
    recurrent vte bleeding #8
    v617f jak2 #8
    warfarin hazard ratio #8
    proximal deepvein thrombosis #8
    duration treatment #8
    homocysteine markers #8
    carriers fvl #8
    apixaban enoxaparin #8
    inr determination #8
    vascular endothelial barrier #8
    incidental pulmonary #9
    thrombosis compared #9
    months efficacy #9
    therapeutic dose patients #9
    factors thrombophlebitis #9
    embolism venous #9
    bled bleeding #9
    thromboembolism cancer #9
    carriers factor leiden #9
    male oligosaccharides #9
    cancer factor #9
    ultrasonogram #9
    nonpermanent #9
    weight heparin #9
    abnormal vaginal #9
    oral antithrombins #9
    cofact #9
    independent committee #9
    postdilution #9
    major bleeding treatment #9
    generation pill #9
    iii concentrate #9
    crcl 60 #9
    characteristics severity #9
    compression stockings prevention #9
    cancer cell extravasation #9
    büller #9
    vte relatives #9
    strategies dimer #9
    enoxaparin factor #9
    patients active cancer #9
    combination stroke #9
    placebo plasma levels #9
    method enoxaparin #9
    hemorr2hages atria #9
    diagnosis mdct #9
    normal ddimer #9
    patients fxa inhibitors #9
    discontinuing anticoagulation #9
    lmwh mortality #9
    acute medical illnesses #9
    concomitant cancer #9
    thrombosis venous thromboembolism #9
    longterm treatment vte #9
    daiichisankyo #9
    oral contraceptive pregnancy #9
    fxa inhibitor #9
    serotonin platelet #9
    treatment prophylaxis #9
    fondaparinux cancer patients #9
    tafi levels #9
    vte rcts #9
    homocysteine women #9
    thrombosis thromboinflammation #9
    atiii concentrates #9
    comorbidities polypharmacy #9
    lipoproteina women #9
    cancer episode #9
    heparin therapy patients #9
    apixaban oral factor #9
    prothrombin 20210a #9
    edoxaban major bleeding #9
    diagnostic prediction model #9
    anticoagulant pathways #9
    incidence postthrombotic syndrome #9
    treatment edoxaban #9
    embolism patients #10
    rabbits administration #10
    intimamedia thickness imt #10
    thr incidence #10
    patients endotoxemia #10
    protein dic #10
    crp test #10
    oral thrombin inhibitor #10
    treatment uedvt #10
    100 years discontinuation #10
    leg veins #10
    anticoagulants #10
    cvd fh patients #10
    cus diagnosis #10
    schedule heparin #10
    ageadjusted cutoff #10
    cancer patients lmwh #10
    thrombophlebitis adult #10
    deficiencies antithrombin #10
    patients venous thrombosis #10
    1215 patients #10
    incidence major bleeding #10
    treatment vitamin #10
    oral administration dabigatran #10
    ddimer concentration #10
    magellan trial #10
    factor levels patients #10
    inherited thrombophilic factors #10
    inr cases #10
    aged antithrombin #10
    asymptomatic pulmonary embolism #10
    induced coagulation #10
    fondaparinux risk #10
    magellan study #10
    venous thrombosis #10
    incidence 1000 personyears #10
    injection avidin #10
    fii mutation #10
    bled scores #10
    extremity deep #10
    vnv #10
    rates recurrent vte #10
    gramnegative septicemia #10
    treatment aprotinin #10
    embolism clinical #10
    vte efficacy #10
    dvt lower extremity #10
    major bleeding crnmb #10
    heparin nomogram #10
    animal heparin #10
    retrospective study efficacy #10
    normohomocysteinemic #10
    wells #10
    rfviia blood loss #10
    venous thromboembolic event #10
    probability pulmonary embolism #10
    hypocoagulable state #10
    4470 #10
    nadroparine #10
    single loss #10
    snp scores #10
    year years #10
    subcutaneous metaanalysis #10
    simplified geneva #10
    factor prevention #10
    pregnancy carriers #10
    598 patients #10
    lmwh studies #10
    thrombosis background #10
    severity clinical #10
    cancer patients vte #10
    vte vwf #11
    gentamicin treatment patients #11
    factor venous #11
    patients probability #11
    patients cancer vte #11
    cancer patients evidence #11
    haemophilia vwd #11
    edoxaban #11
    screening cancer #11
    750 μg #11
    previous venous #11
    cancer patients dvt #11
    pulmonary angiography venography #11
    lmwh pregnancies #11
    fondaparinux hemorrhage #11
    pyridines thiazoles #11
    d‐dimer levels #11
    endotoxin assay #11
    30 microg ethinylestradiol #11
    incidence major #11
    reference testing #11
    recombinant human tnf #11
    sulfates dermatan #11
    patients anticoagulant treatment #11
    embolism recurrence #11
    oral dabigatran #11
    clinical pretest #11
    adult anticoagulants #11
    hospital lmwh #11
    intensity anticoagulation #11
    combination dimer #11
    880 patients #11
    dvt #11
    medical conferences #11
    weight humans #11
    air travel #11
    embolism prevalence #11
    knee clinical trials #11
    mutations prevalence #11
    pcc dabigatran #11
    lmwh pregnancy #11
    gps training #11
    pulmonary embolism incidence #11
    heparinoid org #11
    carriers factor #11
    variation inr #11
    ufh studies #11
    inhibitors hemorrhage #11
    dabigatran enoxaparin #11
    thromboembolism major #11
    levels prolactin #11
    org 10172 #11
    endotoxin pentoxifylline #11
    crnmb 95 #11
    patients cvcs #11
    pregnancyrelated complications #11
    ldfr #11
    livebirth rate #12
    observation risk #12
    treatment crt #12
    bnp cardiac troponin #12
    outpatient management patients #12
    event recurrence #12
    perelated #12
    safety efficiency #12
    9702 #12
    anticoagulation unprovoked #12
    fondaparinux unfractionated heparin #12
    warfarin recurrent vte #12
    geneva score #12
    dvt treatment #12
    recurrent vte anticoagulation #12
    recurrent vte #12
    prevention venous thrombosis #12
    control metaanalysis #12
    female heparin humans #12
    humanized arthroplasty #12
    thrombosis dvt #12
    patients incidental #12
    9295 #12
    outcomes venous thromboembolism #12
    ageadjusted ddimer #12
    annual incidence vte #12
    hirulog1 #12
    72 children #12
    topic venous #12
    pioped study #12
    patients lmwhs #12
    proximal veins #12
    risk venous #12
    warfarin treated #12
    doseadjustment #12
    patients lupus anticoagulant #12
    bayer schering pharma #12
    deficient women #12
    factor leiden prothrombin #12
    proximal vein #12
    warfarin therapy inr #12
    subsegmental pulmonary emboli #12
    thrombin generation fibrinolysis #12
    thrombophilic #12
    stopping anticoagulation #12
    hemodynamically stable #12
    vka noacs #12
    months primary #12
    nephro #12
    venous thromboembolism incidence #12
    women factor #12
    anticoagulant factor #12
    noacs vka #12
    paulin #12
    crd42013003526 #12
    vte recurrence risk #12
    concomitant disorders #12
    peghirudin #12
    dimer testing #13
    86 percent #13
    vte female humans #13
    vte recurrence 95 #13
    selective testing #13
    bleeding events edoxaban #13
    dabigatran 220 #13
    treatment venous thromboembolism #13
    dabigatran vte #13
    safety doacs #13
    rivaroxaban thiophenes #13
    pselectin patients #13
    95 carriers #13
    hematologic pregnancy trimester #13
    daily subcutaneous #13
    time prothrombin #13
    superficial thrombophlebitis #13
    levels factor #13
    marder score #13
    factor leiden mutation #13
    antithrombin iii activity #13
    heparin low #13
    uedvt #13
    conventional anticoagulants #13
    factor viii apc #13
    dvt lower #13
    strain gauge plethysmography #13
    vte major #13
    patients thrombophilia #13
    spiral computed tomography #13
    plethysmography #13
    vte #13
    bayer healthcare #13
    vte 64 #13
    category studies #13
    groups inr #13
    occult cancer #13
    concomitant antiplatelet therapy #13
    thrombosis acute #13
    plethysmograms #13
    arterial thromboembolism ate #13
    arixtra #13
    safety oral #13
    prevention venous thromboembolism #13
    vte groups #13
    nct00986154 #13
    obesity haemophilia patients #13
    indication anticoagulation #13
    patients anticoagulant #13
    association venous thrombosis #13
    dimer threshold #13
    inhibition tnf #13
    continuous intravenous heparin #13
    thrombosis young #13
    major hip #13
    inferiority efficacy #13
    ufh dalteparin #13
    deepvein thrombosis dvt #13
    clinical decision rules #13
    randomized cross #13
    recombinant hirudin rhirudin #13
    placebo rfviia #14
    crnm #14
    thrombophilia patients #14
    aged plethysmography #14
    experimental endotoxaemia #14
    atiii deficiency #14
    effects hyperthyroidism #14
    incidence severe pph #14
    pregnancy venous #14
    higher ddimer levels #14
    vte statin #14
    recurrent venous #14
    plasminogen apoa #14
    fvl carriers #14
    safety edoxaban #14
    treatment duration patients #14
    conventionaltherapy #14
    cadherins endothelium #14
    aspirin women #14
    gastrointestinal bleeding patients #14
    costs dvt #14
    ultrasound strategies #14
    lmwh vka #14
    awareness pad #14
    cancer patients anticoagulation #14
    vte months #14
    patients dvt #14
    acute deep #14
    patients vka therapy #14
    thromboembolism age #14
    symptomatic pulmonary #14
    unprovoked vte vte #14
    obstetric complications women #14
    treated lmwh #14
    anticoagulant rivaroxaban #14
    revised geneva #14
    limited screening #14
    edoxaban warfarin #14
    aged anticoagulants #14
    loss women #14
    patients outpatients #14
    riete score #14
    standard heparin #14
    17 placebo #14
    12 kg1 #14
    thrombosis #14
    recurrent venous thromboembolism #14
    female fibrin #14
    patients acute vte #14
    edoxaban oral factor #14
    low molecular #14
    factor viii levels #14
    dvt lower extremities #14
    bolus intravenous injection #14
    doseranging study #14
    thrombosis diagnosis #15
    abdominal pelvic #15
    patients ctpa #15
    probability assessment #15
    established vte #15
    hyperthyroidism atrial fibrillation #15
    generation oral #15
    control subjects prevalence #15
    symptomatic events #15
    edoxaban treatment #15
    subcutaneous regimen #15
    500 pg #15
    arg506 #15
    vitaminkantagonists #15
    subcutaneous enoxaparin #15
    antagonist vka #15
    fondaparinux efficacy #15
    experimental thrombosis #15
    studies pulmonary #15
    patients vitamin antagonists #15
    cardiovascular diseases thrombosis #15
    recombinant factor viia #15
    thyroid hormone excess #15
    lomoparan #15
    cteph incidence #15
    inr range #15
    coc vte #15
    pregnancy outcome pregnancy #15
    clinically relevant endpoints #15
    primary safety outcome #15
    inr patient #15
    enoxaparin vte #15
    coagulation #15
    diagnosis venous #15
    treatment 12 months #15
    factor leiden #15
    oral direct factor #15
    anticoagulants patients #15
    prior venous thromboembolism #15
    arg562 #15
    activation contact #15
    doacs aspirin #15
    lmwh ufh #15
    thrombus growth #15
    prophylaxis venous thromboembolism #15
    khorana score #15
    thrombinography #15
    6 months placebo #16
    test clinical #16
    100 95 #16
    bleeding aged #16
    positivity threshold #16
    major bleeding anticoagulation #16
    ddimer levels patients #16
    factor inhibitor #16
    vterelated death #16
    abdomino #16
    vte khorana score #16
    deep venous thrombosis #16
    warfarin acenocoumarol #16
    arterial vascular events #16
    thrombosis low #16
    cancer screening patients #16
    combination clinical #16
    thromboembolism time #16
    thrombosis adult #16
    viia activity #16
    cancer cancer patients #16
    risk clinically #16
    factors major #16
    recurrent symptomatic #16
    postthrombotic syndrome children #16
    analysis rivaroxaban #16
    venous thrombosis warfarin #16
    avws patients #16
    netilmicin gentamicin #16
    impaired fibrinolysis #16
    occult cancer detection #16
    women unexplained #16
    thrombosis haemostasis #16
    patients acenocoumarol #16
    major bleeding events #16
    dvt lmwh #16
    subsequent pregnancy loss #16
    thrombosis association #16
    factor monoclonal #17
    management crt #17
    thromboembolism patients #17
    anticoagulants clinical #17
    ctscans #17
    mutation women #17
    516 patients #17
    patients overt hypothyroidism #17
    prohemostatic #17
    female humans vte #17
    vte edoxaban #17
    incidence pts #17
    diagnosis svt #17
    recurrent vte events #17
    lmwhs patients #17
    compared enoxaparin #17
    gentamicin netilmicin #17
    endotoxemia bacteremia #17
    hematoma heparin #17
    factors venous #17
    2688 #17
    dimer assay #17
    scan classification #17
    anticoagulant therapy patients #17
    patients impedance #17
    lower specificity #17
    12 months patients #17
    fibrinolysis treatment #17
    topic hemorrhage humans #17
    thrombosis clinical #17
    fragment f1 #17
    rivaroxaban oral factor #17
    vkorc1 gene #17
    women mutation #17
    pharmo record linkage #17
    dvt prevention #17
    excessive blood loss #17
    permanent patients #17
    anticoagulants drug #17
    aptt heparin #18
    women pregnancy loss #18
    023 #18
    venous thromboembolism rivaroxaban #18
    poc test #18
    4 clinical #18
    simplired #18
    stable anticoagulation #18
    vka edoxaban #18
    apc thrombin generation #18
    cancer vte #18
    combined form #18
    flight hours #18
    commercial airline pilots #18
    hivinfected patients cart #18
    proximal vein thrombosis #18
    weight adjusted #18
    outcome events #18
    treatment vkas #18
    thromboembolism venous #18
    prothrombin g20210a #18
    annual incidence #18
    vka vte #18
    warfarin hazard #18
    relevant nonmajor #18
    intravenous heparin therapy #18
    favor lmwh #18
    antithrombotic treatment patients #18
    thrombosis total #18
    lmwh doacs #18
    patients strategy #18
    edoxaban vte #18
    diagnostic strategy #18
    sanofi aventis #18
    thrombosis pulmonary #18
    symptomatic dvt #19
    fondaparinux enoxaparin #19
    patients elevated biomarkers #19
    56 95 #19
    antibodynegative #19
    dvt rivaroxaban #19
    edoxaban dose #19
    retropubic prostatectomy #19
    low platelets #19
    local angiogenesis #19
    ddimer tests #19
    ipdma #19
    adjusted dose #19
    fibrinolytic response #19
    recurrent venous thrombosis #19
    endogenous fibrinolysis #19
    systemic activation coagulation #19
    acute recurrent #19
    increased fibrinolytic activity #19
    treatment heparin #19
    increased risk relatives #19
    coagulation studies #19
    prognostic echocardiography #19
    venography sensitivity #19
    active search #19
    extended oral #19
    vwf vte #19
    oral dabigatran enoxaparin #19
    venous thromboembolism relatives #19
    35 women #19
    patients prevalence #19
    vitamin antagonist #19
    recurrence vte #19
    abnormal ultrasound #19
    ufh lmwh #19
    subcutaneous dalteparin #19
    lmwh patients #19
    patients derivation #19
    patients sspe #19
    patients major bleeding #19
    versions version #19
    thromboembolism administration #19
    objective testing #19
    doubleblinding #19
    studies factor #19
    blindly #20
    incidences death #20
    excluded patients #20
    synthetic cross #20
    cancer severity #20
    single criterion #20
    warfarin edoxaban #20
    residual venous #20
    absolute risk #20
    therapy rivaroxaban #20
    anticoagulation clinic #20
    distance treatment #20
    shr 95 #20
    abi measurement #20
    treatment vte #20
    new agent #20
    subsegmental #20
    ctnt bnp #20
    proteins thrombin #20
    malignancy time #20
    guidance ssc #20
    prothrombin mutation #20
    nadroparin #20
    patients ddimer testing #20
    standardtherapy hazard ratio #20
    symptomatic venous thrombosis #20
    intravenous injections #20
    thrombophilia vte #20
    versions questionnaire #20
    recurrence bleeding #20
    thrombosis ultrasonography #20
    established atherosclerosis #20
    risk thrombophilia #20
    antagonists vkas #20
    statin vte #20
    calf veins #20
    life venous thrombosis #20
    portola #20
    diagnostic workup patients #20
    antitpo #20
    impedance plethysmography ipg #20
    abi risk factors #20
    control situation #20
    compared ufh #20
    pregnancyrelated vte #20
    injections subcutaneous #20
    carriers prothrombin #20
    dabigatran 150 #20
    risk cohort study #21
    carriers noncarriers #21
    thrombosis anticoagulants #21
    fibrinolysis inflammation #21
    prothrombin 20210 #21
    occult malignancy #21
    hemostatic abnormalities #21
    concomitant anti #21
    treatment acenocoumarol #21
    venogram #21
    distance quality #21
    treatment apixaban #21
    ddimer concentrations #21
    major bleeding patients #21
    current standard treatment #21
    internists cardiologists #21
    thromb #21
    doacs lmwhs #21
    d‐dimer #21
    deep venous #21
    patients 3 months #21
    discriminatory performance #21
    vte patients #21
    outcome incidence #21
    hemodynamically stable patients #21
    disease ischemic #21
    treatment dvt #22
    dichotomously #22
    cmax ctrough #22
    bleeding treatment #22
    cttr #22
    ttr inr #22
    vascular endotoxins #22
    daily enoxaparin #22
    alternative anticoagulation #22
    dose subcutaneous #22
    acute vte #22
    patients immobilization #22
    dimer age #22
    patients recurrent symptoms #22
    venous thromboembolic #22
    riskbenefit ratio #22
    safety treatment #22
    patients severe hf #22
    lpa plasminogen #22
    doppler venous thrombosis #22
    host defense response #22
    recurrent thromboembolism #22
    hormonal cross #22
    anticoagulants humans #22
    public awareness #22
    time inr #22
    thrombophilia screening #22
    anticoagulants heparin #22
    patientyears #22
    n1157 #23
    elevated ctni #23
    ambulatory cancer patients #23
    direct factor inhibitors #23
    hasbled score #23
    clotbound thrombin #23
    prevalence venous thromboembolism #23
    vte studies #23
    percentage increase #23
    thromboembolism anticoagulants #23
    life pulmonary embolism #23
    fondaparinux #23
    recurrence venous #23
    patients coagulation disorders #23
    bidirectional relation #23
    development dic #23
    rivaroxaban dosing #23
    cancer patients risk #23
    kakkar #23
    011 #23
    odis #23
    2 investigators #23
    normal angiogram #23
    venous arterial thrombosis #23
    time platelet #23
    lower extremity amputation #23
    5392 #23
    gentamicin patients #23
    enoxaparin 40 #23
    standardduration #23
    bleeding complication #24
    fondaparinux placebo #24
    presence dvt #24
    specific antidote #24
    parameters fibrinolysis #24
    levels fviii #24
    therapy heparin #24
    patients acute treatment #24
    viiic #24
    a21gly #24
    patients severe bleeding #24
    049 #24
    rates venous thromboembolism #24
    thrombosis carriers #24
    independent external validation #24
    followup incidence #24
    food drugs #24
    years episode #24
    ddimer testing #24
    month incidence #24
    lowmolecularweight humans #24
    predefined criteria #24
    subtherapeutic #24
    overt hyperthyroidism #24
    ufh patients #24
    prevalence deficiencies #24
    desogestrel levonorgestrel #24
    recurrent thromboembolism patients #24
    safety fondaparinux #24
    patients abnormal perfusion #24
    recurrent pulmonary embolism #24
    lmwh treatment #25
    fibrinogen degradation #25
    suggestions improvement #25
    anatomical extent #25
    studies lmwh #25
    patients gastrointestinal bleeding #25
    cha2ds2vasc chads2 #25
    willebrand factor adamts13 #25
    expert radiologists #25
    middeldorp #25
    xii activity #25
    vte clinical #25
    factors anticoagulants #25
    specificity efficiency #25
    influence smoking #25
    fatima #25
    thromboembolism acute #25
    f1 2 levels #25
    amadeus #25
    sepsis intravascular coagulation #25
    perfusion lung scan #25
    treatment symptomatic #25
    rethoracotomy #26
    dalteparin ufh #26
    edoxaban vka #26
    patients essential thrombocythaemia #26
    edoxaban versus #26
    miscarriage stillbirth #26
    venous thromboemboli #26
    hormonal manipulation #26
    major bleeding bleeding #26
    doacs vitamin antagonists #26
    homozygous carriers #26
    rate recurrent vte #26
    unprovoked vte #26
    9715 #26
    failure rate #26
    events year #26
    viia complex #26
    parameters risk #26
    ecq #26
    patients cdr #26
    asymptomatic carriers #26
    thromboprophylaxis hospitalized patients #26
    patients symptomatic dvt #26
    treatment lmwh #26
    specificity negative predictive #26
    extremity venous #27
    cancer spread #27
    patients elevated levels #27
    anticoagulants blood #27
    thrombocytopenia antibodies #27
    vte thr #27
    0·63 #27
    patients 50 #27
    airline pilots #27
    training gps #27
    patients major hemorrhage #27
    current guidance #27
    enoxaparin female #27
    day 35 #27
    perfusion lung #27
    lowmolecularweight heparin patients #27
    thrombosis venous #27
    thrombophlebitis #27
    combined training #27
    female heterozygote #27
    nonmajor #27
    noncarriers 95 #27
    vte doacs #27
    months studies #27
    anticoagulants factor #27
    venous thromboembolism carriers #27
    unprovoked venous #27
    lmwh prophylaxis #27
    low molecularweight heparin #27
    treating physician #27
    npv patients #27
    unexplained #28
    objective tests #28
    coagulation tissue factor #28
    monitoring therapy #28
    receiving rivaroxaban #28
    pembqol #28
    cancer venous thromboembolism #28
    tests diagnostic #28
    vte 6 months #28
    presentation followup #28
    anticoagulants compared #28
    embolism retrospective #28
    rfviia placebo #28
    specific reversal agent #28
    factors recurrent #28
    patients unprovoked #28
    vitamin aged #28
    anticoagulation women #28
    acutely medical patients #28
    4650 #28
    hirudin therapy #28
    #28
    apc plasma #28
    pph severe pph #28
    therapeutic doses #28
    years year #29
    recurrence svt #29
    oral glucocorticoids #29
    dvt pulmonary embolism #29
    pulmonary embolism recurrence #29
    blind trials #29
    acenocoumarol patients #29
    aged morpholines #29
    current management strategies #29
    direct oral anticoagulants #29
    pulmonary angiography #29
    prediction scores #29
    thrombo #29
    pulmonary embolism death #29
    major bleeding rivaroxaban #29
    g20210a mutation #29
    heparin versus #29
    sex‐specific differences #29
    cindexes #29
    8240 #29
    thrombosis treatment #29
    1000 individuals #29
    dabigatran pcc #29
    plateletactivating antibodies #29
    authors incidence #29
    spread cancer #29
    bleeding increased #29
    pbac score #29
    thrombosis 95 #29
    aspirin placebo #29
    diagnosis dvt #29
    patients standard therapy #29
    patients avws #29
    resistance activated protein #29
    dutch famine #29
    aminoglycoside therapy #29
    septicemia #29
    subcutaneous heparin #30
    direct oral factor #30
    vte coc #30
    residual thrombosis #30
    ufh vte #30
    95 risk #30
    rule patients #30
    support techniques #30
    new anticoagulants #30
    thromboembolism warfarin #30
    prevention venous #30
    cancer venous #30
    administration pentoxifylline #30
    patients vte #30
    embolism risk #30
    xii factor #30
    f1 2 #30
    markers coagulation activation #30
    1000 personyears incidence #30
    costs diagnosis #30
    doac vka #30
    rfviia novoseven #31
    recurrent episode #31
    women recurrent miscarriage #31
    bled #31
    placebo observation #31
    vte ufh #31
    pharmacological prophylaxis #31
    term risk #31
    thromboembolism adolescent #31
    events 95 #31
    8755 #31
    recurrent patients #31
    standardtherapy #31
    iii activity #31
    antithrombotic therapies #31
    patients deepvein thrombosis #31
    rhir #31
    2 antiplasmin #31
    incidence cteph #31
    analysis reviewers #31
    dvt pulmonary #31
    incidence pph #31
    activation blood coagulation #31
    imaging sensitivity specificity #31
    inhibitor edoxaban #31
    recurrent vte patients #31
    extended prophylaxis #31
    experimental endotoxemia #31
    prevalence probability #31
    dimer cutoff #31
    apixaban placebo #31
    ventilation scintigraphy #31
    thromboprophylaxis risk #31
    0206 #31
    ufh fondaparinux #31
    leiden mutation #32
    low clinical #32
    year 95 #32
    ufh #32
    parenteral anticoagulation #32
    suspected patients #32
    treatment anticoagulants #32
    negative dimer #32
    generation patients #32
    netherlands predictive #32
    international society thrombosis #32
    factors thrombolytic #32
    age adjusted #32
    khorana score patients #32
    resistance activated #32
    factor female #32
    negative septicemia #32
    parenteral anticoagulants #32
    warfarin vte #32
    normal genotype #32
    varicosis #32
    warfarin risks #33
    subcutaneous male #33
    heparin lmwh #33
    chapter patients #33
    rhirudin #33
    active implementation #33
    nephrotoxicity gentamicin #33
    apixaban treatment #33
    low probability #33
    pulmonary angiogram #33
    anticoagulant protein #33
    additional tests #33
    prophylaxis vte #33
    data meta #33
    mega study #33
    cancer patients diagnosis #33
    factor viii patients #33
    activation factors #33
    unitage #33
    thromboembolism young #33
    pregnancy loss women #34
    9241 #34
    plasmin alpha #34
    control trials #34
    subsegmental pulmonary embolism #34
    phytonadione #34
    590 #34
    warfarin adult #34
    bilateral venography #34
    deficiency protein #34
    vte thrombophilia #34
    anticoagulant #34
    3 months treatment #34
    grade 1a #34
    apcsr #34
    10 95 #34
    compare efficacy #34
    hemorrhage heparin humans #34
    lmwh unfractionated heparin #34
    vte compared #34
    reocclusion patients #34
    thrombosis lower #34
    36 95 #35
    statin association #35
    weekly subcutaneous #35
    risk members #35
    enoxaparin prevention #35
    prevention model #35
    rviia #35
    radiologists diagnosis #35
    pph blood loss #35
    anticoagulants benzimidazoles #35
    neoplasms venous #35
    lung scanning #35
    surgery hip #35
    activation coagulation #35
    embolism #35
    patients efficiency #35
    viii levels #36
    peripheral endovascular #36
    factors travel #36
    venous thromboembolic disease #36
    4139 #36
    venous thromboembolism dabigatran #36
    treatment acute vte #36
    287 patients #36
    iii antithrombin #36
    1698 #36
    catheterrelated infection #36
    hellp patients #36
    thrombophilia venous #36
    regular monitoring #36
    acute symptomatic #36
    levels coagulation #36
    novoseven #36
    inherited risk factors #36
    riskbenefit #36
    dose reduction patients #36
    fibrinolytic activation #36
    fibrinogen depletion #36
    studies echocardiography #36
    factors thrombophilia #37
    ctpa patients #37
    perelated mortality #37
    vte increased #37
    ototoxicity nephrotoxicity #37
    magellan #37
    screening occult #37
    risk venous thrombosis #37
    outcome composite #37
    prophylactic heparin #37
    genotype 95 #37
    anticoagulants prevention #37
    rivaroxaban thromboprophylaxis #37
    suspected venous #37
    bagsvaerd #37
    recombinant hirudin #37
    cumulative incidence vte #37
    anticoagulant action #37
    warfarin 95 #37
    excluding #37
    tat complexes #37
    risk factors pts #37
    venography #37
    pad studies #37
    thrombosis humans #37
    lwmh #37
    recurrence day #38
    congenital deficiencies #38
    catheterrelated thrombosis #38
    3306 #38
    anticoagulants female humans #38
    fetal loss women #38
    patients ddimer levels #38
    sensitivity biomarkers #38
    rivaroxaban placebo #38
    vte cancer patients #38
    doac lmwh #38
    submassive pulmonary #38
    vte bleeding #38
    10 total #38
    age recurrence #38
    restenosis reocclusion #38
    2835 #38
    nonmajor bleeding #38
    coagulation protein #38
    doacs #39
    children familial hypercholesterolemia #39
    septic syndrome #39
    specificity patients #39
    277 patients #39
    compression stocking #39
    low molecular weight #39
    time compression #39
    superficial vein thrombosis #39
    enoxaparin placebo #39
    heparins lmwhs #39
    systemic inflammatory responses #39
    incidence patients #39
    continued treatment #39
    incidence cancer #39
    submassive #39
    subcutaneous intention #39
    fibrin fibrinogen #39
    diagnostic prediction #39
    embolus #39
    endotoxininduced #40
    common femoral vein #40
    patients normal #40
    thrombinantithrombin complexes #40
    clotting activation #40
    day 6 months #40
    dalteparin treatment #40
    standardized definition #40
    international clinical #40
    anticoagulant therapy #40
    fviiic #40
    tfmp #40
    activatable fibrinolysis #40
    pemb #40
    therapeutic dosages #40
    ambulatory cancer #40
    episode venous thromboembolism #40
    anticoagulation therapy patients #40
    arterial vascular #40
    grade 1a patients #40
    bleeding #40
    risk recurrent vte #41
    anticoagulated patients #41
    endotoxin induced #41
    7268 #41
    95 genotype #41
    heparin therapy #41
    calf vein thrombosis #41
    submassive pulmonary embolism #41
    cancer lmwh #41
    placebo 6 months #41
    triage tests #41
    pentasaccharides #41
    dabigatran etexilate #41
    lowmolecularweight heparins #41
    lung scintigraphy #41
    prophylaxis venous #42
    8101 #42
    neoplasms thrombosis #42
    anticoagulation risk #42
    netilmicin #42
    patients vasopressors #42
    cell extravasation #42
    patients silent #42
    major contributor #42
    patients prospective #42
    standardization committee #42
    type graft #42
    stroke thrombosis #42
    thrombosis administration #42
    initial treatment #43
    543 patients #43
    ischemic events #43
    rtap #43
    vkas patients #43
    warfarin anticoagulants #43
    venous thromboembolism vte #43
    post‐thrombotic syndrome #43
    probability patients #43
    cancer adjusted #43
    patients vte risk #43
    fetal loss #43
    heparin risk #43
    monthly incidence #43
    draft document #43
    venous thrombosis thrombophilia #43
    edoxaban therapy #44
    recurrent vte 95 #44
    uedvt patients #44
    restoration euthyroidism #44
    protein sepsis #44
    role coagulation #44
    10–14 #44
    experimental venous thrombosis #44
    expert physicians #44
    95 pulmonary embolism #44
    indications patients #44
    efficiency models #44
    factors thromboembolism #44
    nonvka oral anticoagulants #44
    mild hyperhomocysteinaemia #44
    enoxaparin risk #44
    20 30 #44
    rate venous #44
    patients tinzaparin #44
    wells score #45
    patients bnp #45
    coagulation activation #45
    years algorithm #45
    dose lmwh #45
    dvt patients #45
    treated warfarin #45
    coumarin therapy #45
    venous thrombotic #45
    dose adjusted #45
    fondaparinux patients #45
    oral direct #45
    95 warfarin #45
    revascularisation procedures #45
    day levels #46
    stroke risk assessment #46
    abtpo #46
    daily rivaroxaban #46
    pioped #46
    hospital outpatients #46
    extended duration #46
    patients unprovoked vte #46
    ssc isth #46
    percent confidence #46
    prothrombin fragment f1 #46
    major bleeding placebo #46
    healthcare settings #46
    treatment model #46
    standard therapy #46
    management venous #46
    bleeding rivaroxaban #46
    ruling #46
    bristol myers squibb #47
    new oral anticoagulant #47
    outcome vitamin #47
    ambulatory anticoagulants #47
    mechanical prophylaxis #47
    plasma ddimer levels #47
    male methimazole #47
    central venous lines #47
    roccurve #47
    iiia receptors #47
    episode vte #47
    boehringer ingelheim #47
    mutation pregnancy #47
    risk recurrent #48
    daiichi #48
    thrombotic burden #48
    rivaroxaban compared #48
    patients acute dvt #48
    patients pulmonary #48
    small studies #48
    subcommittee #48
    travel risk #48
    thromboprophylactic #48
    factors rivaroxaban #48
    diagnosis physicians #48
    fondaparinux heparin #48
    intermediate risk risk #48
    recurrence venous thromboembolism #48
    elevated plasma levels #48
    women aspirin #49
    calf vein #49
    rivaroxaban prevention #49
    factor viii deficiency #49
    levels protein #49
    lowmolecularweight heparin lmwh #49
    vte diagnosis #49
    enoxaparin #49
    dvt diagnosis #50
    acute respiratory insufficiency #50
    outpatient therapy #50
    buller #50
    vitamink antagonists #50
    intensity treatment #50
    treatment threshold #50
    atria patients #50
    incidence venous thromboembolism #50
    prospective diagnostic #50
    nonselective betablockers #50
    etexilate #50
    cardiac surgery mortality #50
    transient risk factor #50
    thromboembolism aged #50
    acenocoumarol #51
    effects coagulation #51
    global disease #51
    patients 11 #51
    discrimination model #51
    strategies treatment #51
    tomography pulmonary #51
    factor vte #51
    95 apixaban #51
    previous survey #51
    protein deficiencies #51
    normal perfusion #51
    lung scans #52
    pdvt #52
    3 month #52
    hematologic malignancies patients #52
    unnecessarily #52
    inhibitors heparin #52
    doacs vka #52
    lmwh fondaparinux #52
    risk venous thromboembolism #52
    patients comorbid conditions #52
    apixaban vte #52
    svt patients #52
    1·12 #52
    free thyroxine ft4 #52
    vte major bleeding #52
    hemostatic balance #53
    reported incidence #53
    warfarintreated patients #53
    cross study #53
    40 daily #53
    1522 #53
    thrombophilic factors #53
    postthrombotic syndrome #53
    preference patients #53
    479 patients #53
    thromboembolism prevention #53
    suspected venous thromboembolism #53
    absolute risks #53
    versus enoxaparin #53
    patients initially #53
    patients obese #54
    patients incidence #54
    bled score #54
    vte mortality #54
    378 patients #54
    major bleeds #54
    acquired risk factors #54
    pai1 levels patients #54
    034 #54
    antithrombotic drug #54
    thromboembolism death #54
    prethrombotic #54
    2537 #54
    chads2 cha2ds2vasc #54
    endocrine disorders #54
    familial thrombophilia #54
    male pulmonary embolism #54
    biological pan #55
    dosereduction #55
    methods randomized #55
    proximal extent #55
    treatment thresholds #55
    legs patients #55
    anticoagulants arthroplasty replacement #55
    nondeficient #55
    long term risk #55
    compared lmwh #55
    unfractionated heparin #55
    insurances #55
    unfractionated heparin ufh #55
    rivaroxaban #55
    preeclampsia hellp syndrome #56
    enoxaparin patients #56
    physicians guidelines #56
    venous outflow obstruction #56
    level mortality #56
    deficiency prevalence #56
    risk major bleeding #56
    vte death #56
    vasopressors #56
    inr values #56
    reduced capacity #56
    vitamin warfarin #56
    time event #56
    seventh accp conference #56
    weight heparins #56
    enoxaparin rivaroxaban #56
    tromboembólica #56
    20210a #56
    major bleeding apixaban #56
    calf dvt #57
    ctscan #57
    antithrombin iii heparin #57
    levels survival #57
    inhibitors female humans #57
    clinical models #57
    subsegmental pulmonary #57
    risk factors vte #57
    doacs patients #58
    inhibitors female #58
    malignancy mortality #58
    thrombin activatable #58
    fibrinolysis humans #58
    unfractionated heparin patients #58
    pharmo #58
    ruled #58
    spiral computed #58
    lowmolecular weight heparin #58
    acute venous thromboembolism #59
    risk periods #59
    incidence symptomatic #59
    safety warfarin #59
    direct oral #59
    risk factors sensitivity #59
    clot lysis time #59
    aventis #59
    factor generation #59
    warfarin treatment #59
    bias trial #59
    risk vte #59
    thrombosis aged #59
    mutation prothrombin #59
    heterozygous factor #59
    women difference #60
    prevalence pulmonary #60
    anticoagulants treatment #60
    pulmonary embolism 95 #60
    atrial fibrillation metaanalysis #60
    pediatric venous thromboembolism #60
    target inr #60
    hemorrhage humans #60
    constans #60
    acute pulmonary embolism #60
    fixeddose #60
    awareness risk factors #60
    079 95 #60
    benzimidazoles dabigatran #61
    3633 #61
    free thyroxine #61
    long‐term treatment #61
    rosendaal #61
    dvt 95 #61
    tests prevalence #61
    association protein #61
    hypocoagulable #61
    month surgery #61
    perfusion ventilation #61
    amuse #61
    cdr score #61
    combined contraceptives oral #62
    ttr patients #62
    human endotoxemia #62
    273 patients #62
    procoagulant state #62
    patients administration #62
    250 patients #62
    post thrombotic #62
    activated partial #62
    protein fibrinogen #62
    general practitioners patients #62
    informatizado #62
    physicians predictive #63
    smoking smoking cessation #63
    quantitative test #63
    women mutations #63
    revised geneva score #63
    treatment network #63
    33 women #63
    common odds ratio #63
    symptoms dvt #63
    cvrs #63
    factor leiden risk #63
    rivaroxaban lmwh #63
    venous thromboembolisms #63
    injection endotoxin #63
    management anticoagulation #63
    vte thromboprophylaxis #63
    superficial vein #64
    factor inhibitors #64
    patients aortic valve #64
    decision rules #64
    selfadjustment #64
    prior vte #64
    oral thrombin #64
    acute pulmonary #64
    vkas treatment #64
    postthrombotic #64
    bleeding events patients #64
    blinded trial #64
    dvts #64
    thrombophilic risk #64
    heparin fondaparinux #64
    cancer noncancer patients #64
    treatment pad #65
    accuracy diagnostic tests #65
    prevalence abnormalities #65
    prothrombin g20210a mutation #65
    stroke thromboembolism #65
    fvl vte #65
    ultrasonograms #65
    dvt sensitivity #66
    rapid triage #66
    death classification #66
    0 points #66
    newer anticoagulants #66
    elfa #66
    female heparin #66
    95 bleeding #66
    statin therapy risk #66
    axa #66
    risk factor thrombosis #66
    standard therapy patients #67
    1127 #67
    patients factor #67
    rate major #67
    atrial fibrillation stroke #67
    patients tertiles #67
    apixaban #67
    ranging study #68
    patients bnp levels #68
    3594 #68
    coagulation fibrinolysis #68
    patients benefits #68
    20210g #68
    05 95 #68
    perioperative blood #68
    fibrinolytic #68
    1894 #68
    academic medical centre #68
    postphlebitic #69
    justify #69
    ionis #69
    certoparin #69
    recurrent thrombosis patients #69
    heparin ufh #69
    thrombosis blood #69
    plasma interleukin #69
    suspected #69
    enfermedad tromboembólica #69
    vwfrco #70
    ischemic events patients #70
    rivaroxaban treatment #70
    mantelhaenszel #70
    aged predictive #70
    α2ap #70
    test patients #70
    patients protein #70
    gramnegative sepsis #70
    fixed dose #70
    withhold #70
    cutoff levels #70
    thrombosis recurrence #70
    elevated cardiac #70
    8190 #70
    major bleeding complications #70
    vte vka #71
    tests prospective #71
    diagnostic sensitivity specificity #71
    levels vwf #71
    unfractionated #71
    topic costs #71
    asymptomatic atherosclerosis #71
    thromboprophylaxis #71
    plasminogen plg #71
    clopidogrel placebo #71
    complications hematologic #72
    ddimer values #72
    hf studies #72
    versus vitamin #72
    new anticoagulant #72
    pooled rate #72
    elevated factor #72
    trifurcation #72
    activation prothrombin #72
    antithrombin iii iii #72
    patients lmwh #72
    viia factor #72
    overt hypothyroidism #72
    noacs #73
    ingelheim #73
    reversal agent #73
    soluble fibrin #73
    analysis diagnostic #73
    tomography spiral #73
    prolongations #73
    12 months 95 #73
    ddimer measurement #73
    suspected dvt #74
    carriers #74
    5395 #74
    2550 #74
    study selection #74
    soluble thrombomodulin #74
    1732 #74
    prethrombotic state #74
    longterm risk #74
    experimental metastasis #74
    dvt study #74
    2124 #74
    female hemorrhage #74
    proteins patients #74
    postoperative dvt #75
    incidence bleeding events #75
    selective factor #75
    retrospective follow #75
    carotid femoral arteries #75
    8492 #75
    2904 #75
    thrombolytic therapy patients #75
    1334 #75
    angiography ctpa #76
    duration thromboprophylaxis #76
    factor xii deficiency #76
    early time #76
    tests primary #76
    risk thrombosis #76
    extended anticoagulation #76
    combined contraceptives #76
    oral combined contraceptives #76
    individual patient #77
    patients secondary #77
    thrombosis pregnancy #77
    p023 #77
    social aspects #77
    boehringer #77
    unprovoked #78
    elevated dimer #78
    arterial thromboembolism #78
    20 daily #78
    arterial wall thickness #78
    ipg #78
    women thrombophilia #78
    female fibrinolysis #78
    suspected acute #79
    humans pulmonary #79
    vkas #79
    time therapeutic #79
    topic heparin #79
    vte fvl #79
    limulus test #79
    factor adult #79
    2486 #79
    efficacy agents #79
    daily bid #80
    validation models #80
    95 05 #80
    subhazard ratio #80
    alife #80
    thromboembolism incidence #80
    suspected cancer #80
    heterozygous deficiency #80
    vte rate #80
    bleeding mortality #80
    patient data #80
    sspe patients #80
    prothrombin complex concentrate #81
    weitz #81
    topic risk #81
    vascular events #81
    knee arthroplasty patients #81
    systemic inflammatory #81
    test evaluation #81
    walking distance #81
    outpatient basis #81
    lmwh vte #81
    3month followup #82
    mammography patients #82
    thrombosis thrombophilia #82
    placebo women #82
    prospective validation #82
    common practice #82
    50 micrograms #82
    timeperiods #82
    symptomatic carriers #82
    thrombosis incidence #82
    heparin prevention #82
    thrombolytic drugs #82
    clinical sign #82
    posthoc analysis #82
    crnmb #82
    287 #83
    patients thrombi #83
    elective coronary #83
    dimer patients #83
    2213 #83
    inhibitor dabigatran #83
    bleeding women #83
    bistro #83
    healthcare setting #84
    prophylactic dose #84
    inherited thrombophilia #84
    normotensive patients #84
    heparin treatment #84
    screening humans #84
    diagnostic outcome #84
    inhibitor rivaroxaban #84
    duration therapy #84
    peripheral vascular diseases #85
    endotoxins #85
    venous thrombosis patients #85
    anticoagulants antiphospholipid #85
    normal levels #85
    thrombosis svt #85
    asymptomatic dvt #85
    antithrombin iii protein #85
    venovenous hemofiltration #86
    elevated ddimer levels #86
    rhapc #86
    75 microg #86
    4576 #86
    dabigatran vka #86
    major bleeding warfarin #86
    10⁶ #86
    clinical impact #87
    vidas #87
    obstetric patients #87
    contact activation #87
    post‐hoc analysis #87
    ≤50 #87
    avws #87
    95 100 #87
    patients 28 #87
    acute venous #87
    cdr #88
    internist #88
    lmwhs #88
    3319 #88
    treatment statins #88
    washout period #88
    aged multicenter #88
    activation factor #88
    treatment incidence #88
    venographic #88
    4 points #88
    unexplained recurrent #89
    cytokine release #89
    beta blockers #89
    ventilation lung #89
    smoking incidence #89
    safety noacs #89
    anticoagulants dabigatran #89
    reversal strategies #89
    costs patient #89
    matisse #89
    stroke bleeding #89
    tests test #89
    ddimer #89
    vte venous thromboembolism #89
    severe hf #89
    rates major bleeding #89
    adequate treatment #89
    2293 #90
    vka dabigatran #90
    outweighs #90
    new patients #90
    pediatric venous #90
    thrombophilic risk factors #90
    primary thromboprophylaxis #90
    fibrinolytic factors #90
    venous thrombosis risk #90
    popliteal vein #90
    pyridines pyridones #91
    perfusion ratio #91
    60 95 #91
    20210 #91
    agents hemorrhage #91
    anticoagulants doacs #91
    thrombosis women #91
    inconvenience #91
    cdrs #91
    thromboembolism pregnancy #91
    combined clinical #92
    thrombotic disease #92
    prophylaxis incidence #92
    single intravenous #92
    anticoagulation reversal #93
    rivaroxaban edoxaban #93
    scenario analyses #93
    compression patients #93
    incidence knee #93
    direct thrombin inhibitors #93
    95 years #93
    children vte #94
    vte surgery #94
    heparins #94
    test result #94
    1027 #94
    atherogenic lipid #94
    125 patients #94
    hf severity #94
    patients symptomatic #94
    direct oral anticoagulant #95
    viia rfviia #95
    2 levels #95
    european consensus statement #95
    risk symptomatic #96
    xii deficiency #96
    fondaparinux treatment #96
    ddimer level #96
    efficacy rivaroxaban #96
    symptomatic vte #96
    6 12 months #96
    randomised crossover study #96
    fibrin generation #97
    invasive testing #97
    symptomatic pulmonary embolism #97
    pyrazoles pyridones #97
    studies evaluated #97
    doacs risk #97
    abnormal perfusion #97
    difference rates #97
    haemophilia patients #97
    tpa release #97
    2875 #98
    hypercoagulable #98
    activated protein apc #98
    supervised exercise therapy #98
    pregnancy postpartum period #98
    essential thrombocythaemia #98
    major bleed #98
    simplify #98
    16slice #98
    unselected #99
    perfusion scintigraphy #99
    probast #99
    hirudin #99
    lmwh warfarin #99
    2·0 #99
    risk arterial #99
    acute dvt #99
    fatty foods #100
    3 trials #100
    patient groups #100
    increasing levels #100
    gbd 2010 #100
    previews #100
    warfarin patients #100
    1116 #100
    doubleblind trial #100
    prevention recurrent #100
    morpholines #101
    factor viia #101
    aptts #101
    factor vii factor #101
    alternative diagnosis #102
    venous thromboembolism women #102
    pts patients #102
    40 microg #102
    265 patients #102
    enoxaparin fondaparinux #102
    low pretest probability #102
    cteph patients #103
    therapeutic consequences #103
    338 #103
    adjudicated #103
    arthroscopic anterior #103
    endogenous thrombin #103
    pregnancy puerperium #103
    doppler method #103
    antithrombin iii #104
    fibrin degradation products #104
    term treatment #104
    diagnostic imaging humans #104
    partial restoration #104
    assay variation #104
    recurrence women #104
    oral factor #104
    separate analyses #104
    absolute increase #104
    heparin pregnancy #104
    apparent increase #104
    7 children #105
    embryo loss #105
    1089 #105
    conventional therapy patients #105
    fibrinolytic systems #106
    thromboprophylaxis patients #106
    chest ray #106
    2479 #106
    thrombophilia #106
    hospitalized patients hf #106
    314 #106
    study total #106
    essentials #106
    blind double #106
    elevated levels #106
    thrombosis age #106
    simplified version #107
    survival cancer patients #107
    topic recurrence #107
    thromboembolic #107
    definition classification #107
    ddimer levels #107
    vte risk #107
    grade 1c #108
    cardiovascular death stroke #108
    human volunteers #108
    post thrombotic syndrome #108
    specific subgroups #108
    noncancer patients #108
    patients cancer #108
    500μg #109
    routine coagulation #109
    039 #109
    anticoagulants cohort #109
    evaluation studies #109
    embolism treatment #109
    factor mutation #109
    1235 #109
    synthetic pentasaccharide #109
    viia #109
    thrombin antithrombin #109
    antiplasmin #110
    primary safety #110
    embolism quality #110
    inferiority trial #110
    subsequent pregnancy #110
    cancer activity #110
    vka doac #110
    thrombosis treated #110
    negative predictive 100 #111
    humans intermittent #111
    predefined #111
    siset #111
    obstetric complications #111
    anticoagulants biomarkers #111
    treatment risk factors #111
    comparison control #111
    chromogenic #112
    emergency situations #112
    patients ventricular dysfunction #112
    thromboembolic diseases #112
    recurrence treatment #112
    rivaroxaban enoxaparin #112
    risk rivaroxaban #112
    epidemiology risk factors #112
    efficacy prevention #112
    patients 70 #112
    publication anticoagulants #112
    topic guidelines #112
    metabolic response #113
    lmwh risk #113
    nonionic contrast #113
    inappropriate treatment #113
    patients nephrotoxicity #113
    heterozygous carriers #113
    0·0 #114
    postphlebitic syndrome #114
    study centre #114
    cancerassociated vte #114
    patients intermediate #114
    total knee replacement #114
    dialysers #114
    global public #115
    393 #115
    hyperhomocysteinaemia #115
    fibrinogen vwf #115
    patients recurrent #115
    positive predictive values #115
    reference standard #116
    heparin warfarin #116
    effects tnf #116
    topic dabigatran #116
    agents heparin #116
    major bleeding 95 #116
    women severe preeclampsia #116
    vte data #116
    computed tomography patients #116
    life treatment #116
    anticoagulants arthroplasty #116
    vte children #117
    protein resistance #117
    2460 #117
    fibrinolytic parameters #117
    women caesarean #117
    protein inhibitor pci #117
    arthroscopies #117
    vte complications #117
    patients extensive #118
    proximal dvt #118
    4118 #118
    arterial thrombosis patients #118
    2744 #118
    autopsyconfirmed #118
    patients doac #119
    compared warfarin #119
    incidence pulmonary embolism #119
    compression stockings #119
    humans leg #119
    lactoferrin leukocyte #120
    mortality diseases #120
    thrombosis study #120
    dabigatran factor #120
    risk thromboembolism #120
    previous vte #120
    healthy humans #120
    acquired deficiency #120
    months follow #120
    rivaroxaban patients #120
    patients prostatic cancer #121
    thrombocytopenia thrombosis #121
    patients 6 #122
    oral hormonal #122
    anti factor #122
    studies venous #122
    fatal pulmonary embolism #122
    early dynamics #123
    heparin #123
    heparin hirudin #123
    acute infection #123
    100 patients #123
    venous thromboembolism pregnancy #123
    placebo standard #123
    minor bleeding #123
    factor xia #123
    statin risk #124
    treatment data #124
    atherogenic lipid profile #124
    vte lmwh #124
    association level #124
    ft4 levels #124
    thrombophilia pregnancy #124
    elevated liver enzymes #125
    thromboembolism recurrence #125
    peripheral arterial disease #125
    fibrinolysis inhibitor #125
    bayer #125
    puerperal disorders #125
    treatment indication #125
    skin perfusion #125
    diseases mortality #125
    nonsignificantly #125
    incidence thrombosis #125
    intravenous heparin #125
    doacs treatment #126
    upper extremity #126
    distal dvt #126
    occurrence vte #127
    thromboprophylaxis lmwh #127
    performance scores #127
    patients ventilation #127
    unacceptably #127
    patients permanent #127
    marder #127
    50 age #128
    prevention #128
    direct factor #128
    patients conventional therapy #128
    resistance apc #128
    development vte #128
    treatment months #128
    venous thromboembolism risk #128
    riete registry #129
    ctrough #129
    mortality cancer patients #129
    1041 #129
    060 #129
    elevated biomarkers #129
    220 #130
    hospital discharge records #130
    day 10 #130
    plaster cast #130
    internists #130
    anticoagulants antithrombins #130
    patients episode #130
    194 patients #130
    pooled incidence #131
    tests specificity #131
    linear interpolation #131
    obviating #131
    05 patients #131
    long‐term clinical outcomes #131
    hypocoagulability #132
    hoc analysis #132
    postpartum period women #132
    rivaroxaban versus #132
    fxa inhibitors #133
    80 anticoagulants #133
    avidin #133
    enoxaparin treatment #133
    cha2ds2vasc #133
    started #133
    direct inhibitors #133
    risk pad #134
    pulmonary angiography patients #134
    embolism acute #134
    instituted #134
    rco vwf #134
    selectin levels #134
    anticoagulant prophylaxis #135
    prevalence dvt #135
    activator plasminogen #135
    bnp concentration #135
    east asian patients #136
    clinical prediction #136
    severe pph #136
    followup patients #136
    0056 #136
    months anticoagulation #136
    apixaban edoxaban #136
    thrombotic syndrome #136
    99 patients #137
    sequential application #137
    acquired thrombophilia #137
    phase 3 trials #137
    2283 #137
    point‐of‐care #137
    diagnostic work #137
    factor prothrombin #137
    national guidelines #138
    studies mortality #138
    antidote #138
    intravascular coagulation dic #138
    complete inhibition #138
    bleeding warfarin #138
    enhanced factor #138
    2465 #139
    3 weeks #139
    95 major bleeding #139
    oral anticoagulant treatment #139
    risk fatal #139
    direct inhibitor #139
    factor viii factor #139
    patients comparison #139
    reproducibility risk #139
    0114 #140
    80 cohort #140
    12 95 #140
    20 iu #140
    dvt incidence #140
    distal deep #140
    vwf rco #140
    human activated #140
    ottawa #140
    thromboembolic disorders #141
    pharmacy records #141
    antidotes #141
    thrombin potential #142
    carriership #142
    ischaemic events #143
    points 95 #143
    active malignancy #143
    geneva #143
    escherichia humans #143
    jugular veins #143
    warfarin administration #143
    treatment pulmonary #143
    pregnancy female humans #144
    topic practice patterns #144
    compared treatment #144
    doac treatment #144
    management vte #144
    postoperative venous #144
    fatal pulmonary #144
    filters venous #145
    hyperthyroxinemia #145
    serial testing #145
    patient populations #145
    dose rivaroxaban #145
    referred patients #145
    thrombosis model #145
    derived microvesicles #146
    protein factor #146
    death cancer patients #146
    months treatment #146
    tissue factor pathway #147
    personal fees #147
    rebuttal #148
    embolism diagnosis #148
    acute medical illness #148
    partial thromboplastin #148
    antithrombotic drugs #148
    2076 #148
    intention treat #148
    10 years patients #148
    long‐acting #148
    relevant publications #149
    risk subgroups #149
    vte hospitalization #149
    0·45 #149
    procoagulant #149
    individual patient data #149
    diagnostic score #149
    thrombocyte #149
    dimer level #150
    humans injections #151
    enoxaparin unfractionated heparin #151
    additional imaging #151
    coagulation dic #151
    continuous venovenous #152
    bleeding patients #152
    patient eligibility #152
    patients primary outcome #152
    longterm treatment #152
    hypercoagulable state #153
    point systems #153
    thrombosis prevention #153
    extracorporeal circuit #153
    cardiopulmonary bypass surgery #153
    dimer levels #154
    thrombosis factor #154
    activity mortality #154
    bleeding scores #154
    direct thrombin #154
    active cancer #154
    angioplasty patients #154
    tomography patients #155
    states venous #155
    thromboembolic event #155
    warfarin apixaban #155
    curve sensitivity #155
    drug factor #155
    fiia #155
    coagulant activity #156
    fvl #156
    stockings #156
    09 #156
    recurrent symptoms #156
    daily oral #156
    patients gastrointestinal #156
    enoxaparin dose #156
    vte treatment #156
    increased thrombin #157
    hemodynamically #157
    cross‐sectional survey #157
    prophylaxis patients #157
    dfl #158
    underlying malignancy #158
    duration anticoagulation #158
    months chemotherapy #158
    97 #158
    2126 #158
    adjusted relative risk #159
    increased risk thrombosis #159
    plasma dimer #160
    schering #160
    120 minutes #160
    guidelines prevention #160
    145 patients #160
    children fh #160
    antithrombotic efficacy #160
    thrombotic disorders #160
    antagonists patients #161
    prophylactics #161
    pvo #161
    women time #162
    incidence vte #162
    2206 #162
    lysine analogues #162
    patients imaging #162
    venous thrombus #163
    rates vte #163
    factors bleeding #163
    coagulation blood #163
    lmwh therapy #163
    increased plasma levels #163
    strain gauge #163
    imaging test #163
    198 patients #163
    age comorbidity #164
    justified #164
    inborn humans #164
    observer variability #164
    028 #164
    mutation factor #165
    subhazard #165
    patients enoxaparin #165
    relatives patients #165
    pravastatin therapy #166
    phlebography #166
    stockings compression #166
    strategies patients #166
    viii factor #166
    management venous thromboembolism #166
    microvascular thrombosis #166
    ankle brachial abi #167
    recurrent thrombosis #167
    3658 #167
    thrombin venous #167
    syndrome pts #168
    double heterozygosity #168
    warfarin #168
    cvcs #168
    treatment 3 months #168
    cstatistics #168
    recurrent acute #168
    current clinical practice #168
    therapeutic range #169
    fold increased #169
    postthrombotic syndrome pts #169
    3 12 #169
    risk profile #169
    patients infections #169
    preexistent #169
    cart patients #170
    heavy menstrual bleeding #170
    interobserver agreement #170
    thrombosis cancer #170
    postoperative blood loss #170
    recombinant factor #171
    aged algorithms #171
    venous thrombotic events #171
    57 years #171
    adamts‐13 #171
    patients blood transfusion #172
    clinical trials patients #172
    antifibrinolytic #172
    pulmonology #172
    lmw heparin #172
    vaginal bleeding #172
    risk factors patients #172
    bleeds #173
    pulmonary #173
    hospitalized medical patients #173
    inr #173
    patients initial #174
    laboratory monitoring #174
    arterial occlusions #174
    bleeding tendency #174
    clinically bleeding #174
    reocclusion #175
    arterial venous #175
    vte common #175
    data control #175
    fragment 1 #175
    picotamide #177
    mitsubishi #177
    prothrombin #177
    intention analysis #178
    short‐ #178
    aspirin ticlopidine #178
    122 #178
    hyperthyroidism hypothyroidism #178
    oral female humans #179
    noninferior #179
    vte event #179
    concomitance #179
    baseline day #179
    patients deficiency #180
    referral bias #180
    ventilation perfusion #180
    thromboplastin time #180
    isth #180
    additional risk factors #180
    aged partial #181
    testing patients #182
    antithrombin #182
    acute episode #182
    painkillers #182
    biological variation #183
    hyperhomocysteinemic #183
    patients major #183
    2–4 #183
    pregnancy vte #184
    subsequent diagnosis #184
    treat analysis #184
    coagulation factors #184
    thromboinflammation #184
    incidental #184
    prognosis pulmonary #184
    n110 #184
    4150 #184
    antithrombin iii atiii #184
    risk bleeding #184
    deficient patients #185
    vte age #185
    patients intensive units #186
    symptomatic #186
    hemostatic effects #186
    studies heparin #186
    live birth rate #186
    brain natriuretic #186
    anticoagulated #186
    patients thromboprophylaxis #186
    risk composite #187
    patients haemophilia #187
    antifibrinolytic agents #187
    cutoff level #187
    safety apixaban #187
    926 #188
    doacs vkas #188
    prevalence cancer #188
    absolute rate #188
    humans international #188
    spontaneous rupture #188
    ratio inr #188
    willebrand factor antigen #189
    fibrinolysis #189
    clinical validity #189
    blood loss patients #189
    riete #189
    64slice #189
    patients netherlands #189
    heparin administration #189
    viia female #189
    current views #190
    ccus #190
    thrombosis patients #190
    ischemic event #190
    anticoagulant drugs #190
    score patients #191
    gogh #191
    attending physicians #191
    acute thrombosis #191
    07 #191
    venous outflow #191
    stroke systemic #192
    1495 #192
    058 #192
    endothelial cell activation #193
    coagulation assays #193
    blood coagulation #194
    070 #194
    anticoagulation #194
    prothrombin activation #194
    heparin patients #194
    65 months #195
    risk major #195
    recurrent ischemic events #195
    antixa levels #195
    antagonist treatment #195
    target range #195
    complications cardiovascular #196
    abnormal test #196
    coagulation status #196
    29 95 #196
    treatment groups patients #198
    vii rfviia #198
    ate #198
    difference treatment #198
    sew2871 #198
    vwf adamts13 #198
    coagulation monitoring #199
    cachectin #199
    patient diagnosis #199
    incidence cardiovascular events #200
    patients 12 months #200
    screening patients #200
    obese controls #200
    patients abnormal #201
    thromboembolic disease #201
    validation sets #201
    vte incidence #201
    thrombin factor #201
    arterial thrombosis #202
    peritoneovenous #202
    17 95 #202
    johnson #202
    heparin dose #203
    worldwide survey #203
    invitees #203
    induced activation #203
    symptomatic pad #203
    levonorgestrel #204
    antithrombotic agents #204
    low incidence #205
    stroke systemic embolism #205
    thrombophilia risk #205
    0 95 #205
    period time #205
    extended thromboprophylaxis #205
    venous ultrasonography #206
    data synthesis #206
    varese #206
    patients anticoagulant therapy #206
    fgt #206
    methods consecutive #207
    platelet activation patients #207
    06 #207
    objectively #207
    death female humans #207
    desogestrel #207
    fviii #207
    cardiologist #207
    algorithms anticoagulants #207
    imt patients #207
    systematic review studies #207
    patients hypothyroidism #208
    thrombocythaemia #208
    bleeding compared #208
    deficiency risk #209
    free protein #209
    women frequency #210
    tgt #210
    antixa activity #210
    hirudins #210
    ioxaglate #211
    toxaemia #211
    stocking #211
    systemic embolism patients #211
    anticoagulation management #212
    atrial fibrillation study #212
    plasminogen activator activity #213
    heparitin sulfate #213
    topic practice #214
    correct interpretation #214
    dabigatran dose #214
    thrombin inhibition #215
    factors vte #215
    current developments #215
    studies rivaroxaban #215
    standard duration #215
    deamino #216
    warfarin stroke #216
    duplex venous #216
    community hospital #216
    betatg #216
    undergoing total #217
    mildest #217
    diagnostic algorithm #217
    obviates #217
    studies difference #217
    conclusive evidence #218
    cstatistic #218
    g20210a #218
    plasminogen activator inhibitor #218
    npv 100 #218
    cancer #219
    deamino arginine #219
    patients cart #219
    077 95 #219
    data extraction #220
    techniques female #220
    viii female #220
    vii factor #220
    hip replacement surgery #220
    postoperative vte #221
    healthy human subjects #221
    preventive measures #221
    hmvec #221
    heparin humans #221
    proximally #222
    vte events #222
    apc resistance #222
    engl #223
    substantial proportion #223
    pulmonologists #223
    1541 #223
    1 january #223
    subsequent cancer #224
    thromboendarterectomy #224
    protein pathway #224
    topic factor #224
    thrombosis warfarin #225
    neoplasms prospective #225
    balloon coronary anticoagulants #225
    kruskalwallis #225
    org #225
    extremity amputation #226
    vascular events patients #226
    0·67 #226
    inr monitoring #226
    16 95 #226
    acute medical #227
    tests diagnosis #227
    haemostasis #227
    35 ± #227
    ipe #228
    mild hyperhomocysteinemia #228
    residual thrombus #229
    scant #229
    dalteparin #229
    cgp #229
    advocated #230
    037 #230
    major orthopaedic surgery #231
    resource utilisation #231
    equinox #231
    urosepsis #231
    6 studies #231
    habitual abortion #231
    patients discontinuation #231
    severe preeclampsia #231
    ft4 #231
    thiazoles #231
    aspirin dipyridamole #232
    patients warfarin #232
    recurrence risk factors #233
    surgical embolectomy #233
    endogenous thrombin potential #233
    anticoagulant effects #233
    dimer #233
    cancer prevalence #233
    humans netherlands #233
    effective alternative #234
    graduated compression #235
    doac #235
    prothrombotic state #235
    brain natriuretic peptide #236
    venous thromboembolic events #236
    humans meta #236
    oral anticoagulants #237
    myocardial infarction 95 #237
    treatment continuation #237
    predictive tests #238
    patients vkas #238
    6500 #238
    009 #238
    crossover study #239
    factor tnf #239
    anticoagulants aspirin #239
    rational approach #239
    factor viii fviii #239
    arterial venous thrombosis #240
    patients initial treatment #240
    hip knee arthroplasty #241
    aspirin heparin #241
    045 #241
    bleeding incidence #242
    time therapeutic range #242
    pivotal trials #243
    prothrombin fragment #243
    patients intermittent claudication #243
    iohexol #244
    n89 #245
    vte risk factors #245
    children neonates #246
    casecontrol #246
    vte cases #246
    thrombogenesis #246
    23 95 #247
    warfarin aged #247
    lipoproteina levels #247
    antithrombotic #247
    coronary anticoagulants #248
    patients solid tumours #248
    committees #248
    treatment compared #248
    anti activity #248
    multiple comorbidities #249
    diagnostic models #249
    score risk #249
    bleeding rates #249
    ischemic strokes #250
    fv leiden #250
    protein risk #250
    ioxaglic #250
    microthrombosis #251
    patients contraindications #251
    finalized #251
    8595 #251
    simplification #252
    vkas doacs #252
    somit #252
    thrombin thrombosis #253
    incidence #253
    agents anticoagulants #254
    treatment duration #254
    palga #255
    fibrinolytic activity #255
    medea #256
    haul #256
    activation humans #256
    activity assay #257
    q24h #257
    continuous intravenous #257
    bleeding risk #257
    cost‐effectiveness #257
    clinical utility #257
    ctpa #258
    fibrin degradation #258
    patient subgroups #258
    unpublished data #259
    30 50 #259
    dvt risk #260
    sspe #260
    thrombus size #261
    noncarriers #261
    toxicosis #261
    heparin dosing #261
    patients hospitalization #262
    risk pulmonary #263
    optimal duration #263
    blind study #264
    graft type #265
    400 patients #266
    pbac #267
    einstein #267
    statins risk #268
    endotoxaemia #268
    relation time #269
    lysis time #269
    malignancy patients #269
    propeptide #269
    versus aspirin #269
    randomised cross #269
    discontinuing #270
    exclusion #270
    protein patients #270
    single test #270
    platelet serotonin #271
    3·0 #271
    protein apc #271
    orthopaedic patients #271
    hormonal replacement therapy #271
    thrombosis inflammation #271
    clopidogrel ticlopidine #272
    groups levels #272
    bleeding patient #272
    patients combination #272
    vte recurrence #272
    efficacy analysis #273
    ankle brachial #273
    prevalence pad #274
    risk levels #274
    cleavage sites #274
    months 12 #274
    international normalized #275
    performance score #275
    parenteral nutrition patients #275
    fourth quartile #276
    antithrombotic agent #276
    smoking hypertension #277
    time aptt #277
    normalized ratio #278
    imaging sensitivity #278
    dose reduction #278
    aptt #279
    blood test #279
    rco #279
    exclusion criteria #280
    hospitalized medical #280
    partial thromboplastin time #280
    intracranial hemorrhage patients #280
    propositi #280
    obviate #280
    patients presence #281
    thromboplastin #282
    diagnostic test #282
    diagnostic sensitivity #283
    thyroid diseases #283
    puerperal #283
    presentation patients #283
    neutrophil degranulation #283
    noninferiority margin #284
    test characteristics #284
    favor #284
    departments #284
    outpatient treatment #284
    animals anticoagulants #284
    major orthopaedic #285
    plasma bnp #286
    2630 #286
    gentamicin treatment #286
    patients apixaban #286
    patients pancreatic cancer #287
    clinically #287
    disseminated intravascular #287
    subdistribution #287
    levels measured #287
    227 #288
    oral combined #288
    premature atherosclerosis #288
    md patients #288
    vte women #289
    substantiation #289
    clot lysis #289
    cvt patients #289
    vte rates #289
    0·50 #290
    n59 #290
    thrombin time #290
    current clinical #291
    extracted data #291
    carriers mutation #291
    016 #291
    oral contraceptives #291
    2 studies #292
    activator inhibitor #292
    willebrand disease vwd #292
    1603 #292
    1000 personyears #293
    patients dabigatran #293
    plasmin activity #293
    pentasaccharide #293
    adverse outcome patients #293
    patients rivaroxaban #294
    lower extremities #294
    cardiac troponin ctnt #294
    tissuetype plasminogen activator #294
    scenario analysis #295
    1025 #295
    extremity dvt #295
    peripheral vascular #296
    classified #296
    coagulation factor viii #296
    observer agreement #297
    routine monitoring #297
    episode patients #298
    recurrent miscarriage #298
    thrombocytes #298
    specificity npv #298
    patients inr #299
    inferiority #300
    heparitin #301
    041 #301
    thromboglobulin #302
    toxemia #302
    subclinical thyroid dysfunction #302
    aged neoplasms #302
    155 patients #302
    absolute difference #304
    1214 #304
    rivaroxaban dabigatran #305
    prophylactic administration #306
    medline embase #306
    chimpanzees #307
    noninvasive testing #308
    complex concentrate #309
    vte pregnancy #310
    thrombotic #310
    surgery day #310
    hematologic pregnancy #310
    patients 100 #311
    clinical presentation #311
    percentage points #311
    antithrombins blood #311
    105 patients #311
    598 #312
    leg male #312
    negative reactions #313
    hereditary thrombophilia #313
    vte 95 #313
    obesity risk factor #313
    diagnosis #314
    funding #315
    heparin aspirin #315
    puerperium #315
    postpartum haemorrhage #315
    cardiologists #315
    therapeutic dose #316
    apixaban versus #316
    adjudicators #317
    patients followup #317
    0·92 #318
    deciding #318
    safety outcomes #319
    failure rates #319
    decision model #319
    influenza infections #320
    patients pregnancy #320
    catheter thrombosis #320
    1731 #320
    bnp levels #320
    combined administration #320
    ventricular dysfunction patients #321
    patients noacs #322
    intermediate phenotype #322
    difference risk #322
    additional data #322
    peripheral arterial #324
    inrs #324
    glaxosmithkline #324
    mortality odds ratio #325
    convincing evidence #325
    122 patients #326
    blood coagulation factor #326
    mechanical heart valves #326
    pulmonary embolus #326
    surgery trauma #327
    clinical #327
    association vte #329
    thrombotic event #331
    incidence bleeding #331
    pregnancy outcome women #331
    vitamin administration #331
    new oral #332
    analysis trials #333
    95 percent #333
    embase databases #333
    n69 #333
    incidences #334
    complicate #334
    95 confidence limits #334
    minor effects #334
    rationale design #335
    fibrillation benzimidazoles #335
    patients healthy volunteers #335
    pulmonary perfusion #336
    septicaemia #336
    central venous catheter #336
    recurrent #337
    plethysmographic #337
    total hip replacement #337
    035 #337
    2 points #337
    065 #337
    coagulation abnormalities #338
    aged netherlands #338
    outpatient management #338
    fatal bleeding #338
    placebo trials #339
    noacs warfarin #339
    prospective clinical study #339
    antithrombotic effects #340
    patients 12 #340
    024 #340
    217 #341
    coagulation markers #341
    activatable #341
    noac patients #342
    knee arthroscopy #342
    pretest #344
    patients covid19 infection #344
    splanchnic vein thrombosis #345
    antithrombotic strategies #345
    vte prevention #345
    rfviia #345
    diagnosis vte #346
    embolisms #346
    activated protein resistance #347
    patients thrombosis #347
    073 #347
    cochrane central #348
    044 #348
    chads2 #349
    bsf #349
    2575 #349
    tafia #350
    trousseau #350
    brain predictive #350
    randomized studies #350
    factor viii #351
    013 #351
    versus warfarin #351
    anticoagulants noacs #352
    selection bias #352
    dermatan sulphate #352
    factor activation #352
    1590 #353
    vein #353
    relative efficacy #353
    oral anticoagulant therapy #353
    5075 #353
    international normalized ratio #354
    aged pulmonary #354
    patients gp #355
    studies diagnostic accuracy #355
    protein deficiency #356
    tests prospective studies #357
    categorised #357
    post hoc #357
    intestinal microbiome #357
    127 patients #358
    sucra #360
    pilots #360
    intermittent claudication #361
    consensus agreement #362
    treatment risk #362
    anticoagulation patients #364
    humans risk #365
    conventional therapy #365
    topic female #366
    bleeding rate #366
    prediction models #367
    time recurrence #368
    patients 3 #368
    infrainguinal #368
    thrombin inhibitor #369
    influenza infection #370
    6week #370
    patients acl reconstruction #370
    venous stasis #371
    endotoxin infusion #371
    803 #372
    055 #372
    recombinant activated #373
    clinical suspicion #373
    patients svt #373
    aprotinin blood #373
    knee surgery #373
    patients scores #374
    helical computed tomography #374
    human cytomegalovirus infection #374
    hmb #375
    subcutaneous #375
    lyg #377
    subclinical hyperthyroidism #378
    stroke venous #380
    contraceptives oral #380
    ethinyloestradiol #381
    tafi #381
    antitnf #382
    prefilter #383
    standardized questionnaire #384
    thromboembolic complications #384
    reassessed #384
    0·8 #384
    multivariate regression analysis #384
    systemic activation #385
    alpha2m #385
    surrogate outcome #386
    bleeding events #386
    conference proceedings #386
    sensitivity npv #387
    cumulative incidences #387
    antithrombins #387
    delegates #388
    major orthopedic #388
    safety rivaroxaban #389
    880 #389
    referred #389
    systemic embolism #389
    vitt #390
    tinzaparin #390
    apixaban warfarin #390
    drug prescription #391
    abi #391
    increased bleeding #391
    postop #391
    biosis #391
    comparison patients #391
    patients chest #392
    time presentation #392
    topic female humans #392
    kappa values #393
    factors thrombosis #393
    clinical score #394
    background patients #394
    injections intravenous #394
    pulmonary emboli #394
    007 #395
    95 12 #396
    bleeding event #396
    popliteal #396
    factors factor #397
    665 #397
    embolic events #397
    hirudins humans #397
    replacement surgery #397
    risk score patients #399
    heparin induced #400
    patients risk #400
    echography #400
    risk factors asthma #400
    hemostatic parameters #401
    fibrinolytic agents #402
    controversy #403
    dabigatran #403
    increased risk vte #403
    massive pulmonary embolism #405
    treatment patient #406
    2215 #406
    thrombolytic agents #406
    075 #406
    oral anticoagulant #408
    factor levels #408
    biologic effects #410
    patients assigned #411
    noacs patients #411
    fviii levels #411
    safety combination #411
    transfusion patients #412
    20 microg #412
    major risk factor #412
    coagulation patients #414
    euthyroidism #414
    maastricht #414
    xii #415
    hypocortisolism #415
    aged odds #415
    deserve #416
    intravascular coagulation #416
    pai1 levels #416
    dose heparin #416
    95 10 #417
    comparable #417
    data risk #417
    95 #418
    pretest probability #418
    carotid femoral #418
    269 #419
    dermatan #419
    risk factors thrombosis #419
    xia #420
    ototoxicity #420
    fibrillation risk #421
    1989 #422
    tests radiography #422
    fibrillation clinical #422
    2850 #422
    fibrinolysin #423
    fviia #424
    subanalysis #424
    prevalence patients #425
    adjunct #426
    randomised double #426
    fii #426
    cancer cohort #426
    consecutive #427
    activated factor #427
    excessive bleeding #428
    plg #428
    daily practice #428
    conferences #428
    daily clinical practice #429
    idiopathic myelofibrosis #429
    patients testing #429
    undergoing elective #429
    prolactin levels #429
    1904 #430
    heparinoids #431
    rule #431
    bleeding complications #431
    04 #432
    outpatients #433
    incidence length #433
    ncb #434
    patients systematic review #434
    blood cultures #436
    firstdegree relatives patients #436
    bolus injection #437
    059 #437
    composite point #439
    dose adjustment #439
    proven #439
    prostatic cancer #439
    women compared #439
    highrisk populations #441
    concomitant medications #441
    074 #442
    rate vte #442
    standard therapies #444
    –control study #444
    prespecified #445
    patients atrial fibrillation #446
    febrile patients #446
    female fibrinolytic #447
    utrecht #449
    patients parenteral nutrition #449
    58 #449
    hellp #449
    3 12 months #450
    prevalence distribution #450
    category #451
    stigmatisation #451
    pipecolic #452
    aspirin risk #453
    noninvasive tests #453
    fatal disease #453
    thrombin generation #453
    30 40 #454
    portal blood #454
    placebo day #454
    factor xii #454
    microthrombi #455
    026 #455
    12week #455
    dichotomized #456
    fviii vwf #456
    onwards #457
    dicumarol #457
    squibb #457
    hazard ratio 95 #458
    anti levels #458
    iii complexes #458
    svt #460
    recommend #460
    plasma lipoprotein #460
    gastrointestinal cancer #461
    factor fxa #461
    expert consensus document #462
    curve biomarkers #462
    hip arthroplasty replacement #462
    guidelines patients #463
    haemolysis #463
    gp iib #464
    studies ultrasonography #464
    patients values #464
    month follow #465
    diabetes stroke #466
    cancerassociated thrombosis #466
    accuracy detection #467
    thrombin formation #467
    intimamedia thickness #468
    prophylaxis #468
    patients nsaids #468
    bmi≥30 #469
    teaching hospitals #469
    eligible studies #469
    inr patients #470
    077 #470
    test probability #470
    roc analysis #470
    hemihepatectomy #470
    placebo recipients #471
    prophylactic anticoagulation #472
    case control study #472
    hypercoagulability #472
    cardiovascular risk assessment #473
    thrombophilia testing #474
    heterozygote humans #475
    endotoxemia #475
    intermittent pneumatic #475
    15 95 #475
    plethysmograph #475
    patients heparin #475
    atria #477
    haemophiliacs #479
    patients score #479
    08 #479
    versus standard #480
    hit patients #481
    thrombosis cvt #481
    acutely #481
    advisory #482
    postoperative blood #482
    1162 #482
    transportability #482
    thrombin inhibitors #483
    events mortality #484
    patients hematologic malignancies #485
    diagnostic efficacy #485
    awaited #486
    secondary prophylaxis #487
    composite scores #487
    travel #488
    silent #488
    activity patients #489
    98 #490
    blinded #491
    residual risk #493
    new therapy #493
    treatment period #493
    p00007 #493
    pan troglodytes #493
    hemophilic #493
    vcf #494
    activated protein #495
    favour #496
    dose oral #496
    replacement hip arthroplasty #496
    heterozygote #496
    271 #497
    topic risk factors #497
    discriminative ability #498
    willebrand disease #498
    blockages #498
    risk factors stroke #498
    hip knee #501
    nri #502
    ptp #502
    subcategories #503
    ft4 tsh #503
    deficiencies #503
    rapid decrease #504
    complications pulmonary #505
    1107 #505
    nondiagnostic #505
    patients referred #505
    310 #506
    net clinical #506
    nonionic #507
    day surgery #507
    oftentimes #507
    inhibitors rivaroxaban #508
    aminocaproates #509
    13 95 #509
    guidelines diagnosis #509
    contraceptives #509
    coagulation tests #509
    angiography patients #510
    degradation products #510
    thrombosis animals #510
    new oral anticoagulants #510
    viii fviii #511
    epiphenomenon #512
    019 #512
    serial #513
    highintensity #514
    interim analysis #514
    056 #514
    daycare #515
    safety #516
    crcl #517
    sensitivity diagnosis #518
    thrombophilia thrombosis #518
    bleeding outcomes #518
    thrombotic diseases #518
    protein antithrombin #518
    treatment cancer patients #519
    groups treatment #519
    study sensitivity #520
    1599 #521
    8090 #521
    duration intensity #521
    warfarin therapy #524
    general practitioner #525
    fixed doses #525
    062 #527
    cancer age #528
    cindices #528
    convincing #529
    923 #529
    378 #529
    051 #529
    fatal #530
    health female #530
    thrombosis hemostasis #531
    medically patients #531
    humans postoperative #531
    betaalanine #531
    intensive units icu #532
    068 #532
    thrombosis risk #532
    ≥50 years #532
    factor thrombin #534
    therapy cancer #534
    730 #536
    factor pathway #537
    humans neoplasms #538
    449 #538
    patients idiopathic #538
    cbo #539
    concise #539
    ddavp #539
    comprehensive search #539
    diagnostic accuracy studies #540
    diagnosis acute #540
    clinical review #540
    patients eligible #543
    thrombotic risk #543
    bleeding episodes #543
    234 #543
    vascular obstruction #543
    conventional treatment #543
    jak2 mutation #544
    00 #544
    coagulative #544
    pad abi #544
    v617f #545
    prospective cohort study #545
    perc #545
    hellp syndrome #545
    association statin #546
    screening strategies #546
    prothrombin complex #547
    bureau #547
    primary #548
    adequate #549
    95 difference #549
    overt #549
    platelet inhibitors #550
    reviewers #550
    percent patients #550
    conduction anesthesia #550
    cancer type #550
    1103 #550
    management bleeding #552
    day patients #552
    amsterdam #552
    studies sensitivity #552
    500 patients #552
    careful #552
    femoral arteries #553
    general population patients #554
    ttr #556
    humans infusions #557
    66 patients #558
    factor vii #558
    vivo treatment #558
    orthopedic surgery #559
    bleeding time #559
    limulus #561
    patients transfusion #563
    board directors #563
    risk development #563
    female humans tests #563
    anamnesis #564
    appears #564
    hip replacement #564
    hyperfibrinolysis #565
    increasing risk #565
    solid tumours #566
    withholding #566
    cardiac troponins #566
    roc curves #568
    patients 2 years #568
    n46 #568
    levothyroxine #571
    alpha1antitrypsin #571
    aggravation #572
    ctnt #573
    cutoff point #574
    revascularization procedures #574
    menstrual bleeding #574
    women proportion #575
    subcutaneously #575
    major bleedings #575
    progression cancer #577
    patients vka #578
    endothelial barrier #578
    endotoxin #579
    pharma #579
    thiophenes #579
    notice #580
    diagnostic tools #580
    99 #580
    cancer thrombosis #581
    subgroups patients #583
    dummy #584
    unselected patients #584
    coagulation disorders #585
    094 #585
    chondroitin sulfates #586
    feasibility safety #588
    major orthopedic surgery #588
    helminth proteins #589
    healthy human #590
    reversal agents #590
    thrombophilias #590
    malignancy #590
    beta alanine #590
    massive pulmonary #592
    conventional management #592
    doppler ultrasound #592
    bmi30 #594
    factor fv #595
    ldf #597
    patency rates #597
    severe bleeding #597
    replacement knee #597
    major hemorrhage #597
    infusions intravenous #598
    analysis topic #599
    tests sensitivity #600
    loss surgical #600
    046 #601
    association patients #602
    vwd #603
    comorbid conditions #604
    events occurred #604
    clinical characteristics patients #604
    diagnostic studies #606
    activated coagulation #607
    0·3 #607
    patients antibodies #607
    initial increase #607
    treatment acute #608
    pfizer #609
    tissue factor #609
    arbitrage #609
    patients death #610
    100 years #610
    benefit risk #610
    airline #610
    clinical evaluation #611
    ultrasonography #613
    coagulation inflammation #614
    leg #615
    reluctant #615
    patients bariatric surgery #615
    complications risk #616
    treatment rivaroxaban #617
    arterial disease #617
    467 #618
    occurred #618
    stroke atrial fibrillation #618
    fh patients #620
    compared placebo #620
    advisory committees #621
    patients elevated #621
    1002 #622
    sgs #623
    thrombocytopenia hit #623
    thyrotoxic #623
    peptide bnp #625
    cochrane central register #625
    topic practice guidelines #626
    stopped #626
    stroke warfarin #627
    warfarin risk #628
    66 #628
    women risk factors #628
    5000 #628
    referral patients #629
    human subjects #629
    physical training #629
    diagnostic algorithms #629
    absolute #630
    sanofi #630
    atiii #632
    risk treatment #633
    screening strategy #634
    uneventful #635
    outweigh #635
    pentoxifylline #637
    travelling #638
    95 allcause mortality #640
    14 95 #640
    study quality #641
    proceedings #641
    3050 #642
    predictive performance #642
    threatening bleeding #643
    neutrophilia #643
    primary outcome measure #647
    association mortality #647
    studies efficacy #648
    statin treatment #648
    necessitating #648
    036 #651
    thrombolysis patients #651
    fixed #651
    organisations #652
    troglodytes #652
    hemorrhagic stroke #653
    fxa #653
    127 #655
    patients review #657
    bleeding death #659
    69 #659
    coronary stent implantation #659
    haematoma #660
    physical examination #661
    tertiles #661
    coagulation proteins #661
    haemophilia #662
    clinical presentations #662
    95 studies #663
    1028 #663
    long term treatment #664
    provoked #664
    sepsis shock #665
    deep #666
    phase iii studies #666
    presence patients #667
    guideline adherence #667
    patients completed #667
    onethird #667
    male medical #668
    8 wk #669
    1110 #671
    phenprocoumon #672
    elevated plasma #673
    patients cteph #673
    hospitalization hf #674
    managing #674
    il6 levels #675
    inhibitor 1 #675
    clotting factors #675
    highincome countries #676
    prothrombotic #676
    asymptomatic subjects #677
    favourably #678
    jugular #679
    medicine humans #681
    pulmonary endarterectomy #681
    suspicion #682
    conclude #687
    apolipoproteina #688
    efficacy safety #690
    patients bleeding #692
    ambulatory patients #692
    graduated #693
    activator pa #693
    myocardial infarctions #693
    precise mechanisms #694
    composite outcome #694
    intracranial bleeding #694
    administer #694
    1718 #695
    combined oral contraceptives #696
    stroke prevention patients #696
    moyamoya #696
    difference 95 #698
    ratio male #698
    participant data #698
    episode #700
    compression devices #700
    diagnostic errors #702
    prothrombin gene #702
    therapeutic management #702
    surgery risk #703
    patients confirmed #703
    veins venous #703
    willebrand #704
    data incidence #706
    subclinical hypothyroidism #708
    clinical expression #709
    directors #709
    starters #711
    gastrointestinal bleeding #712
    medical patients #712
    gynaecology #712
    048 #712
    radionuclide imaging #713
    1098 #714
    rate death #714
    neurosurgical patients #714
    intravenous bolus #715
    rivaroxaban stroke #716
    menstrual period #716
    cancer groups #717
    adequately #717
    falsely #718
    10 30 #718
    solid cancer #718
    reagent kits #719
    plasminogen #719
    pulmonary medicine #720
    nordisk #721
    pyrazoles pyridines #721
    clinical judgment #721
    accp #721
    s1p1 #722
    95 hazard ratio #724
    follow period #726
    abnormal #726
    gentamicins #727
    59 patients #727
    orthopaedic surgery #728
    diagnostic therapeutic #728
    diagnostic tests #730
    gentamicin #732
    leeches #732
    oral contraception #733
    tumor necrosis factor #733
    relative risk 95 #734
    patients levels #735
    hull #735
    disease pad #735
    atrial fibrillation risk #736
    tests retrospective studies #736
    clinical prediction rule #736
    6 12 #739
    post hoc analysis #739
    anti tnf #740
    evaluable patients #741
    early pregnancy loss #742
    040 #742
    unclear #742
    topic predictive #743
    betathromboglobulin #744
    molecular weight #744
    illness time factors #744
    patients 50 years #746
    etp #746
    285 #746
    antithrombin activity #746
    leukocyte activation #748
    thrombolytic therapy #749
    hospitalization heart failure #750
    indication #752
    advisable #754
    fibrin formation #754
    primary patients #755
    answer #756
    pneumatic compression #756
    95 combination #756
    95 risk factors #756
    hf risk #756
    venovenous #757
    1·7 #758
    loe #759
    85 #759
    inflammation coagulation #760
    patients peripheral #761
    435 #763
    proportion women #763
    start treatment #764
    cprs #764
    hip surgery #765
    689 #767
    aspirin clopidogrel #767
    risk pregnancy #767
    732 #768
    method drug #769
    566 #770
    relevant #770
    groups patients #770
    baseline values #772
    graft patency #772
    patients criteria #773
    bmi patients #774
    subcutaneous injections #774
    1·5 #776
    992 #777
    dose intravenous #778
    patients 65 years #778
    study groups #778
    dose warfarin #778
    miscarriage #779
    plasmin generation #780
    066 #780
    thromboembolism prophylaxis #780
    patients hyperthyroidism #780
    age ≥ #782
    factor ixa #785
    onefifth #785
    abnormalities patients #786
    cteph #787
    general practitioners #787
    100 personyears #787
    polypharmacy #787
    topic disease models #787
    preferable #788
    secondary outcome #791
    mechanical heart #793
    recombinant tissue #793
    inactivators #795
    047 #795
    risk factors risk #795
    patency #796
    patient years #796
    eligible #797
    studies prevalence #797
    netherlands #797
    lupus anticoagulant #798
    femoropopliteal #798
    estrogen therapy #799
    theme #799
    patients lower #799
    hemophilia patients #800
    willebrand factor #802
    randomized patients #804
    subclinical #804
    anticoagulant agents #805
    microvesicles #805
    adverse outcomes patients #806
    fibrillation blood #806
    stroke risk factors #807
    ventricular dysfunction #808
    efficacy patients #809
    hypertension cteph #809
    activator inhibitor1 #810
    069 #811
    model patients #813
    primary aim #814
    factor vwf #816
    flights #816
    0·4 #818
    irrespective #820
    vehicle control #820
    health predictive #820
    abruptio #821
    neuroradiologist #822
    reduction mortality #823
    prevention patients #823
    coc #824
    single administration #824
    risk benefit #825
    study incidence #827
    gp #828
    cardioembolic stroke #828
    patients anticoagulants #830
    cava filters #832
    antithrombotic treatment #833
    93 #833
    myers #833
    abortion habitual #835
    oral adult #836
    plough #836
    versus placebo #837
    noac #837
    87 #838
    057 #839
    genetic defect #841
    risk scores #844
    antithrombotic therapy #846
    49 #846
    072 #847
    multidetector row #847
    advise #848
    recurrence risk #849
    patients diagnosis #850
    caesarean #850
    area roc curve #852
    pre‐eclampsia #853
    reference method #853
    30 patients #853
    advanced prostate #854
    clopidogrel aspirin #855
    fibrin #855
    patients mutation #859
    ultrafiltrate #860
    dutch population #861
    microg #862
    cardiometabolic disease #863
    090 #865
    placebo study #866
    diagnostic methods #868
    1046 #869
    pyridones #870
    6 month #870
    individual participant #872
    longterm clinical outcomes #872
    favoring #873
    tasman #873
    thromboembolic pulmonary #874
    imaging reproducibility #874
    targeted inhibition #874
    plasminogen activation #875
    titles #875
    n15 #876
    cha2ds2 #877
    risk thromboembolic #878
    dabigatran rivaroxaban #878
    57 #879
    anticoagulants atrial #879
    oral #881
    angiograms #882
    control trial #883
    92 #884
    imaging tests #885
    prostate turp #888
    handbook #890
    male mexico #894
    084 #894
    domiciliary #894
    p011 #896
    loading dose #896
    repeatedly #897
    uln #901
    indefinite #902
    bleedings #904
    vkorc1 #905
    wml #906
    064 #908
    factor activity #908
    subcutaneous administration #909
    patients clinical trials #911
    documented #911
    initially #912
    haemostatic #912
    impedance #913
    specificity sensitivity #914
    combined approach #916
    haemodialysis patients #916
    317 #917
    022 #918
    thromboembolic events #918
    chronic thromboembolic #919
    antagonist oral #920
    randomeffects model #920
    standard patients #920
    loss patients #921
    optimal dose #921
    ultrasound examination #921
    estimate male #923
    practise #923
    study medication #925
    multifactorial disease #925
    total hip #926
    902 #928
    safer #928
    004 #929
    recurrent events #930
    fxi #931
    wording #934
    treatment placebo #934
    84 #936
    publication clinical trials #937
    60 patients #938
    subgroup patients #938
    rrr #940
    families patients #941
    teaching hospital #943
    stroke atrial #944
    women preeclampsia #944
    echocardiographically #944
    emboli #945
    predictive values #946
    ssc #946
    anticoagulation treatment #947
    extensive disease #948
    knee replacement #948
    diagnostic #948
    previous diagnosis #951
    adjudication #954
    network metaanalysis #956
    registro #956
    cancer humans #956
    dic #956
    venous insufficiency #957
    reassuring #957
    efficacy #958
    day1 #958
    combined oral #961
    retropubic #961
    guidelines recommend #962
    3 months #963
    blood product #964
    travellers #965
    inhibitor1 #966
    reference lists #966
    peaking #969
    greater risk #970
    allogeneic blood #971
    risk allcause mortality #973
    hoc #973
    antiplatelet #973
    prevalence characteristics #973
    segmental #974
    patients anticoagulation #975
    vascular humans #976
    female fibrinogen #976
    fvii #978
    false negative #979
    50 100 #980
    onset aged aged #980
    071 #980
    early gestation #984
    426 #986
    prophylactic treatment #987
    randomised trials #987
    patients safety #988
    vascular patency #989
    study treatment #990
    missed #991
    rises #991
    academic medical center #992
    seminar #992
    normal lung #993
    counteracted #993
    treatment bleeding #994
    aged #999
    226 #999
    justification #1000
    lower extremity #1000
    thromboembolic risk #1000
    tissue type #1001
    parenteral administration #1002
    rivaroxaban apixaban #1002
    eclamptic #1003
    extended #1005
    interleukin 6 #1005
    hyperprolactinaemia #1005
    pyridines #1006
    orthosis #1007
    easier #1007
    50 patients #1007
    valsalva maneuver #1009
    venous catheter #1011
    individual participant data #1012
    weighing #1014
    ticlopidine #1018
    pounds #1018
    clotting time #1019
    prostatic carcinoma #1020
    200 patients #1022
    years risk #1023
    cha2ds2 vasc #1023
    international prospective #1024
    humans randomized #1024
    076 #1025
    diagnostic challenge #1026
    prothrombin time #1027
    firstdegree relatives #1030
    decision analysis #1030
    ixa #1031
    prolactin #1032
    risk hemorrhage #1033
    relatives #1033
    cardiovascular event #1033
    052 #1035
    male netherlands #1037
    graft occlusion #1037
    2 hours #1039
    detect #1040
    025 #1041
    3 6 months #1046
    vwf levels #1047
    patients severe asthma #1047
    patients massive #1050
    examiner #1050
    continuation #1052
    patients analysis #1053
    mean±sd #1054
    221 #1054
    free triiodothyronine #1056
    diseases liver #1057
    coagulant #1060
    179 #1060
    birth rate #1060
    pad #1061
    610 #1061
    published literature #1062
    primary data #1062
    false #1064
    prekallikrein #1065
    150 #1065
    live birth #1066
    101 #1066
    00008 #1066
    lysosphingolipid #1067
    cut #1067
    pmol #1068
    95 increased risk #1070
    register controlled #1070
    observer variation #1071
    specialties #1072
    continued #1073
    laboratory diagnosis #1074
    thorax #1074
    systematic search #1078
    advocate #1080
    063 #1080
    drawbacks #1082
    longterm therapy #1087
    f1 #1087
    bandages #1089
    clarifications #1095
    stopping #1095
    mandated #1096
    idarucizumab #1096
    diagnostic utility #1096
    083 #1099
    1223 #1099
    62 #1102
    96 #1104
    blueprint #1105
    fourfold #1105
    peptide brain #1107
    clinical protocols #1107
    pending #1111
    incidence pulmonary #1112
    assigned #1113
    diagnostic approach #1115
    haemodialysis #1116
    bypass grafts #1116
    252 #1117
    qualified #1118
    sensitivity specificity #1119
    critical appraisal #1120
    randomized controlled trials #1122
    probands #1123
    resistance factor #1123
    new developments #1124
    advised #1125
    new perspectives #1126
    445 #1126
    heparininduced thrombocytopenia #1127
    cip #1127
    patients pad #1128
    discretion #1132
    judged #1132
    statistic #1133
    ≤10 #1133
    95 confidence interval #1134
    pulse rate #1135
    gram negative #1137
    1043 #1139
    disseminated #1140
    superior efficacy #1141
    635 #1141
    86 #1143
    734 #1145
    844 #1147
    roc curve #1150
    refusal #1150
    medical records #1151
    medline #1151
    embolectomy #1153
    longterm complications #1154
    risk recurrence #1155
    anticoagulation therapy #1156
    blood loss #1156
    patients influenza #1156
    prophylaxis treatment #1157
    3040 #1158
    patients increased #1159
    extension study #1161
    cvc #1162
    bristol #1163
    published guidelines #1163
    safety concerns #1164
    hyperhomocysteinemia #1164
    intermittent #1164
    stable angina #1164
    viii #1164
    thromboembolism risk #1165
    age 65 years #1165
    angiogram #1167
    crossover design #1172
    glucocorticoid treatment #1172
    perioperative bleeding #1172
    atherosclerotic disease #1172
    practice guideline #1173
    occlusive diseases #1173
    macroglobulin #1176
    5 years patients #1176
    findings patients #1178
    analysis studies #1178
    79 #1179
    conceive #1181
    concealed #1181
    hospitalized patients #1182
    patients obesity #1182
    unaware #1182
    conclusive #1186
    combined therapy #1186
    degree relatives #1189
    occult #1189
    adult analysis #1191
    cus #1194
    administration oral #1195
    21 patients #1197
    international society #1199
    mandate #1199
    cardiotonic agents #1199
    hypercortisolism #1200
    83 #1203
    015 #1204
    quantitative trait locus #1204
    categorized #1204
    increase plasma #1205
    31 #1207
    biomarkers blood #1210
    56 patients #1212
    pph #1214
    multicenter randomized #1214
    103 #1218
    warranted #1221
    patient treatment #1221
    scores patients #1221
    ultrasound screening #1222
    6months #1223
    64 patients #1224
    peak levels #1224
    vasc #1225
    16 patients #1226
    blind #1227
    sixfold #1227
    metabolic syndrome patients #1228
    consensus guidelines #1228
    peptide hydrolases #1229
    trial background #1229
    radionuclide #1229
    65 patients #1230
    doubles #1232
    rules #1232
    aspirin #1234
    milliliter #1238
    postoperative hemorrhage #1238
    coronary angiography patients #1238
    humans length #1240
    clinical criteria #1241
    patients fh #1242
    vte prophylaxis #1244
    neurohormone #1245
    multinational #1246
    thrombolytic #1247
    knee arthroplasty #1248
    intermediate risk #1250
    subgroups #1252
    matter lesions #1252
    ml1 #1252
    artery pulmonary #1254
    search strategy #1257
    extensive #1257
    oral vitamin #1257
    prospective cohort #1258
    symptomatic patients #1259
    major surgery #1262
    troponins #1266
    visiting #1266
    entity #1266
    macroglobulins #1267
    172 #1270
    amputations #1273
    equally #1274
    intensive patients #1274
    design study #1276
    antiplatelet agents #1278
    proportionally #1279
    75 years #1281
    routine screening #1281
    statin users #1281
    factors ultrasonography #1285
    thyroxine #1287
    050 #1288
    blockers #1290
    dermatan sulfate #1292
    scan #1295
    janssen #1295
    perfusion defects #1295
    predictive #1297
    hemofiltration #1297
    insufficiently #1298
    cardiovascular complications #1299
    low prevalence #1299
    dutch #1300
    prolong #1302
    pf4 #1303
    61 #1303
    pulmonary circulation #1304
    scores #1305
    95 mortality #1307
    risk difference #1312
    1st #1312
    cyproterone #1312
    apoa #1312
    adamts13 activity #1313
    tests severity #1314
    current strategies #1314
    0·7 #1314
    atrial fibrillation #1316
    claudication #1316
    carotid imt #1317
    international guidelines #1318
    replacement hip #1320
    study time #1321
    coagulation factor #1322
    vienna #1323
    increases risk #1324
    lipoproteina #1325
    glycoprotein gpiib #1325
    patients coronavirus disease #1326
    beneficial #1329
    antibodies monoclonal antibodies #1329
    vascular diseases #1329
    plasminogen activators #1330
    low moderate #1330
    thyroid disorders #1330
    coagulation cascade #1331
    6 months patients #1331
    77 #1331
    126 #1332
    frequent complication #1333
    adjusted age #1335
    transurethral resection #1336
    91 #1342
    likelihood ratio #1342
    venous catheters #1342
    blood sample #1343
    daily patients #1344
    surgical trauma #1347
    antitrypsin #1347
    patients relatives #1351
    neurosurgery #1355
    arthroplasty patients #1356
    patients stable angina #1357
    experimental model #1359
    allcause mortality 95 #1359
    15 patients #1359
    limb salvage #1363
    vwf #1363
    arsenal #1363
    vtes #1365
    95 patients #1366
    operatively #1367
    12 month #1369
    heart valves #1370
    starting #1372
    ethinyl #1373
    acetylsalicylic #1375
    costeffectiveness analysis #1376
    utmost #1378
    consented #1382
    management patients #1383
    gps #1384
    224 #1385
    noninferiority #1385
    dl1 #1385
    disorders blood #1386
    ivt #1389
    patients cvd #1392
    substitute #1394
    screening tests #1399
    record linkage #1400
    patients control subjects #1400
    equipoise #1402
    antisense oligonucleotide #1402
    82 #1402
    mandatory #1403
    clinical challenges #1404
    1886 #1405
    patients advanced cancer #1405
    pregnancy loss #1406
    obese patients #1406
    categories #1408
    515 #1408
    994 #1409
    reflected #1410
    inception #1411
    tranexamic #1413
    adamts13 #1417
    0·1 #1418
    6 weeks #1419
    3 6 #1419
    7 weeks #1419
    thrombotic complications #1419
    total knee #1420
    95 0 #1421
    followup data #1422
    university hospitals #1422
    061 #1424
    daily #1424
    ≥55 #1424
    eightfold #1425
    randomised controlled trials #1427
    080 #1427
    rgs #1430
    casecontrol study #1430
    outcome pregnancy #1438
    imaging radiopharmaceuticals #1439
    096 #1439
    78 #1443
    principal #1443
    1123 #1445
    weight bmi #1446
    outcome studies #1446
    drug levels #1446
    underreporting #1451
    support systems #1452
    confusion #1454
    population patients #1454
    platelet factor #1455
    aged blood #1455
    dip #1456
    mbe #1457
    conclusions patients #1459
    prospectively #1460
    multicenter studies #1461
    humans #1463
    inaccuracy #1464
    actual #1466
    funded #1466
    0·9 #1468
    avoided #1468
    26 patients #1469
    heart failure hf #1469
    groin #1471
    risk factors mortality #1472
    1215 #1473
    prevalences #1473
    centrally #1474
    systemic infection #1477
    probability #1477
    lowest tertile #1478
    remained #1480
    atherothrombotic #1481
    undetermined #1482
    dysfunction patients #1483
    cushing syndrome #1485
    analysis randomized #1485
    methodologic #1486
    phase iii trials #1486
    general practice #1491
    patients control #1495
    procoagulant activity #1495
    randomly #1496
    64 #1498
    aged natriuretic #1499
    exposing #1501
    imt #1507
    fracture surgery #1510
    specificity 100 #1512
    odds ratio 95 #1513
    growing body #1514
    adverse outcome #1514
    proximal #1516
    pregnancy postpartum #1520
    ganz #1520
    patients 10 #1520
    subgroup #1521
    factor deficiency #1522
    gsk #1524
    chills #1526
    thrombotic events #1527
    contraindicated #1527
    time study #1529
    score #1529
    oral contraceptive #1534
    mechanical compression #1536
    immobilisation #1539
    comparator #1540
    patients life #1541
    humans neoplasm #1542
    hemostatics humans #1545
    089 #1548
    tsh levels #1551
    live births #1552
    patients severe sepsis #1552
    23 #1554
    vascular thrombosis #1555
    fees #1556
    neonatal period #1558
    patients year #1559
    discriminatory #1562
    hypothyroidism #1563
    enfermedad #1564
    pfa #1564
    iii topic #1565
    treatment prevention #1566
    topic #1566
    cushings syndrome #1568
    95ci #1568
    deficient #1568
    hyperlipoproteinemia type #1568
    aged biomarkers #1571
    plasminogen activator #1575
    36 #1575
    humans platelet #1576
    012 #1577
    hyperlipoproteinemia #1580
    risk myocardial infarction #1584
    cocs #1586
    activation markers #1586
    study entry #1586
    thyroid dysfunction #1586
    studies association #1587
    adjusted hazard ratio #1589
    volunteers #1591
    1·1 #1594
    total mortality #1594
    translates #1597
    placebo #1598
    noncancer #1598
    exclude #1599
    lmw #1601
    figures #1604
    paroxetine #1606
    abdominal surgery #1607
    complement pathway #1609
    curability #1610
    general surgery #1613
    162 #1613
    ethinylestradiol #1614
    recommending #1615
    factors tomography #1616
    positive effects #1616
    prospective cohort studies #1616
    tests reproducibility #1616
    postpartum period #1616
    155 #1618
    perinatal outcome #1618
    female hemostasis #1619
    cvd patients #1619
    imaging tomography #1619
    proportion #1620
    12month followup #1621
    uncertain #1621
    079 #1623
    competing risk #1628
    isis #1630
    major #1631
    pa patients #1632
    incidentally #1632
    venous disease #1632
    clinical patients #1633
    fresh frozen plasma #1633
    study outcomes #1639
    double #1639
    029 #1642
    181 #1643
    stroke prevention #1644
    ctni #1644
    patients hospitalized #1647
    mismatched #1648
    997 #1651
    dorsiflexion #1651
    ≤4 #1652
    35 years #1652
    studies data #1653
    thrombin activity #1653
    clotting #1656
    remaining #1660
    plasma concentration #1661
    outcome data #1663
    spiral #1669
    disease adult #1670
    homocysteine levels #1670
    thrombi #1674
    daily dosing #1676
    inpatient treatment #1676
    deficiency #1677
    plasma level #1677
    warfarin dose #1680
    arthroscopy #1684
    unreliable #1686
    steroidal anti #1686
    patients acs #1687
    thrombin #1690
    severe renal #1694
    patients brain metastases #1695
    prospective #1702
    necrosis factor #1705
    highest risk #1707
    cancer screening #1708
    awaiting #1710
    033 #1712
    yielded #1712
    hemorheology #1715
    intravenous #1715
    bronchospasm #1720
    hematologic malignancies #1720
    female femoral #1721
    mb #1721
    diagnostic evaluation #1721
    cardioembolic #1722
    cumulative incidence #1723
    laser doppler #1724
    conference #1726
    107 #1726
    derived microparticles #1729
    volunteer #1730
    021 #1730
    161 #1733
    percentage patients #1734
    clinical scores #1735
    east asian #1735
    patients icu #1736
    rico #1737
    500 #1738
    minor #1739
    revised #1744
    patients ventricular #1745
    table #1745
    691 #1745
    profession #1746
    hyperinsulinaemia #1747
    risk cardiovascular events #1747
    turp #1749
    apc #1749
    homozygosity #1750
    pselectin #1750
    replacement #1750
    128 #1752
    133 #1753
    intracranial hemorrhages #1753
    3 studies #1755
    spontaneous #1756
    arterial occlusive #1758
    patients randomized #1759
    audiometry #1760
    assessor #1760
    treatment recommendations #1760
    current treatment #1761
    primary setting #1762
    long‐term #1763
    human insulin #1764
    fx #1764
    duplicate #1769
    initial management #1770
    arteriosclerosis #1770
    hemorrhage #1770
    allcause death #1774
    2 6 #1774
    28 weeks #1781
    hemostasis humans #1782
    trough levels #1785
    infusions #1787
    ethinyl estradiol #1789
    selfmanagement #1790
    clinical consequences #1790
    microparticle #1793
    reid #1793
    vascular surgical #1794
    cardiac troponin #1794
    healthy male volunteers #1799
    042 #1800
    020 #1802
    aggregation inhibitors #1802
    retrospective analysis #1805
    hemophilia humans #1808
    unpublished #1810
    slc6a4 #1812
    tumor necrosis #1812
    95 specificity #1812
    overlapped #1814
    51 #1815
    078 #1818
    conjoint #1819
    economic evaluation #1819
    interobserver #1823
    awareness #1824
    screening middle #1825
    preference #1825
    303 #1828
    placebo 95 #1832
    undergoing coronary #1834
    compressibility #1837
    definite #1837
    cushing #1838
    kaplanmeier estimate #1838
    severe sepsis #1839
    1 week #1842
    central venous #1842
    workup #1848
    orthopaedic #1849
    hydroxyethyl starch #1852
    explanations #1852
    160 #1854
    fibrinopeptide #1862
    cancer therapies #1865
    alpha 2 #1867
    gramnegative #1869
    serially #1870
    humans pregnancy #1874
    separately #1876
    oral anticoagulation #1880
    shrs #1892
    diagnostic techniques #1892
    thromboses #1892
    lower incidence #1893
    stable patients #1895
    067 #1897
    5 10 #1897
    contraindications #1900
    extremity #1901
    tnf #1901
    diagnostic testing #1901
    clt #1905
    plaster #1906
    hazard ratio #1906
    induced thrombocytopenia #1906
    differential effects #1907
    95 year #1909
    efficacy treatment #1910
    referral #1910
    random #1911
    plato #1913
    experimental mice mice #1916
    238 #1918
    randomized #1919
    13 patients #1920
    793 #1920
    administration #1921
    pregnancy treatment #1922
    868 #1923
    stroke 95 #1923
    biotin #1924
    55 years #1924
    trials patients #1926
    venous pressure #1926
    intracranial hemorrhage #1927
    μg #1927
    coronary syndromes #1928
    272 #1929
    cardiovascular events patients #1930
    chimpanzee #1931
    adjusted #1932
    glucocorticoid #1934
    nonfatal #1934
    relative risks #1935
    3months #1935
    acute #1936
    17 #1936
    thrombolytic treatment #1937
    27 #1938
    randomized placebo #1947
    safety effectiveness #1950
    femoral vein #1950
    0·5 #1952
    medical illness #1954
    overtreatment #1955
    prolongation #1958
    intravascular #1959
    major risk #1960
    advanced age #1961
    investigators #1962
    observer #1962
    1050 #1965
    permanent #1966
    80 female #1967
    hyperglycaemia #1970
    coronary angioplasty #1971
    surgical blood #1973
    fibrin clot #1973
    48 hours #1973
    potent inhibitor #1976
    renewed #1976
    topic clinical trials #1978
    specificity ultrasonography #1981
    771 #1981
    hyperaldosteronism #1981
    computerised #1982
    patients pancreatic #1985
    treatment cancer #1986
    1·0 #1986
    randomized controlled #1988
    coumarins #1990
    177 #1991
    prospero #1992
    018 #1992
    cmax #1994
    drug drug therapy #1994
    cvt #1995
    computerized #1995
    hemorrhage patients #1996
    ors #1998
    602 #1999
    autopsy #2000
    clinical severity #2000
    transient increase #2000
    3 months patients #2000
    53 #2003
    7 patients #2006
    pneumonia patients #2006
    pih #2011
    mantel #2013
    catheterization central #2014
    angina unstable #2017
    mongrel #2017
    poc #2019
    225 #2020
    type plasminogen #2023
    pathophysiologic #2024
    35 #2025
    patients statins #2026
    annual #2028
    15th #2031
    atheroma #2032
    patients lung #2033
    097 #2033
    pertechnetate #2036
    costs cost #2041
    medical record #2041
    undergoing major #2042
    abstracts #2042
    questioned #2043
    thrice #2045
    prediction rule #2045
    dichotomous #2046
    normal #2048
    superior vena cava #2051
    quartiles #2051
    inadequately #2052
    277 #2053
    pregnancy trimester #2053
    controversial #2055
    stent implantation #2056
    adherence guidelines #2056
    hospitalized #2057
    randomized comparison #2060
    outpatient #2061
    interobserver variability #2062
    varies #2063
    requested #2063
    biological neoplasms #2064
    clinical indications #2064
    hemostatics #2070
    national institute #2074
    mcnemar #2074
    188 #2074
    familial hypercholesterolemia #2077
    unavailable #2079
    searched #2082
    disseminate #2083
    ristocetin #2086
    bypasses #2087
    media thickness #2087
    03 #2089
    versions #2091
    square distribution #2092
    114 #2092
    tissue plasminogen #2093
    preformed #2099
    reference range #2099
    038 #2100
    lifetime risk #2101
    59 #2101
    desmopressin #2101
    placebos #2102
    concealment #2104
    hospital treatment #2106
    fibrin deposition #2107
    argatroban #2108
    031 #2109
    substantial #2109
    1966 #2109
    aged 80 #2111
    debated #2116
    jugular vein #2117
    independently #2118
    unnecessary #2118
    exists #2119
    initial #2119
    development validation #2120
    clinicaltrialsgov #2122
    11 #2122
    coronary stent #2122
    original #2125
    acl reconstruction #2125
    patients cardiovascular disease #2127
    topic surveys #2127
    controlled #2129
    chose #2129
    current recommendations #2131
    odds ratios #2132
    congress #2134
    protamines #2134
    190 #2136
    788 #2137
    hip arthroplasty #2139
    heterozygous #2141
    antagonists #2142
    live #2145
    clot #2145
    bodyweight #2146
    professionals #2146
    pancreatic cancer patients #2157
    committee #2160
    oestrogens #2160
    lowdose aspirin #2163
    academic medical #2167
    drains #2170
    embase #2171
    fibrinogen #2175
    1998 #2178
    trimesters #2179
    reproductive age #2182
    advanced cancer #2183
    674 #2183
    giant cell arteritis #2185
    fifty #2185
    2 × #2185
    patients diagnosed #2187
    631 #2188
    controlled study #2192
    superficial #2194
    difference incidence #2198
    adjust #2202
    diagnostic performance #2204
    pravastatin #2205
    increased patients #2205
    antagonist #2206
    clinical implications #2208
    lower limbs #2209
    neutrophil elastase #2212
    diagnosis differential #2212
    doubled #2213
    364 #2219
    pao2 #2219
    insufficient #2221
    comparing #2222
    94 #2225
    differential female #2225
    lung perfusion #2226
    italian society #2227
    76 #2233
    takeda #2236
    nationwide cohort study #2245
    clot formation #2247
    congenital heart disease #2252
    hemorrhages #2253
    hivinfected patients #2257
    clots #2257
    kilogram #2259
    aprotinin #2261
    8000 #2264
    hyperthyroidism #2265
    stroke aged #2265
    12 #2266
    metaanalysis #2267
    6 months #2267
    reverses #2273
    patients developed #2273
    arterial #2274
    intrinsic pathway #2275
    famine #2278
    656 #2279
    ultrasonographic #2281
    setting #2284
    based case #2284
    14 patients #2286
    ft3 #2288
    case control #2291
    patients heart failure #2293
    aged molecular #2295
    daily dose #2296
    sole #2298
    strategy #2303
    88 #2308
    0047 #2310
    normalised #2312
    metaanalysis studies #2314
    tests #2314
    nephelometry #2316
    initial therapy #2316
    obstetrics #2317
    adjustments #2319
    method female #2324
    humans myocardial #2324
    methodological #2325
    60 #2327
    normalized #2329
    brachial #2332
    gradually #2335
    random sample #2336
    positive predictive #2337
    transfusion requirements #2340
    ultrasonography doppler #2341
    543 #2343
    lacked #2344
    inhibitor #2344
    prescribe #2347
    illness severity #2350
    20 weeks #2351
    thr #2353
    prefer #2354
    cancer progression #2364
    053 #2371
    118 #2372
    receiving #2374
    risk bias #2375
    099 #2375
    patients active #2376
    predictable #2377
    hemostasis #2377
    enrolling #2379
    acute coronary syndromes #2379
    187 #2381
    dosing regimen #2382
    anticardiolipin #2382
    145 #2387
    scintigraphy #2389
    140 #2391
    244 #2393
    complication rate #2400
    757 #2401
    patients liver cirrhosis #2401
    086 #2402
    letters #2405
    curable #2406
    postinjection #2413
    periodicals #2413
    protein #2413
    risk estimates #2414
    sphingosine1 #2415
    22 #2415
    internal medicine #2424
    study drug #2424
    32 #2425
    guidelines #2426
    sensitivity 100 #2426
    0048 #2430
    coagulants #2430
    002 #2430
    legs #2430
    patients adult #2431
    ci95 #2432
    normal range #2433
    ptca #2434
    prolonging #2434
    aminoglycoside #2435
    cindex #2437
    030 #2438
    cumulative #2439
    166 #2441
    endogenous #2445
    microplate #2446
    719 #2448
    turbidimetry #2448
    administration schedule #2449
    transmigration #2453
    homocysteine #2454
    anticoagulant activity #2455
    ≥75 #2459
    extensively #2463
    prognostic patients #2464
    watchful #2464
    potential benefits #2466
    nephrotoxic #2468
    therapy acute #2468
    477 #2469
    comprised #2469
    pharmacologic #2473
    consisted #2474
    current review #2476
    cancer population #2476
    05 #2481
    50 #2482
    pathway inhibitor #2485
    648 #2485
    treatment efficacy #2489
    1015 #2490
    829 #2490
    chest #2493
    duration #2493
    25 #2495
    illness tomography #2503
    616 #2503
    bnp #2504
    subsequent pregnancies #2505
    522 #2507
    movie #2508
    recurrence retrospective #2509
    unstable angina #2510
    presentation #2512
    superinfection #2513
    comprising #2515
    drug female humans #2516
    479 #2516
    sulfates #2519
    750 #2520
    neutrophil extracellular traps #2521
    463 #2521
    152 #2523
    accurate diagnosis #2523
    treatment arms #2524
    scientific #2529
    establish #2534
    0046 #2537
    164 #2537
    874 #2537
    nematode #2540
    67 #2542
    pyrazoles #2547
    arrive #2549
    decided #2552
    effectiveness analysis #2553
    hours #2560
    haematology #2560
    hydroxyethyl #2560
    928 #2565
    radiologist #2566
    roc #2568
    biologic #2569
    clinical settings #2570
    infrequent #2572
    humans logistic #2574
    kits #2574
    73 #2574
    prevalence #2575
    pill #2575
    patients total #2577
    translate #2577
    973 #2578
    specificity #2580
    cancer chemotherapy #2581
    374 #2582
    591 #2585
    efficacious #2585
    pivotal #2588
    analysed #2589
    bolus #2595
    657 #2596
    multiple organ failure #2599
    hypercholesterolaemia #2600
    doppler duplex #2602
    laboratory investigation #2603
    manifest #2605
    burden disease #2605
    parenteral #2606
    metaregression #2606
    fatal outcome #2608
    patients 2 #2608
    098 #2610
    p0001 patients #2613
    died #2615
    886 #2618
    percent #2619
    aviation #2620
    cost analysis #2620
    concentrate #2621
    occlusive #2622
    presenting #2625
    assess #2626
    prescribed #2631
    agents steroidal #2633
    coincided #2635
    trials rcts #2635
    chondroitin #2635
    10 day #2637
    345 #2641
    attractive #2641
    mutation patients #2642
    greatest risk #2643
    23 patients #2645
    decision #2649
    risk cardiovascular disease #2656
    134 #2659
    recurrence #2660
    hamilton #2661
    c677 #2662
    benzimidazoles #2662
    679 #2663
    shr #2667
    quartile #2674
    receive #2675
    439 #2677
    valsalva #2680
    trials #2682
    outcome ultrasonography #2683
    516 #2683
    initial dose #2685
    iii #2685
    inconclusive #2686
    tmax #2687
    mortality 95 #2688
    tissue plasminogen activator #2690
    aso #2691
    594 #2691
    bleed #2692
    schedule female #2694
    stillbirth #2698
    patients risk factors #2702
    early discharge #2703
    14 #2706
    previous stroke #2720
    prematurely #2725
    897 #2727
    txb2 #2729
    management strategies #2732
    dose low #2732
    cart #2736
    595 #2737
    427 #2739
    classifications #2739
    therapeutic options #2744
    risk ratio #2745
    predetermined #2746
    848 #2746
    baseline characteristics #2747
    patients asthma #2747
    direct comparison #2752
    pan #2755
    nephrotoxicity #2758
    randomised trial #2764
    contusions #2765
    management acute #2768
    143 #2768
    confounded #2769
    expert consensus #2772
    alpha animals #2772
    antithyroid #2772
    active control #2775
    thrombomodulin #2776
    inpatient #2776
    563 #2777
    compression #2778
    dosages #2779
    leukocyte count #2781
    mass screening #2782
    466 #2783
    hemostatic #2784
    primary outcomes #2785
    percentiles #2788
    90th #2789
    nadph2 #2791
    402 #2802
    consecutive series #2802
    reaching #2805
    cirrhosis patients #2805
    international #2809
    standardized #2811
    secondary #2811
    embolic #2812
    406 #2813
    follow studies #2813
    prevalence risk factors #2814
    httlpr #2816
    discriminant analysis #2817
    selectins #2819
    consisting #2823
    equivalency #2825
    antiplatelet drugs #2826
    bid #2826
    genetic variations #2830
    557 #2833
    male mass #2834
    recurrence rate #2835
    contacting #2835
    helminth #2836
    ketoprostaglandin #2836
    kruskal #2839
    crossover #2839
    554 #2843
    partum #2847
    anterior cruciate ligament #2850
    carboxypeptidase #2851
    iii trials #2852
    doppler ultrasonography #2852
    ≤2 #2853
    postoperative patients #2854
    post discharge #2857
    new treatment #2857
    specialised #2858
    methods prospective #2862
    497 #2870
    discontinuation #2871
    264 #2876
    628 #2877
    52 #2879
    trimester pregnancy #2880
    excessive #2880
    hit #2884
    mdct #2885
    balloon angioplasty #2886
    anterior cruciate #2887
    670 #2895
    eligibility #2896
    systematic review metaanalysis #2897
    21 #2897
    central venous catheters #2900
    statin #2902
    slight #2903
    severe asthma #2903
    feasible #2903
    12 patients #2908
    concomitantly #2910
    supposed #2911
    insulin receptors #2914
    lowrisk patients #2917
    leading death #2917
    39 #2919
    routine clinical practice #2920
    referrals #2921
    older children #2922
    993 #2928
    proportions #2928
    clear #2932
    2400 #2934
    risk stratification patients #2934
    aggregation platelet #2941
    control subjects patients #2945
    meier estimate #2946
    addison #2952
    portal #2954
    100 #2956
    returned #2957
    010 #2960
    270 #2960
    20 #2961
    exercise therapy #2962
    followup #2962
    transabdominal #2963
    132 #2974
    echocardiography patients #2975
    123 #2978
    risk myocardial #2981
    declare #2984
    lecture #2984
    eclampsia pregnancy #2986
    glucose levels #2987
    preoperatively #2988
    adult blood #2990
    pneumatic #2991
    point #2991
    n4 #2992
    undefined #2993
    treatable #2996
    cvr #2997
    microvessels #2998
    499 #3004
    prostacyclin #3012
    dipyridamole #3013
    factors surveys #3015
    antigen levels #3015
    2 patients #3016
    081 #3019
    double‐blind #3022
    35 patients #3023
    nested case #3025
    early recognition #3025
    comorbidity #3026
    contraindication #3028
    intention #3035
    extremities #3038
    50 years #3040
    419 #3040
    patients hf #3041
    lymphopenia #3043
    relevant articles #3044
    095 #3045
    prenatal exposure #3047
    summarize #3050
    respondents #3052
    respects #3060
    subcutaneous injection #3062
    80 #3063
    nomogram #3063
    fourteen #3065
    95 p0001 #3066
    patients data #3067
    study prevalence #3071
    subsequently #3076
    2 4 #3076
    disease aged #3077
    524 #3082
    342 #3083
    angioplasty #3088
    chronic renal failure #3088
    independent risk factors #3089
    healthy #3090
    clinical risk factors #3098
    lancet #3102
    reviewer #3104
    practice guidelines #3109
    trimester #3110
    benchmark #3110
    npv #3115
    pregnant woman #3119
    neutrophil activation #3120
    oac #3122
    lifelong #3122
    wallis #3122
    inadequacy #3123
    intravenously #3129
    claimed #3132
    12 months #3134
    136 #3134
    meta‐analysis #3137
    082 #3142
    levels risk #3142
    placentae #3143
    randomized clinical trial #3145
    time interval #3147
    arthroscopic #3149
    507 #3153
    idiopathic #3153
    marathon #3155
    mega #3156
    avoiding #3158
    radiologists #3165
    initial presentation #3172
    seventh #3173
    cornerstone #3182
    test #3184
    494 #3188
    revascularisation #3191
    409 #3193
    diethylstilbestrol #3194
    pregnancy women #3194
    pacientes #3197
    945 #3198
    plasmin #3198
    tenth #3199
    therapy risk #3199
    gold standard #3200
    vivo model #3205
    res #3207
    patient preference #3211
    catheter #3212
    suggested #3219
    cancer types #3219
    153 #3223
    intravenous infusion #3223
    72 hours #3225
    605 #3227
    methodological quality #3238
    observers #3239
    recombinant #3241
    meetings #3241
    intravenous administration #3242
    risk stroke #3246
    alternative #3249
    198 #3251
    bivalirudin #3251
    29 #3253
    hypothyroid #3253
    judgement #3255
    scoring #3255
    normotensive #3256
    054 #3257
    patient preferences #3261
    glargine #3265
    validated #3266
    patients evidence #3267
    116 #3268
    immunoassay #3271
    414 #3275
    6 #3277
    tranexamic acid #3279
    gbd #3280
    contraceptive #3281
    inclusion #3284
    arthroplasty replacement #3288
    coumarin #3289
    tumor markers #3289
    replace #3290
    65 years #3291
    swan #3292
    recurrence rates #3294
    efficacy outcomes #3299
    812 #3314
    rtpa #3315
    reversibility #3316
    anticardiolipin antibodies #3319
    discriminant #3321
    vascular risk #3322
    104 #3325
    hemophilia #3328
    972 #3329
    reduces #3330
    465 #3330
    cruciate ligament #3331
    patients symptoms #3334
    74 #3337
    meta #3338
    acute coronary syndrome #3339
    inpatients #3344
    cerebrovascular disease #3344
    evaluating #3349
    362 #3349
    diagnosing #3354
    spontaneous abortion #3354
    273 #3355
    common complication #3356
    diagnosis cancer #3356
    15 #3357
    lysate #3358
    581 #3359
    092 #3361
    miscarriages #3365
    prevalent #3371
    thrombolysis #3376
    treatment modalities #3377
    363 #3378
    concluded #3379
    humans lower #3379
    301 #3379
    intima media #3380
    computed tomography #3382
    hematomas #3387
    calf #3389
    function patients #3389
    contraception #3390
    repeated #3394
    413 #3395
    p0002 #3397
    cava #3399
    311 #3400
    tunica #3403
    acute treatment #3403
    553 #3403
    humans kaplan #3408
    saved #3415
    differs #3418
    preventive #3419
    randomisation #3419
    hypothesised #3420
    surgical patients #3420
    study risk #3420
    thrombocythemia #3422
    odds #3424
    confirm #3425
    testimony #3430
    competing #3434
    natriuretic #3437
    70 #3439
    ease #3443
    asian patients #3444
    124 #3445
    519 #3447
    487 #3451
    168 #3452
    prevalence incidence #3452
    evening #3458
    covid19 infection #3464
    34 #3470
    differ #3470
    intensive chemotherapy #3471
    patients receive #3472
    pregnancy complications #3472
    worsened #3476
    induced platelet #3479
    undiagnosed #3482
    antiphospholipid #3485
    cancer metastasis #3485
    increased morbidity #3486
    asymptomatic #3487
    lower leg #3487
    personyears #3490
    paradox #3490
    pacemaker #3493
    statistical methods #3494
    convergent validity #3496
    failure hf #3497
    201 #3504
    inhibitors #3506
    hemorrhagic complications #3506
    treat #3506
    938 #3513
    tomography angiography #3521
    discusses #3522
    confirmed #3522
    291 #3527
    quintiles #3529
    95 confidence intervals #3530
    human cytomegalovirus #3533
    lupus #3533
    areas covered #3537
    societies #3541
    guidance #3541
    113 #3544
    current practice #3551
    gastro #3551
    10 #3552
    stroke risk #3559
    baboons #3560
    344 #3562
    benefits risks #3564
    neutralize #3565
    nsaids #3566
    bibliographic #3567
    depends #3571
    patients recurrence #3573
    inconsistent #3575
    safety profiles #3580
    508 #3584
    evaluates #3592
    necessity #3596
    prognosis prospective #3596
    patient management #3598
    prognostic significance #3604
    vitamin #3605
    risk stratification #3606
    consensus document #3617
    treated #3619
    platelet function #3619
    platelet activation #3622
    interval #3622
    mutation #3624
    lipid profiles #3626
    kappa #3629
    q3 #3629
    organ damage #3635
    analysis performed #3640
    75 #3641
    bypass surgery #3642
    homozygote #3642
    undergo #3642
    p006 #3645
    externally #3645
    occlusions #3646
    1960 #3649
    30 #3649
    fibrillation #3651
    interindividual variability #3651
    coronary events #3656
    atherogenic #3658
    newer #3662
    patients 95 #3667
    optimal management #3671
    outcome administration #3671
    endovascular treatment #3678
    blinding #3679
    treatment complications #3680
    limited data #3683
    68 #3684
    clopidogrel #3685
    mammography #3693
    myalgia #3703
    478 #3706
    rationale #3707
    813 #3708
    rebound #3720
    drug monitoring #3721
    diagnostic process #3721
    pharmacodynamics #3725
    inhibitors humans #3725
    130 #3729
    unknown #3731
    patient population #3733
    serine proteases #3736
    349 #3738
    humans intracranial #3739
    effective #3739
    factor 4 #3741
    585 #3743
    299 #3744
    network meta #3746
    homozygous #3747
    495 #3750
    practitioner #3752
    randomised #3754
    deterioration #3754
    objectives #3759
    subgroup analyses #3762
    8 patients #3762
    00001 #3765
    host defense #3769
    statin therapy #3772
    scarce #3773
    clinicians patients #3774
    computed ultrasonography #3774
    inherited #3775
    517 #3778
    interpretable #3778
    483 #3782
    aminoglycosides #3789
    thyroid hormones #3789
    total knee arthroplasty #3789
    525 #3791
    412 #3795
    441 #3797
    life illness #3801
    333 #3802
    versus #3803
    vessel wall #3804
    compelling #3804
    preexisting #3808
    outcome measure #3814
    patients lung cancer #3815
    330 #3815
    valid #3816
    iu #3818
    55 patients #3821
    fv #3823
    stasis #3824
    lost #3825
    compares #3830
    itching #3831
    proved #3834
    osmolar #3837
    elective #3838
    hydrolases #3839
    patient education #3843
    197 #3849
    irs #3856
    meeting #3856
    anaesthesia #3857
    4 patients #3858
    congresses #3859
    acquired resistance #3860
    review data #3860
    male neoplasms #3862
    preferred #3864
    occurring #3867
    death #3880
    optimisation #3884
    cancer survival #3884
    record #3885
    sensitivity #3885
    avoids #3887
    calculated #3888
    184 #3890
    351 #3890
    difference #3890
    10000 #3902
    halflives #3903
    methylamines #3903
    methimazole #3904
    patients time #3905
    incidence prevalence #3908
    angiography #3915
    specificity tomography #3915
    coronary thrombosis #3918
    decide #3927
    474 #3931
    ankle #3932
    955 #3935
    458 #3938
    jak2 #3939
    extravasation #3945
    405 #3946
    case fatality #3946
    preeclampsia #3952
    neurology #3953
    56 #3956
    p004 #3961
    dichotomy #3961
    randomized clinical trials #3963
    women #3964
    carboxypeptidases #3965
    postoperatively #3966
    clinical effectiveness #3968
    uncontrolled #3970
    risk cancer #3970
    austrian #3971
    behalf #3971
    cardiovascular events #3972
    data studies #3975
    2nd #3975
    quality assurance #3980
    986 #3982
    pregnancy #3982
    continuous infusion #3983
    unstable #3986
    flying #3986
    month #3987
    488 #3990
    systematic analysis #3994
    sequentially #4006
    calculate #4010
    lower risk #4011
    limited evidence #4014
    patients evaluated #4016
    scored #4023
    secondary prevention #4026
    538 #4028
    equivalence #4029
    gln #4031
    meyer #4032
    cerebral venous #4041
    introduction #4045
    296 #4045
    423 #4047
    262 #4051
    ended #4052
    validating #4058
    received #4062
    recurrent disease #4066
    cruciate #4073
    elevated #4074
    compare #4075
    pcc #4077
    bariatric #4077
    avoid #4080
    429 #4081
    326 #4083
    hour #4088
    natriuretic peptide #4089
    oligosaccharides #4089
    angioplasty balloon #4091
    maneuver #4092
    3000 #4093
    16 #4098
    indications #4099
    cutoff #4099
    activation #4099
    contact #4102
    pharmacological #4106
    infusion rate #4109
    392 #4113
    335 #4117
    6 months treatment #4119
    ptm #4120
    completing #4125
    patients low risk #4133
    008 #4137
    withdrawn #4137
    41 #4138
    bms #4146
    patients died #4149
    medical students #4152
    haemorrhagic #4154
    continue #4158
    study control #4161
    nulliparous #4167
    2030 #4171
    patients prostate cancer #4171
    antitumour #4177
    steroidal #4178
    multidisciplinary approach #4189
    direct #4192
    therapy combination #4198
    casts #4200
    411 #4212
    485 #4212
    medical center #4214
    408 #4215
    weighted #4221
    additional #4222
    452 #4223
    289 #4226
    121 #4226
    trough #4229
    p0005 #4230
    crosssectional analysis #4230
    hormonal #4234
    veins #4235
    cox regression #4242
    patients mortality #4242
    178 #4246
    nsaid #4261
    263 #4263
    abbreviated #4267
    encountered #4268
    atrial fibrillation patients #4274
    fab #4279
    late pregnancy #4285
    pai1 #4286
    rise #4287
    oral aged #4294
    q4 #4296
    228 #4303
    share #4304
    10 patients #4306
    105 #4310
    rehospitalization #4314
    patients increased risk #4315
    185 #4316
    tat #4319
    separate #4322
    concentrates #4328
    intima #4329
    devised #4331
    294 #4339
    102 #4340
    455 #4340
    pronounced #4342
    incidental findings #4345
    potential risk factors #4350
    managed #4350
    detrimental #4356
    253 #4359
    agreed #4360
    young age #4363
    specialist #4379
    minutes #4383
    rapid #4383
    retrospective studies #4384
    447 #4385
    cd11b #4387
    288 #4391
    170 #4392
    slice #4394
    concurrently #4394
    risk cardiovascular #4396
    steadily #4402
    239 #4406
    negative #4407
    bowel diseases #4407
    71 #4407
    general #4407
    guideline recommendations #4408
    postoperative day #4409
    ventilation #4413
    splanchnic #4417
    lacking #4417
    dose aspirin #4419
    immunoassays #4419
    recombinant proteins #4423
    3 patients #4426
    author #4427
    148 #4428
    281 #4429
    primary myelofibrosis #4430
    appropriateness #4433
    profoundly #4436
    completed #4438
    platelet #4440
    cellulitis #4441
    sixteen #4442
    concomitant #4445
    assays #4453
    334 #4458
    vascular surgery #4459
    192 #4459
    cytomegalovirus infection #4461
    proband #4461
    total costs #4474
    377 #4479
    443 #4482
    clinical manifestations #4486
    cd18 #4486
    pancreatic cancer #4487
    inadequate #4487
    coronavirus disease covid19 #4489
    smr #4492
    risk prediction #4493
    bus #4497
    current management #4498
    476 #4499
    doubling #4500
    infected patients #4502
    comprises #4503
    activation platelet #4503
    54 #4513
    primary diagnosis #4515
    alpha2 #4516
    therapeutic #4532
    septic #4534
    3 groups #4535
    male pulmonary #4541
    526 #4542
    elastase #4544
    hitherto #4546
    fairly #4552
    cardiovascular death #4559
    985 #4564
    1250 #4567
    calculating #4571
    cerebrovascular disorders #4571
    multicenter trial #4574
    2c #4585
    debate #4586
    disadvantage #4588
    plasma concentrations #4591
    283 #4592
    preserves #4594
    attenuating #4594
    gradual #4595
    eventually #4595
    simplified #4596
    204 #4596
    4 #4601
    4000 #4601
    encouraged #4603
    icer #4610
    frequently #4611
    acetylsalicylic acid #4613
    vii #4613
    vaginal #4614
    917 #4619
    assay #4634
    subclinical atherosclerosis #4636
    risks benefits #4640
    hospital costs #4640
    242 #4642
    genetic risk factors #4644
    escalating #4648
    priori #4654
    003 #4658
    habitual #4658
    survey #4659
    transurethral #4663
    myelofibrosis #4670
    171 #4670
    thyroid hormone #4673
    40 #4675
    407 #4679
    day #4680
    fh #4680
    recurrent stroke #4681
    wheezing #4693
    ranging #4698
    unchanged #4698
    5 patients #4701
    complicated #4703
    truncated #4709
    therapeutic intervention #4715
    differential humans #4719
    immobilization #4725
    129 #4727
    orthopedic #4735
    cardiovascular morbidity #4738
    current guidelines #4739
    therapeutic strategies #4744
    ranged #4769
    027 #4774
    baseline patients #4775
    chronic renal #4775
    acute coronary #4784
    scheduled #4785
    44 #4785
    molecular #4792
    knee #4800
    insulin glargine #4801
    prophylactic #4802
    arthroplasty #4803
    alternatively #4810
    extracranial #4813
    courses #4819
    diagnostic imaging #4825
    therapy humans #4836
    echocardiography #4846
    174 #4848
    cholesterol levels #4853
    acl #4861
    definition #4861
    efficiency #4869
    nonvalvular atrial fibrillation #4870
    gpiib #4870
    increased plasma #4875
    unexposed #4876
    gynecological #4880
    antiphospholipid syndrome #4881
    screening tool #4884
    322 #4886
    antiplatelet therapy #4891
    total #4891
    treating #4896
    abstracted #4897
    doses #4902
    ischemic heart disease #4905
    preparations #4906
    tests prognosis #4906
    served #4910
    fmd #4913
    chlamydophila #4913
    560 #4914
    recommendation #4918
    geriatrics #4920
    acute ischemic #4923
    renal dysfunction #4929
    556 #4932
    154 #4933
    870 #4934
    cpb #4939
    325 #4951
    26 #4952
    satisfied #4957
    appeared #4959
    fund #4972
    manufacturers #4976
    dose #4976
    orthopedics #4982
    albeit #4982
    recommended #4987
    cardiology #5000
    389 #5006
    references #5006
    reminder #5009
    epoprostenol #5009
    probnp #5014
    point mutation #5018
    risk women #5023
    syndrome patients #5033
    156 #5040
    screening test #5040
    proposal #5042
    global burden #5044
    primary health #5045
    analytic #5047
    obstetrical #5048
    lasted #5049
    patients sepsis #5051
    limitations #5055
    diagnosis management #5058
    patients myocardial infarction #5062
    spinal surgery #5065
    255 #5068
    conflicting #5070
    saphenous #5075
    inaccessible #5078
    1a #5079
    switched #5084
    evaluable #5089
    regarded #5089
    hip fractures #5090
    relation #5090
    transluminal #5093
    menstrual #5094
    fashion #5098
    amputation #5102
    external validation #5103
    arteritis #5107
    inflammatory responses #5109
    oxadiazoles #5110
    dalys #5112
    tailor #5115
    admission patients #5118
    composite #5120
    discriminative #5123
    bay #5124
    vivo studies #5124
    108 #5125
    282 #5129
    0018 #5130
    ischaemic stroke #5130
    female #5131
    131 #5131
    transfused #5134
    contrast media #5136
    balancing #5136
    fetal death #5138
    activator #5139
    scans #5143
    341 #5146
    n6 #5150
    kg1 #5151
    shortly #5157
    disagreement #5157
    preclinical studies #5160
    doppler #5165
    11 patients #5170
    predispose #5170
    hazard #5171
    readers #5173
    prescriptions #5174
    graft failure #5178
    weaknesses #5185
    renal impairment #5186
    70 patients #5190
    infarctions #5191
    screening #5193
    threefold #5198
    highest #5202
    extracellular vesicles #5204
    acs #5205
    144 #5206
    hospital patients #5208
    remains #5209
    excess mortality #5210
    doppler color #5221
    polysaccharides #5223
    heparan #5229
    emergencies #5233
    articles #5233
    indwelling #5241
    flowmetry #5242
    gram #5244
    3 #5248
    platelet aggregation #5252
    considerably #5253
    comparison #5262
    testing #5264
    plasma levels #5265
    estimate #5288
    pooling #5289
    365 #5289
    aware #5300
    36 patients #5301
    thrombus #5301
    urokinase #5302
    atherogenesis #5302
    triage #5303
    case reports #5305
    benefit #5308
    reversal #5310
    stroke treatment #5314
    contrasted #5316
    orthomyxoviridae #5319
    openlabel #5320
    70 years #5325
    aged postoperative #5330
    animal drug evaluation #5332
    dizziness #5334
    absent #5335
    factor humans #5336
    stratify #5340
    acute ischemic stroke #5341
    reagent #5341
    blood vessel #5343
    ultrasound imaging #5344
    fatality #5347
    contrast agents #5355
    arose #5361
    schedule drug #5363
    male #5363
    based guidelines #5370
    hyper #5372
    obstetric #5376
    accepted #5383
    thyrotropin #5401
    informed consent #5402
    blood products #5405
    selected patients #5406
    adult #5407
    heart valve #5409
    intracranial #5411
    questionnaire #5414
    register #5415
    summarized #5416
    19 #5417
    noninvasive #5421
    clinical risk #5424
    nonsignificant #5429
    protein levels #5430
    concerns #5439
    charts #5440
    hyperprolactinemia #5441
    familiarity #5442
    37 #5445
    630 #5448
    retrieved #5450
    cancer growth #5455
    presently #5456
    congenital heart #5465
    registered #5470
    recombinant human #5474
    intermediate #5475
    340 #5476
    395 #5484
    allocation #5488
    247 #5490
    occurrences #5490
    moyamoya disease #5491
    ntprobnp #5493
    kaplan meier #5496
    patient risk #5497
    260 #5497
    continuing #5499
    discomfort #5499
    9 patients #5500
    postal #5503
    ssris #5515
    correctly #5517
    weight #5524
    309 #5530
    period #5533
    erythema #5539
    limitation #5539
    suggestions #5541
    survival benefit #5542
    imputed #5545
    receptor1 #5563
    established #5563
    175 #5565
    545 #5566
    management #5569
    46 #5573
    reduce risk #5573
    324 #5595
    excludes #5597
    equivalent #5598
    circulating levels #5598
    categorical #5600
    stm #5607
    grounds #5617
    expert #5620
    02 #5624
    microgram #5626
    minus #5627
    premenopausal women #5629
    retrieve #5633
    food preferences #5637
    drug administration #5641
    platelet count #5643
    80 years #5644
    reclassification #5644
    65 #5651
    trial #5653
    087 #5667
    published data #5671
    48 #5676
    seventy #5684
    214 #5689
    latex #5690
    platelet glycoprotein #5692
    reproducible #5696
    1997 #5698
    meier #5714
    370 #5718
    return #5721
    40 years #5729
    atherosclerotic #5730
    89 #5732
    perform #5734
    995 #5748
    091 #5755
    stand #5756
    0014 #5761
    metabolic effects #5764
    milder #5771
    semiquantitative #5771
    241 #5777
    recurrence patients #5781
    varied #5784
    creatinine clearance #5788
    3rd #5791
    mpo #5804
    incidence rates #5804
    95 women #5809
    orthopedic procedures #5810
    male middle aged #5811
    url #5812
    1000 #5819
    aircraft #5819
    income countries #5828
    diagnosed #5840
    undergoing surgery #5843
    true #5852
    atrial #5852
    088 #5854
    attending #5856
    290 #5857
    women pregnancy #5857
    hip #5866
    advantageous #5875
    complete resolution #5878
    occurrence #5894
    reliable #5894
    excluded #5899
    aged models #5919
    adding #5923
    safety patients #5927
    22 patients #5928
    aged platelet #5928
    graded #5934
    premenopause #5938
    revision #5938
    353 #5945
    prodrugs #5946
    rrs #5949
    141 #5952
    gastrointestinal hemorrhage #5954
    janus kinase #5959
    43 #5962
    rcts #5962
    families #5967
    328 #5971
    deemed #5977
    savings #5980
    counseling #5985
    blood platelets #5987
    blood #5990
    receiver operating #5996
    guideline #5998
    cancer incidence #6006
    current standard #6013
    therapeutic interventions #6028
    nadir #6034
    registries risk #6039
    patients experience #6042
    allocated #6044
    ≥3 #6052
    wash #6059
    advance #6062
    quarter #6065
    spect #6068
    glycosaminoglycans #6069
    decompensated #6074
    24 #6076
    bacteremia #6090
    topics #6101
    type iii #6101
    suggestive #6105
    emerging evidence #6113
    prevent #6117
    safety data #6120
    directly #6133
    72 #6135
    267 #6136
    lipid profile #6140
    ≥2 #6144
    normalization #6151
    centuries #6153
    47 #6157
    ffa #6160
    generation #6160
    lobar #6161
    agents blood #6164
    292 #6165
    informed #6173
    pharmacodynamic #6188
    lung male #6190
    updating #6192
    advantages disadvantages #6194
    lower #6195
    bilateral #6198
    cyclosporine #6208
    tumour growth #6212
    pathogenetic #6221
    femoral artery #6224
    mortality morbidity #6228
    terminated #6228
    new drugs #6229
    312 #6230
    evidence base #6232
    vitro studies #6234
    crp #6235
    discontinued #6236
    111 #6240
    abdomen #6248
    denmark #6254
    proportional #6268
    practitioners #6273
    colleagues #6273
    administered #6277
    1978 #6283
    screened #6293
    infused #6297
    840 #6318
    prostatectomy #6330
    017 #6334
    saphenous vein #6339
    135 #6340
    63 #6340
    percentile #6344
    higher doses #6345
    adequacy #6347
    divided #6348
    apache #6351
    screen #6357
    opinions #6360
    opposed #6362
    percentage #6370
    longterm followup #6372
    risk mortality #6386
    dyslipidemias #6390
    kaplan #6391
    consensus #6392
    208 #6397
    potential mechanisms #6404
    roche #6405
    factor gene #6405
    initiated #6408
    compensated #6411
    investigating #6427
    ultrasound #6441
    restenosis #6442
    bootstrap #6452
    collection #6457
    post operative #6464
    enzyme linked #6467
    bariatric surgery #6468
    coronary syndrome #6469
    decreased risk #6471
    218 #6472
    perfusion #6475
    imbalance #6484
    angina pectoris #6493
    calendar #6498
    accuracy #6501
    peripheral artery disease #6501
    incidence risk #6502
    cancer cell #6502
    complement activation #6505
    pregnancies #6519
    surgical procedure #6520
    supervised #6521
    models male #6522
    138 #6523
    washout #6524
    triiodothyronine #6524
    318 #6524
    peripheral #6525
    vena #6527
    highrisk patients #6532
    cochrane #6532
    increased incidence #6532
    placebo patients #6536
    replaced #6537
    bowel #6538
    exogenous #6538
    thirteen #6540
    aspirin patients #6540
    year #6546
    superior #6549
    clinical assessment #6550
    cohorts #6555
    dilemma #6560
    crt #6561
    dosing #6576
    tertile #6581
    231 #6586
    limited #6589
    md #6592
    prediction #6596
    treatment choice #6600
    pooled #6601
    occurs #6610
    510 #6611
    belgium #6620
    crude #6621
    injections #6638
    pancreatic neoplasms #6641
    genetic testing #6641
    individual #6650
    complications #6650
    complaints #6652
    degranulation #6663
    methylenetetrahydrofolate #6665
    liver diseases #6674
    patents #6680
    smoking cessation #6696
    17 patients #6704
    routinely #6706
    tumour progression #6708
    saline #6709
    194 #6713
    approval #6727
    recognised #6729
    hazard ratios #6729
    thromboxane #6734
    allcause mortality #6744
    multicenter #6747
    appropriately #6748
    increasing age #6751
    body temperature #6766
    385 #6766
    q1 #6768
    clinical signs #6771
    age patients #6774
    defined #6780
    2 groups #6780
    expense #6781
    42 patients #6791
    train #6796
    hyperglycemia #6801
    premedication #6803
    reached #6803
    plasma proteins #6807
    response relationship #6807
    benefits #6810
    cardiovascular risk #6821
    256 #6831
    280 #6838
    iqr #6839
    glucocorticoids #6840
    summary #6850
    279 #6854
    cancer diagnosis #6856
    systematic #6870
    points #6877
    ambulatory #6883
    weekly #6884
    reviews #6891
    physicians #6893
    fibrillation patients #6898
    disturbances #6912
    adverse event #6912
    sought #6918
    112 #6923
    251 #6940
    complications patients #6948
    vasopressin #6957
    failure #6965
    subsequent #6971
    hematologic #6974
    intensity #6976
    246 #6976
    humans hydroxymethylglutaryl #6982
    papers #6983
    tpa #6986
    intervals #6987
    addressed #6989
    259 #6992
    222 #6995
    shock septic #6995
    adapted #6998
    disclosed #7001
    incidence risk factors #7008
    hazards models #7015
    cardiovascular disease #7019
    myeloperoxidase #7020
    lung cancer patients #7023
    stenting #7024
    responded #7026
    cohort #7037
    1 patient #7038
    unacceptable #7039
    interleukin8 #7042
    reductases #7045
    preventing #7056
    curve #7058
    patients baseline #7065
    animal doseresponse relationship #7071
    reduced risk #7075
    written #7080
    applicability #7084
    asymptomatic patients #7086
    monoclonal antibody #7098
    hospitalization humans #7101
    computed #7104
    betacoronavirus covid19 #7104
    novartis #7108
    complications pregnancy #7111
    infarction stroke #7114
    superiority #7116
    interquartile range #7120
    select #7122
    carotid intima #7141
    internationality #7146
    surveys questionnaires #7160
    163 #7166
    pharmacy #7167
    patients renal #7171
    physicians patients #7177
    randomization #7184
    liver cirrhosis #7187
    211 #7188
    brain metastases #7190
    oral animals #7192
    walking #7195
    drawn #7196
    combination #7197
    withdrawal #7204
    5year #7204
    acting #7210
    cardiovascular disease cvd #7210
    disposition #7212
    paucity #7218
    humans lung #7221
    20 patients #7225
    sulfate #7240
    operating characteristic #7244
    treatment children #7250
    vldl #7250
    hematocrit #7255
    199 #7257
    retrospective cohort study #7257
    alongside #7258
    clinical benefit #7265
    controls #7267
    diagnostics #7270
    option #7273
    grouped #7275
    young women #7278
    products #7282
    likelihood #7284
    modest #7290
    sensitivity analysis #7290
    atrium #7291
    360 #7303
    types #7304
    factors stroke #7305
    undergoing #7327
    partial #7330
    patients isolated #7332
    pectoris #7338
    ischemic stroke #7338
    interleukin6 #7352
    1c #7352
    myocardial infarction #7356
    p0001 #7356
    standardised #7356
    betacoronavirus #7357
    simple #7360
    radiology #7379
    pap #7392
    patients aspirin #7400
    angiopathies #7401
    regimens #7405
    109 #7409
    bias #7411
    peptide fragments #7413
    iiia #7424
    intravenous injection #7429
    420 #7431
    propranolol #7438
    favourable #7440
    hypercholesterolemia #7441
    respective #7444
    dose dependent #7447
    infusion #7448
    clinical setting #7454
    ways #7465
    risk adverse #7497
    il6 #7510
    mortality rates #7515
    209 #7516
    considerations #7517
    exclusions #7518
    patient safety #7520
    angina #7522
    urgently #7522
    cmv infection #7541
    phase iii #7555
    257 #7558
    #7559
    interim #7561
    injection #7564
    cinahl #7578
    comorbid #7578
    191 #7578
    pheochromocytoma #7585
    ischaemic #7598
    antibodies monoclonal #7601
    reasons #7602
    tended #7608
    pooled analysis #7609
    azathioprine #7615
    13 #7616
    predictor #7620
    femoral #7640
    random allocation #7646
    epidemiological studies #7647
    29 patients #7647
    abrupt #7655
    derivation #7662
    interquartile #7675
    manifestation #7676
    temporary #7679
    positive patients #7687
    medical conditions #7705
    18 #7705
    seventeen #7710
    304 #7719
    ligament #7732
    consent #7733
    study association #7735
    cytomegalovirus #7736
    severe #7742
    adverse outcomes #7745
    costs #7753
    cardiac surgical #7760
    189 #7770
    cochrane library #7771
    pregnancy outcome #7787
    110 #7802
    manufacturer #7802
    #7803
    9 #7811
    oxygenases #7813
    male gender #7815
    interleukin #7816
    pts #7819
    31 patients #7828
    hormone replacement #7828
    label #7828
    cpr #7829
    5 #7833
    abortion #7838
    influenza #7845
    radiation exposure #7850
    regular #7877
    tramadol #7878
    academic #7878
    septic patients #7880
    95 confidence #7884
    replacing #7886
    patients chemotherapy #7888
    iib #7908
    journals #7922
    strict #7927
    expertise #7928
    bioavailability #7930
    adoption #7934
    urogenital #7939
    highrisk #7939
    diseased #7944
    increasing evidence #7947
    disadvantages #7949
    243 #7965
    patients 1 #7972
    human blood #7973
    fragment #7975
    new class #7976
    28 #7989
    individualized #7990
    aim #7992
    premenopausal #7995
    advice #8016
    qol #8022
    malignant disease #8026
    pulmonary disease #8031
    99mtc #8034
    oligonucleotides #8040
    vascular disease #8049
    600 #8051
    preventable #8051
    medical #8051
    list #8059
    selective #8062
    routine clinical #8068
    fact #8078
    lasting #8080
    helpful #8084
    36 months #8086
    outcome acute #8092
    extracorporeal #8095
    248 #8113
    90 #8114
    patients heart #8120
    training #8120
    2004 #8122
    initiating #8123
    tsh #8125
    cholesterol ldl #8138
    sensorineural #8140
    imaging studies #8141
    investigational #8141
    mild #8156
    nosocomial #8164
    multiple organ #8175
    stroke #8176
    237 #8183
    158 #8184
    arteries #8190
    parenteral nutrition #8204
    confidence #8204
    renal dialysis #8209
    33 #8223
    impairment #8228
    renal function #8228
    81 #8233
    therapy #8235
    quantitative #8240
    smoking #8243
    lowest #8250
    lists #8250
    version #8260
    activated #8264
    125i #8264
    minimum #8270
    mortality #8280
    leukopenia #8281
    0008 #8284
    agents #8286
    119 #8290
    utilisation #8298
    practice #8310
    suffered #8316
    schedule #8320
    thrombectomy #8322
    postulated #8338
    endothelium vascular #8338
    immunosorbent assay #8339
    elimination #8341
    linked immunosorbent #8345
    hematology #8351
    absence presence #8382
    2 years #8382
    cell derived #8384
    229 #8394
    draw #8405
    occur #8415
    28 patients #8415
    ≥50 #8416
    reports #8427
    137 #8433
    mentioned #8436
    covid19 coronavirus #8447
    265 #8452
    glucuronidase #8458
    patient characteristics #8459
    transient ischemic #8463
    procedures operative #8463
    295 #8466
    exceed #8486
    knowledge #8493
    27 patients #8496
    covariate #8501
    evaluate #8501
    criterion #8504
    inborn #8519
    validate #8528
    rabbits #8537
    atherosclerosis #8557
    large cohort #8558
    menstrual cycle #8563
    193 #8565
    250 #8568
    adjusted life #8574
    leukocytes #8581
    146 #8582
    adolescent #8582
    row #8590
    carotid arteries #8596
    thirty #8596
    safety profile #8602
    cox #8604
    intensities #8605
    risks #8606
    fish oil #8624
    15 years #8624
    attenuates #8625
    entry #8639
    thresholds #8646
    presumed #8652
    emissioncomputed #8654
    223 #8655
    hydroxymethylglutaryl coa #8656
    valves #8658
    syndrome #8664
    factors patients #8666
    evaluations #8679
    certainty #8687
    markers #8689
    renal failure #8690
    biomarkers #8693
    polytetrafluoroethylene #8698
    publication aged aged #8706
    portal vein #8708
    hold #8723
    1 2 #8723
    additional studies #8726
    cardiotonic #8729
    definitions #8731
    address #8733
    judgment #8744
    platelet counts #8754
    requiring #8755
    practical #8756
    cardiovascular #8756
    endovascular #8756
    vasoactive #8762
    236 #8763
    interpret #8766
    undetected #8778
    subpopulation #8789
    medical treatment #8792
    illnesses #8798
    cardiovascular mortality #8802
    249 #8834
    internship #8836
    convenient #8837
    hydroxymethylglutaryl #8837
    resolving #8863
    representative #8864
    2 #8872
    cesarean #8876
    merits #8887
    endarterectomy #8896
    chronic liver disease #8902
    mimics #8903
    early treatment #8910
    surgical intervention #8911
    planned #8914
    micrograms #8914
    epoxide #8916
    aged myocardial #8919
    influenced #8934
    normal subjects #8936
    signs symptoms #8945
    proportional hazards #8945
    clinicians #8956
    cessation #8958
    experienced #8960
    heparan sulfate #8962
    leads #8973
    24 hours #8977
    rct #8980
    options #9002
    patients placebo #9002
    chemoprevention #9005
    comprise #9005
    societies medical #9007
    clinical events #9007
    reply #9017
    receiver #9026
    rank #9043
    7 #9061
    databases factual #9064
    early mortality #9075
    mps #9080
    diagnose #9080
    frequency #9083
    jan #9088
    statins #9090
    alpha1 #9115
    blood proteins #9116
    prone #9142
    valve prosthesis #9147
    time points #9147
    patient patients #9150
    pelvis #9158
    square #9165
    life threatening #9170
    molecular mechanisms #9179
    75 patients #9183
    advanced stage #9184
    lysis #9190
    editor #9193
    consensus statement #9209
    361 #9213
    considerable #9225
    platelets #9226
    1 month #9227
    dyspnea #9230
    pci #9230
    performs #9233
    contrast #9238
    4 hours #9259
    extrinsic #9263
    hazards #9264
    illness surveys #9264
    experts #9266
    uncomplicated #9267
    mumol #9278
    attenuation #9283
    rabbit #9286
    positive #9286
    trial registration #9297
    corresponded #9298
    dialysis #9319
    feasibility #9320
    earlier #9339
    suboptimal #9342
    patients negative #9355
    p0004 #9355
    preceded #9376
    loss #9378
    014 #9380
    higher incidence #9380
    purposes #9383
    invited #9384
    single center #9385
    death patients #9391
    radioactivity #9394
    bacterial infections #9401
    fourth #9402
    2b #9412
    ascending #9415
    haemorrhage #9425
    167 #9436
    properly #9442
    rheumatic #9446
    hospitalised #9448
    dysfunction #9460
    belonged #9480
    secondary analysis #9483
    respiratory tract #9486
    169 #9490
    240 #9493
    ipd #9502
    factual #9503
    valvular #9505
    thyroid function #9507
    selectin #9509
    hrs #9524
    inflammatory agents #9529
    confirms #9530
    designed #9535
    cardiopulmonary bypass #9540
    swelling #9542
    3 4 #9544
    insight #9557
    cooperation #9561
    requirements #9566
    hemoglobins #9573
    rose #9592
    il10 #9597
    observational cohort #9598
    lpa #9600
    rates #9617
    comparative effectiveness #9630
    kidney failure #9638
    primary point #9638
    successful treatment #9639
    laboratories #9644
    cardiogenic #9645
    optimal treatment #9650
    2008 #9656
    hf #9670
    published #9674
    congestive #9695
    pathophysiological #9704
    patients hospital #9713
    spontaneously #9720
    modalities #9721
    inappropriate #9724
    reuptake #9727
    acts #9729
    identifier #9730
    2007 #9732
    lactoferrin #9734
    42 #9744
    substitutes #9747
    hypothetical #9754
    nested #9764
    nonesterified #9768
    90 patients #9777
    reproducibility #9778
    sepsis #9802
    210 #9803
    absence #9813
    straightforward #9814
    easily #9817
    precise #9817
    coa reductase #9828
    nmol #9828
    classification #9836
    212 #9839
    craniotomy #9839
    0006 #9849
    utility #9855
    danish #9857
    labile #9865
    heterozygotes #9871
    nonhuman primates #9871
    discordant #9908
    moderately #9919
    cmv #9930
    60 years #9933
    lower limb #9936
    promise #9937
    degradation #9941
    2003 #9941
    tomography #9944
    treatment strategy #9951
    216 #9958
    low dose #9971
    investigator #9983
    detecting #9992
    regimen #9995
    pancreatic #9997
    casecontrol studies #9997
    12 hours #9997
    213 #10000
    neoplasm metastasis #10001
    chance #10008
    physician #10015
    extending #10027
    informative #10028
    hereditary #10041
    protective #10045
    obstacles #10045
    addressing #10051
    medication adherence #10052
    mthfr #10079
    presentations #10082
    familial #10087
    higher prevalence #10089
    chart #10108
    recipients #10113
    qualitative #10117
    1980 #10134
    completely #10145
    tested #10150
    aged obesity #10170
    182 #10176
    invasive #10181
    abnormalities #10186
    regularly #10189
    cast #10193
    multicentre #10198
    investigations #10199
    cell activation #10199
    cardiovascular risk factors #10209
    medical therapy #10213
    clinical data #10213
    tumor necrosis factoralpha #10215
    replacement therapy #10225
    routine #10234
    syndrome humans #10253
    heart failure #10265
    183 #10280
    gaps #10291
    blood transfusion #10293
    hospitalization #10293
    postpartum #10305
    measuring #10314
    aetiology #10315
    8 #10318
    photon emission #10329
    032 #10336
    dilution #10336
    worldwide #10337
    667 #10337
    greatly #10352
    aorta #10352
    indirectly #10377
    restoration #10378
    creatinine #10381
    cardiopulmonary #10385
    pneumonia viral #10397
    medical management #10404
    outcome measures #10408
    p0003 #10408
    tissue injury #10411
    bidirectional #10419
    circulation #10432
    reductase inhibitors #10432
    transfusion #10435
    enrolment #10446
    reflux #10457
    patients age #10461
    priority #10461
    quality life #10471
    phase 3 #10481
    activity levels #10489
    increased prevalence #10489
    1991 #10491
    style #10491
    147 #10501
    predictive factors #10514
    sex age #10526
    assessing #10529
    necrosis #10534
    matched #10556
    lower rate #10558
    portable #10563
    patients moderate #10570
    ray #10570
    125 #10574
    p002 #10576
    pulmonary artery #10578
    inform #10580
    recurrences #10583
    antisense #10583
    293 #10584
    180 #10598
    manifestations #10601
    closer #10602
    159 #10605
    microvascular #10605
    vasoconstrictor #10607
    hospitals #10612
    medical oncology #10615
    november #10628
    percutaneous coronary #10633
    persist #10635
    fragments #10637
    ascertained #10641
    1b #10647
    publication administration #10653
    postoperative #10659
    held #10674
    concerned #10674
    pulmonary vascular #10690
    term #10697
    discriminate #10697
    risk developing #10704
    synergism #10709
    multivariable analysis #10713
    neutrophil #10729
    consultation #10735
    centres #10751
    median duration #10755
    decisions #10759
    entire #10774
    haemoglobin #10797
    perioperative #10798
    patients cirrhosis #10804
    term mortality #10829
    300 #10832
    38 #10849
    prospective observational #10855
    sustained #10865
    randomised controlled #10867
    anatomical #10873
    diagnoses #10903
    airways #10903
    neurosurgical #10905
    monoclonal antibodies monoclonal #10909
    coronavirus infections #10921
    maximal #10924
    threatening #10963
    amniotic #10987
    coronary intervention #10989
    relative #10990
    blocker #10996
    needed #11009
    obese #11037
    neutropenia #11057
    ischemic #11057
    ethical #11062
    summarizes #11062
    attained #11062
    treatment option #11070
    balloon #11071
    12 weeks #11074
    originally #11083
    inability #11108
    location #11108
    catheters #11143
    beta2 #11159
    ischemic attack #11165
    hematoma #11189
    confirmation #11199
    neoplasms risk #11201
    metabolic syndrome #11202
    iia #11204
    strokes #11217
    choice #11228
    eligible patients #11247
    risk groups #11263
    1992 #11272
    humans kidney #11281
    cerebrovascular #11281
    waiting #11282
    ≥1 #11291
    endothelial function #11297
    troponin #11304
    determine #11306
    202 #11308
    aged prevalence #11331
    post #11332
    adherent #11338
    acute respiratory #11345
    acute myocardial infarction #11361
    event #11363
    combination therapy #11380
    glycoprotein #11391
    factors smoking #11395
    reconstructive #11397
    apply #11399
    developed #11405
    2005 #11415
    competent #11416
    medically #11426
    treatment decisions #11427
    prostaglandins #11434
    diuretics #11439
    hematological malignancies #11443
    morbidity #11445
    media #11464
    protocol #11487
    satisfying #11502
    performances #11525
    hospital admission #11526
    occlusion #11533
    placebo treatment #11533
    multicenter study #11542
    outflow #11542
    enrolled #11545
    humans intensive #11570
    55 #11577
    chronic inflammation #11600
    definitive #11621
    younger patients #11624
    baseline #11624
    sct #11638
    investigate #11670
    normal controls #11684
    contribution #11687
    reference #11694
    life qol #11697
    lipopolysaccharides #11699
    hypotension #11715
    ascites #11717
    myoglobin #11741
    independent risk #11745
    acute myocardial #11753
    radiopharmaceuticals #11783
    extent #11786
    orally #11790
    involving #11792
    2010 #11802
    nonspecific #11809
    vena cava #11829
    distinction #11841
    episodes #11865
    eclampsia #11872
    release #11874
    woman #11885
    151 #11891
    006 #11906
    elicited #11912
    icu patients #11915
    vasculitis #11937
    activating #11948
    age #11953
    sulphate #11955
    began #11957
    lethality #11967
    collectively #11970
    inferior #11978
    serum creatinine #11979
    myocardial injury #11980
    adp #11981
    immunosorbent #12006
    cardiovascular diseases #12015
    mortality rate #12041
    reduced #12043
    thirds #12057
    dietary intake #12057
    minority #12058
    monitored #12061
    differently #12066
    early pregnancy #12076
    humanized #12077
    wounds injuries #12079
    fair #12096
    thoracotomy #12111
    evidenced #12130
    1995 #12135
    elevated risk #12140
    085 #12141
    profile #12143
    prostate #12153
    149 #12157
    120 #12170
    digoxin #12177
    offset #12179
    uncommon #12187
    healthcare #12202
    causality #12208
    lung #12208
    spent #12219
    takes #12233
    tendency #12271
    pregnancy risk #12276
    expectancy #12281
    resolve #12300
    flaps #12302
    micromol #12326
    mismatch #12335
    favored #12342
    births #12351
    obstructive pulmonary #12358
    epinephrine #12365
    dependently #12372
    prescription #12394
    registration #12398
    incremental #12399
    switzerland #12409
    inflammatory response #12409
    consistent #12418
    potential confounders #12425
    echocardiographic #12450
    fifty patients #12451
    arginine #12475
    patient discharge #12480
    apparent #12483
    prospective randomized #12486
    sensitivity analyses #12490
    117 #12494
    switch #12513
    10 years #12521
    standards #12524
    requires #12540
    guide #12540
    statistically #12548
    prognostic #12579
    chronic obstructive #12584
    monoclonal #12589
    rapidly #12597
    tomography ray #12611
    lipoprotein #12619
    literature #12637
    repeat #12653
    single dose #12673
    drug interactions #12680
    hypertension pulmonary #12684
    physiological #12687
    pharmacogenetics #12706
    45 #12708
    prostatic #12708
    endocrine #12709
    ifngamma #12722
    minute #12733
    dosage #12736
    congestive heart failure #12747
    cardiac surgery #12756
    personal #12770
    estrogens #12778
    animal model #12796
    thyroid #12808
    settings #12820
    malignancies #12823
    infections #12836
    burden #12849
    intraoperative complications #12862
    cancer patient #12864
    reporting #12866
    196 #12881
    1999 #12904
    cvd #12906
    raised #12910
    endpoints #12912
    extracted #12940
    confirming #12947
    18 years #12976
    ray computed #12983
    postoperative complications #12990
    filters #13009
    monotherapy #13017
    transiently #13024
    oral administration #13041
    instance #13041
    located #13049
    tumor angiogenesis #13067
    based cohort #13094
    fold #13100
    severity #13106
    escalation #13107
    cancer risk #13107
    vomiting #13112
    physical #13112
    latin #13125
    sexes #13143
    drug therapy #13144
    0 #13145
    ratio #13159
    focused #13189
    appearance #13195
    compliance #13199
    pregnant women #13202
    optimal #13213
    expensive #13226
    support #13231
    exist #13235
    142 #13236
    lack #13240
    narcotic #13261
    formal #13262
    commercially #13265
    participant #13273
    median follow #13286
    indirect #13288
    emission computed #13352
    mediator #13366
    maintain #13391
    electronic databases #13394
    hypothesized #13395
    advantage #13432
    admitted #13437
    p00001 #13442
    anti #13455
    reliably #13459
    surveys #13463
    endothelial dysfunction #13466
    transient #13478
    patients experienced #13481
    provided #13489
    crosssectional study #13491
    patients patient #13494
    surrogate #13537
    vivo #13545
    retrospectively #13548
    maintained #13555
    195 #13556
    pulmonary hypertension #13563
    accurate #13563
    longterm outcomes #13585
    monitoring #13620
    laboratory #13629
    elucidated #13643
    abdominal #13652
    whilst #13665
    mitral #13682
    north america #13705
    marker #13707
    competence #13708
    vascular #13708
    45 years #13716
    2009 #13734
    icu #13748
    drug effects #13753
    medicine #13755
    healthy individuals #13758
    inhibitory effects #13763
    establishing #13766
    explanation #13773
    pelvic #13773
    participating #13774
    phospholipid #13776
    heart diseases #13789
    women risk #13816
    conservative #13820
    circulating #13824
    condition #13859
    kidney diseases #13860
    systematically #13868
    tissue #13876
    coronary angiography #13889
    internal #13916
    techniques #13923
    microparticles #13927
    dissemination #13928
    1993 #13939
    176 #13979
    require #13986
    castration #13998
    radioisotopes #14011
    48 patients #14013
    insufficiency #14022
    algorithms #14029
    risk death #14033
    members #14033
    requirement #14046
    independent predictors #14058
    continuous #14060
    organ failure #14072
    situations #14084
    focus #14084
    vasoconstriction #14119
    offer #14137
    supporting #14164
    activates #14188
    cardiac output #14194
    leukocyte #14204
    mitral valve #14205
    sensitivities #14216
    document #14242
    primary prevention #14248
    newborns #14256
    nausea #14276
    making #14285
    effectiveness #14304
    independent #14342
    inhibition #14357
    4 years #14367
    meaningful #14371
    pathologic #14372
    female fetal #14377
    acquired #14378
    6 patients #14391
    min1 #14391
    amniotic fluid #14403
    substances #14409
    pregnant #14423
    disease chronic #14460
    interleukin1 #14489
    infarction #14491
    influence #14509
    interventions #14510
    costeffectiveness #14535
    locations #14586
    participated #14592
    similarities #14608
    205 #14632
    statistics #14637
    renal insufficiency #14637
    reasonable #14646
    comparative #14648
    natural #14667
    blood samples #14672
    surgery patients #14696
    entered #14698
    pandemics #14707
    classify #14715
    institutes #14736
    surveyed #14741
    39 patients #14742
    sampled #14749
    2017 #14783
    arms #14785
    independent predictor #14787
    validity #14787
    databases #14808
    heart association #14814
    white matter #14816
    complete #14819
    stable #14828
    cox proportional #14835
    pge2 #14844
    duplex #14845
    population #14872
    contribute #14928
    retest #14931
    criteria #14938
    premature #14952
    critical illness #15004
    phospholipids #15030
    european society #15041
    cardiac catheterization #15042
    prostheses #15059
    questionnaires #15082
    treatment failure #15087
    sf36 #15089
    elective surgical #15107
    controlled clinical #15109
    flight #15110
    ldl #15120
    relate #15127
    health costs #15128
    initiation #15140
    obstruction #15142
    obstructive #15146
    stratification #15164
    proper #15177
    selection #15187
    registries #15197
    decrease #15201
    copd #15201
    randomized controlled trial #15210
    unilateral #15223
    ongoing #15230
    induces #15231
    individuals #15239
    young patients #15247
    previous #15250
    methods retrospective #15255
    disorders #15278
    drug #15278
    myocardial #15279
    4 weeks #15296
    quantitation #15298
    fewer #15300
    hospital discharge #15328
    quantify #15340
    activators #15356
    neonates #15370
    consequence #15405
    locally #15441
    impaired #15446
    pedigree #15471
    randomised controlled trial #15474
    women age #15474
    grafts #15484
    zealand #15509
    asthma #15511
    undetectable #15512
    current literature #15513
    records #15520
    1994 #15522
    aggregation #15535
    thrombocytopenia #15537
    implementation #15538
    pa #15540
    intended #15567
    reviewed #15577
    surgery #15590
    updated #15592
    discharged #15616
    immunoenzyme #15617
    purpose #15634
    heterozygosity #15660
    centre #15666
    standard #15679
    patients admitted #15702
    perinatal #15711
    explain #15726
    view #15729
    unexpected #15737
    detection #15766
    start #15808
    examination #15813
    effectively #15813
    prescribing #15823
    vary #15829
    febrile #15847
    confer #15849
    serologic #15853
    reach #15876
    interpretation #15881
    janus #15892
    numerous #15899
    inter #15907
    quality adjusted #15919
    dyslipidemia #15942
    prominent #15961
    blocked #15985
    discuss #15997
    severely #15997
    alanine #15998
    external #16007
    causal #16021
    hepatectomy #16025
    complication #16054
    compared controls #16057
    rarely #16076
    systemic inflammation #16077
    fever #16082
    metabolic #16112
    demonstrates #16117
    insensitive #16125
    affect #16135
    conditional #16136
    basis #16144
    carotid #16168
    bypass #16221
    early #16262
    antiretroviral #16271
    neoplasms #16294
    hospital #16314
    special #16336
    signs #16384
    cost #16418
    recommendations #16420
    aimed #16432
    area #16442
    syndromes #16485
    unable #16508
    prevented #16513
    develop #16513
    cancer treatment #16516
    106 #16543
    radiography #16545
    calibrated #16568
    multivariable #16576
    2021 #16583
    descriptive #16618
    alternatives #16629
    integrins #16641
    creactive protein #16645
    gained #16652
    consists #16666
    weeks #16674
    downregulation #16681
    residual #16708
    prior #16725
    explained #16763
    fat #16775
    electrocardiography #16807
    epidemiology #16821
    potent #16848
    thought #16868
    genetic risk #16876
    survival #16892
    093 #16911
    humans liver #16932
    constitute #16939
    gestational age #16946
    vasodilator #16950
    driven #16958
    critically patients #16965
    enable #16976
    verify #16984
    smokers #16998
    inherent #17023
    carotid artery #17040
    apolipoproteins #17063
    individual patients #17078
    markedly #17097
    units #17139
    estimates #17144
    assayed #17145
    elderly patients #17150
    regard #17197
    critically #17220
    adjustment #17237
    cooperative #17262
    lung neoplasms #17262
    estimated #17274
    acute phase #17288
    largest #17288
    400 #17295
    clinician #17339
    desirable #17347
    2019 #17393
    limb #17439
    dilated #17443
    disease cvd #17451
    synthetic #17459
    increasingly #17488
    kinds #17510
    antibodies #17538
    prompt #17565
    demographics #17584
    cirrhosis #17586
    0002 #17604
    finding #17620
    applicable #17636
    obtaining #17637
    coronary #17653
    sex factors #17688
    prosthesis #17710
    independent risk factor #17712
    distal #17714
    multivariate analysis #17792
    gastrointestinal #17804
    selecting #17815
    3 years #17833
    2006 #17840
    illustrated #17852
    1 #17853
    hemorrhagic #17855
    drugs #17878
    current evidence #17881
    undergone #17883
    marked #17903
    epidemiologic #17920
    hospitalizations #17922
    nationwide #17924
    global #17933
    percutaneous #17942
    essential #17964
    corticosteroids #17975
    distant #18007
    intensive #18031
    reductase #18047
    verified #18052
    peptide #18060
    defects #18070
    000 #18092
    operated #18111
    trend #18115
    centers #18134
    protein crp #18152
    clinical significance #18164
    consistently #18169
    quality #18175
    chemotherapy #18203
    prenatal #18250
    participate #18252
    deaths #18263
    year follow #18286
    ventricular function #18296
    metastases #18296
    inflammatory bowel #18314
    gestation #18344
    tolerated #18425
    attributable #18434
    and or #18480
    coa #18497
    larger #18513
    mutations #18533
    humans hypertension #18543
    stratified #18569
    heart disease #18579
    commercial #18589
    bayes #18675
    #18700
    extra #18726
    mechanisms #18742
    questions #18760
    plasma #18797
    conventional #18799
    monoclonal antibodies #18844
    increases #18850
    life #18851
    vessel #18855
    oligopeptides #18887
    clearance #18903
    validation #18907
    classical #18919
    hormone #18938
    molecular basis #19034
    single #19069
    worse #19094
    statistical #19103
    soluble #19124
    simultaneously #19131
    tailored #19134
    real #19158
    5 years #19189
    variable #19205
    moderate #19239
    contributes #19241
    decade #19291
    infarct #19308
    ages #19312
    pubmed #19345
    0005 #19412
    essentially #19469
    ventricular #19481
    investigates #19493
    2 3 #19507
    therapies #19511
    called #19515
    partially #19535
    explore #19544
    endothelium #19553
    systemic #19561
    january #19567
    uterine #19582
    reversed #19601
    procedures #19611
    tka #19675
    etiology #19677
    operating #19692
    guided #19709
    histology #19727
    characterised #19753
    inflammation #19779
    median followup #19863
    exclusively #19881
    autologous #19886
    graft #19904
    endothelial cell #19986
    controlled trial #20019
    comorbidities #20045
    2002 #20050
    gestational #20050
    additionally #20057
    cytokines #20058
    salvage #20102
    inversely #20149
    concentration #20153
    predisposition disease #20162
    diastolic #20170
    small #20201
    alterations #20228
    body #20230
    alpha #20261
    polymorphism genetic #20264
    variables #20277
    subjects #20283
    combine #20369
    adjusting #20377
    catheterization #20391
    introduced #20458
    1 3 #20492
    younger #20499
    hormones #20508
    length #20512
    theoretically #20515
    ability #20536
    analyses #20553
    clarify #20561
    elisa #20562
    persistent #20562
    improves #20570
    september #20598
    persons #20696
    humans models #20753
    active #20756
    observational #20823
    incorporated #20843
    prognosis #20934
    fetal #20955
    reduce #21005
    measure #21033
    auc #21046
    report #21048
    intrinsic #21055
    responsible #21081
    constructed #21098
    innate #21135
    attenuated #21137
    operative #21137
    1 year #21144
    designated #21167
    october #21177
    performing #21185
    × #21191
    upper #21226
    reflecting #21230
    selected #21264
    depending #21267
    preschool female #21270
    005 #21324
    hemodynamics humans #21403
    symptoms #21425
    center #21469
    differed #21501
    1990 #21507
    0004 #21546
    logistic #21639
    explored #21757
    animals antibodies #21767
    young #21860
    majority #21894
    139 #21894
    observe #21969
    facilitate #21994
    decreased #22047
    progression #22078
    genotype #22116
    imaging #22125
    coronary disease #22178
    tract #22180
    neoadjuvant #22207
    generally #22291
    regression #22321
    surgical procedures #22327
    authors #22330
    demonstrated #22352
    inhibiting #22426
    newborn male #22473
    varying #22556
    significance #22586
    represented #22593
    slower #22607
    allogeneic #22614
    grade #22615
    phase #22698
    older #22831
    differential #22835
    july #22843
    modified #22851
    march #22907
    application #22920
    combining #22961
    ratios #22986
    2012 #23037
    anti inflammatory #23123
    offered #23214
    protocols #23283
    2016 #23284
    challenging #23285
    yielding #23334
    prevents #23432
    resting #23488
    includes #23496
    renal #23566
    median #23599
    inhibits #23686
    inbred c57bl mice #23705
    increasing #23723
    endopeptidases #23727
    advanced #23745
    naive #23767
    adverse #23767
    reactive protein #23807
    minimal #23827
    interestingly #23831
    showing #23885
    longer #23967
    surgical #24020
    vascular endothelial #24085
    prolonged #24478
    generate #24487
    count #24514
    december #24569
    unrelated #24572
    determining #24577
    activity #24581
    changed #24651
    implies #24682
    underlying #24749
    suggests #24813
    august #24821
    linearly #24940
    february #24945
    frequent #25109
    june #25175
    representing #25214
    acceptable #25300
    carried #25310
    illness #25373
    suitable #25501
    enhance #25503
    0003 #25598
    linked #25616
    local #25663
    mm #25732
    fully #25888
    reducing #25912
    describes #25923
    difficult #26054
    supported #26091
    scanning #26181
    differentiate #26212
    respect #26378
    promising #26384
    asked #26410
    define #26421
    defective #26510
    female heart #26685
    dependent #26722
    leading #26774
    improving #27057
    contained #27059
    national #27215
    strongest #27229
    quantitatively #27333
    recognized #27386
    commonly #27411
    mass bmi #27411
    implicated #27484
    caused #27495
    remain #27689
    correlate #27710
    artery #27999
    cross #28142
    recorded #28182
    detected #28405
    inflammatory #28439
    multivariate #28454
    examine #28475
    beta #28655
    allowed #28793
    hypothesis #28801
    improved #28920
    required #29047
    large #29116
    chemically #29137
    short #29272
    patients chronic #29316
    genetic predisposition #29434
    bmi #29470
    female health #29531
    achieved #29589
    001 #29634
    underwent #29797
    2011 #30149
    indicating #30233
    approved #30511
    declined #30756
    participants #30828
    predisposition #30981
    genotype humans #31051
    aims #31216
    measured #31265
    antineoplastic agents #31706
    expected #31791
    specific #31901
    endothelial #32294
    modality #32386
    inhibit #32629
    conducted #32675
    predicted #32889
    inhibited #33631
    agreement #33673
    sensitive #34362
    antineoplastic #34560
    correlated #34744
    greater #34856
    poor #35078
    neoplasms male #35230
    humans magnetic #35433
    0001 #35646
    free #35793
    sectional #35852
    include #39773
    collected #40746
    examined #41010
    mediated #41310
    neoplasm #47468

    Key People For Pulmonary Embolism

    Top KOLs in the world
    #1
    Samuel Zachary Goldhaber
    pulmonary embolism atrial fibrillation major bleeding
    #2
    Henri M Bounameaux
    pulmonary embolism deep vein thrombosis clinical probability
    #3
    Harry Roger Büller
    pulmonary embolism venous thrombosis major bleeding
    #4
    Menno V Huisman
    pulmonary embolism atrial fibrillation major bleeding
    #5
    Paul D Stein
    pulmonary embolism deep venous thrombosis aortic valve
    #6
    Philip Stephen Wells
    pulmonary embolism major bleeding deep vein thrombosis

    Harry Roger Büller:Expert Impact

    Concepts for whichHarry Roger Büllerhas direct influence:Pulmonary embolism,  Venous thromboembolism,  Venous thrombosis,  Major bleeding,  Deep vein thrombosis,  Atrial fibrillation,  Vein thrombosis.

    Harry Roger Büller:KOL impact

    Concepts related to the work of other authors for whichfor which Harry Roger Büller has influence:Venous thromboembolism,  Pulmonary embolism,  Atrial fibrillation,  Deep vein thrombosis,  Oral anticoagulants,  Major bleeding,  Vte patients.


     

    Tools

    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


    Department of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands | From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therap